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Abstract 
Introduction 
Pneumococcal conjugate vaccine (PCV) immunization of children decreases their risk of 
nasopharyngeal acquisition of vaccine serotypes and concurrently reduces the 
transmission thereof to PCV unvaccinated age groups. We studied the impact of routine 
infant PCV immunization at population level, on the epidemiology of nasopharyngeal 
pneumococcal colonization in a rural (Agincourt) and an urban (Soweto) South African 
community with high prevalence of HIV-infection. Furthermore, we delineated the effect 
of infant PCV immunization on bacterial interactions of Streptococcus pneumoniae with 
Haemophilus influenzae and Staphylococcus aureus at the population level. Lastly, we 
assessed the utility of colonization data to predict the impact of childhood PCV 
immunization on the direct and indirect effect against invasive pneumococcal disease 
(IPD). 
 
Materials and Methods 
A series of cross sectional colonization surveys were undertaken (in Agincourt and 
Soweto) between 2009 and 2012.  These years were representative of the pre- or early-
PCV-era and PCV-era years. The seven valent PCV (PCV7) was introduced into the 
South African national immunization program in April 2009, using a 6, 14 and 40 weeks 
of age dosing schedule with no catch up campaign of older children. Subsequently, PCV7 
was replaced by 13-valent PCV (PCV13) in May 2011, with a limited catch up campaign.  
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Nasopharyngeal swabs were collected among household members and mother-infant 
pairs and processed for S. pneumoniae, H. influenzae and S. aureus using standard 
microbiologic techniques. Additionally, the trends in incidence of IPD for 2005 to 2012 
were evaluated. Multivariate logistic regressions were performed to assess the impact of 
PCV on carriage in different age groups. Adjusted risk ratios (aRR) or adjusted odds 
ratios (aOR) are reported as measures of impact and association. We compared the 
predicted changes in IPD among children and their mothers, stratified by HIV, using a 
theoretical model and compared this to the observed changes in IPD. 
 
Results 
Among rural households, the prevalence of PCV7 serotype colonization among all ages 
decreased from 18.3% in 2009 to 11.4% in 2011; p<0.0001. This included reductions 
(adjusted risk ratio; aRR) of 50% (95% Confidence Interval [95%CI]:0.42-0.59), 34% 
(95%CI: 0.48-0.92) and 64% (95%CI: 0.18-0.74) in age groups <2 years, 6-12 years and 
adults, respectively. The prevalence of PCV7 serotype colonization among primary 
caregivers decreased from 10.2% in 2009, to 5.4% in 2011, (p<0.001). Non-vaccine 
serotype colonization prevalence increased by 35% (95%CI: 1.17-1.56) among children 
<2 year of age in 2011, however, it declined by 45%-54% among adolescents and adults.   
 
In urban mother-infant pairs, PCV13serotype colonization decreased from 2010 
compared to 2012 among HIV-uninfected (aOR: 0.32; 95%CI: 0.25-0.40) and HIV-
infected children (aOR: 0.37; 95%CI: 0.28-0.49), whilst there was an increase in non-
vaccine serotype colonization. Decreases in PCV13 serotype colonization were also 
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observed in HIV-uninfected women (aOR: 0.44; 95%CI: 0.23-0.81); with a similar trend 
in HIV-infected women. Non PCV13 serotype colonization declined in 2012 compared to 
in 2010 among HIV-infected women (aOR: 0.69, 95%CI: 0.48-0.99). HIV-infected 
compared to HIV–uninfected women had higher prevalence of overall (20.5% vs. 9.7% in 
2010; 13.8% vs. 9.7% in 2012) and PCV13 serotype colonization (8.7% vs. 5.4% in 
2010; 4.8% vs. 2.0% in 2012) in both sampling periods; p<0.04 for all observations. 
 
For bacterial associations  in the rural population, from 2009 to 2011 in children 0-2 
years and 3-12 years of age, the prevalence of overall S. pneumoniae colonization 
decreased from 74.9% to 67.0% (p<0.001). Although there was also a decrease in 
prevalence of H. influenzae colonization in the 3-12 year age group (55.1% to 45.3%, 
p<0.001), this was not evident among those <2 years of age. The prevalence of S. aureus 
colonization remained unchanged in all childhood age groups. In individuals older than 
12 years of age, the prevalence of colonization decreased for all studied bacteria 
including S. pneumoniae (11.2% vs 6.8%), H. influenzae (16.7% vs. 8.8%) and S. aureus 
(31.2% vs. 23.7%);  p<0.001 for all comparisons. 
 
Analysing the colonization and IPD findings, between the pre PCV era (2007-2009) and 
the PCV13 era (2012), we observed reductions in vaccine serotype colonization and IPD 
due to PCV7 serotypes and the additional six serotypes included in PCV13 among 
children and women. Using the changes in vaccine serotype colonization over time, the 
hypothetical model accurately predicted changes in vaccine serotype IPD incidence 
compared to the observed changes in PCV-unvaccinated HIV-infected and HIV-
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uninfected adults; and among children too old to have been immunized. The model, 
however, underestimated the reduction in vaccine serotype IPD among the child age-
group targeted for immunization. The model was, however, not useful in predicting the 
changes that occurred for non-vaccine serotypes either among PCV-vaccinated or PCV-
unvaccinated age-groups. 
 
Discussion and Conclusion 
Infant PCV immunization resulted in population wide decreases in vaccine serotype 
colonization of S. pneumoniae including among HIV-infected adults in both rural and 
urban settings. Surveillance of colonization prior and following childhood PCV 
immunization can be used to infer indirect effects against vaccine serotype IPD in the 
community even in high HIV-prevalence settings such ours.  
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Chapter 1  
1.1 Background 
 
Streptococcus pneumoniae is the leading cause of death in children (1, 2) and the 
commonest cause of community acquired pneumonia among adults (3). An estimated 
826,000 deaths due to pneumococcal disease occurred in children aged 1-59 months in 
2000, including 91,300 deaths among HIV-infected children. Most of these deaths were 
attributable to pneumonia (90%), followed by meningitis (7%)(4). By 2013, the annual 
number of deaths due to S. pneumoniae had declined to 436,000, nevertheless, the 
majority (>90%) of these deaths still occurred in low-income countries, where childhood 
immunization with pneumococcal conjugate vaccine (PCV) was yet to be introduced (5).  
 
Immunization of children with PCV offers the opportunity to reduce pneumococcal 
morbidity and mortality, particularly among children with limited access to curative 
health-care where the risk of mortality is likely the greatest (6). In 2007, the World 
Health Organization (WHO) recommended vaccination of children with PCV in all  
countries with  under-five mortality rate greater than 50 per 1,000 live births, where 
greater than 50,000 children die annually and in countries with a high HIV prevalence 
(7).  
 
The introduction of  seven-valent PCV (PCV7) into childhood immunization programs of 
high-income countries, first initiated in USA in 2000, has been associated with reduced 
nasopharyngeal (NP)-acquisition of the vaccine serotypes among vaccinated-children. 
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This has also resulted in reduced transmission of these serotypes to unvaccinated-
individuals, (8, 9) which has consequently decreased the incidence of vaccine serotype 
invasive pneumococcal disease (IPD) among PCV-vaccinated and -unvaccinated 
individuals (i.e. indirect effect)  (10-12). The indirect effect has also benefited young  
infants who were too young to be immunized (13), and PCV-unvaccinated HIV-infected 
adults in USA (14, 15). In the USA, the number of IPD cases prevented through the 
indirect effect of PCV is almost 2.5 fold greater than the number prevented among the 
vaccinated childhood population (11). Similarly, childhood PCV immunization has been 
associated with reduction in all-cause pneumonia among age-groups targeted for 
vaccination, and with even greater number of cases being prevented among PCV-
unvaccinated adults in USA (16). Although, an increase in non-vaccine serotype IPD has 
partly offset the decrease in vaccine serotype IPD, overall IPD rates remain significantly 
lower than in the pre-PCV era (10).  
 
PCV uptake in low and middle income countries has lagged behind high-income 
countries. Among the WHO member states, 60% of members from the Americas region, 
50% Western Mediterranean region, 41% African region, 33% Western Pacific region 
and none from Asia had introduced PCV in December 2012 (17). Global efforts to 
accelerate the introduction of PCV in low-income countries through GAVI supported 42 
countries to introduce PCV into their national immunisation programs (18). To date 116 
countries have introduced PCV into the NIPs, including widespread private market in 
Portugal. Despite this progress 59% of the world’s children live in 43 nations that are yet 
to make a decision regarding PCV introduction (18).  
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Beginning in April 2009, South Africa implemented PCV7 immunization for infants 
through its national immunization program. Vaccination was targeted specifically at 
infants who had yet to receive their first dose of other vaccines given at 6 weeks of age, 
with no catch-up campaign of older children. The PCV dosing schedule adopted in South 
Africa was a two dose primary series at 6 and 14 weeks of age, followed by a booster 
dose at 9 months of age (19, 20).  
 
This thesis reports on the impact of infant PCV immunization on the bacterial ecology of 
the nasopharynx among PCV-vaccinated and -unvaccinated age-groups, in rural and 
urban South African communities, and where there is a high prevalence of HIV infection.  
 
1.2 Nasopharyngeal carriage of S. pneumoniae          
 
S. pneumoniae is a normal commensal of the upper respiratory tract acquired from early 
on in life. Most serotypes of pneumococci that cause disease in children are also 
identified as colonizing healthy carriers. Although NP pneumococcal colonization does 
not always result in pneumococcal disease, the risk for developing disease is greatest 
within the first 1-2 months of acquisition of a new serotype (21). Consequently, there is a 
close association between the prevailing colonizing pneumococci and those causing 
disease (21-23). This is corroborated by animal-model studies in which nasal inoculation 
of S. pneumoniae leads to otitis media or invasive disease (24-28). Furthermore in 
longitudinal cohort studies in children less than two years age, a recent acquisition (less 
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than two months) of a new serotype was associated with acute otitis media or respiratory 
infection. Thus, there is >90% concordance between disease-causing serotype and NP 
serotype at time of illness (21-23, 29). This is further corroborated by >90% of children 
with IPD simultaneously being colonized with the homotypic serotype, compared to a 
prevalence of 52% among healthy controls (30, 31).  
 
Serotypes commonly isolated from the nasopharynx of children prior to PCV 
immunization programs were from serogroups 6, 14, 19 and 23 (21, 32-34). All of these 
serogroups are represented by at least one serotype in the 7-valent (PCV7), 10-valent 
(PCV10) and 13-valent (PCV13) PCV formulations. These vaccine serotypes are less 
commonly isolated from adults, among whom there is a higher prevalence among women 
and particularly those infected by HIV (35). Additional PCV serotypes included in 
PCV10 and PCV13 are serotypes 1 and 5. Although these serotypes are rarely  associated 
with NP colonization in healthy individuals, they cause a significant burden (15-20%) of 
pneumococcal disease in Africa and other low-middle income  countries (36). These 
serotypes are also commonly identified in the nasopharynx of individuals with 
pneumococcal disease due to the homotypic serotype, as well as among household 
contacts of cases during outbreaks (30, 37). 
 
Young children colonized by pneumococci, are the major source of transmission of 
pneumococci in the community (33). This is further corroborated by children without 
siblings acquiring the pneumococcus later in life and being colonized by fewer serotypes 
than children  with siblings (21). Also, there is heightened pneumococcal transmission 
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and acquisition in environments where many children are concentrated, such as in day-
care centers (8, 21, 32, 38). Day-care attendance by children is also associated with 
transmission of these acquired serotypes to community contacts not attending day care 
(39). Both younger children and adults in households where there are children attending 
day-care, have a higher prevalence of pneumococcal colonization (38, 40). This 
observation is independent of the longer duration of pneumococcal colonization among 
young children compared to adults (41). Although day-care attendance may be less 
common in low-income African settings, an analogous situation in these countries is 
overcrowding in the household, as well as many children from households playing 
together in groups. 
 
There are notable differences regarding age of first pneumococcal acquisition and 
prevalence of colonization during childhood and in adults in low-income countries (and 
high-risk populations such as American Indians, Alaskan Natives and Australian 
Aboriginals) compared to those in high-income countries (33). Colonization by the 
pneumococcus is acquired in the first few weeks of life in low-income countries. As an  
example in The Gambia, the mean age of first acquisition of the pneumococcus was 33 
days, while  >80% of children were colonized by pneumococcus at three-months of age 
(42).  Similarly in Papua New Guinea, all children had acquired the pneumococcus by 3 
months of age, (43) while in Bangladesh 50% and 90% of the infants had at least one 
acquisition of the pneumococcus at 8 and 21 weeks respectively (44).  
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In contrast, colonization of infants by pneumococci in high-income countries occurs later 
in childhood. A study in USA reported the mean age of first colonization at 6 months of 
age, with an upper range of 18 months (21). Similarly, most Finnish children only 
acquired pneumococci between 12 to 24 months of age (45). Colonization prevalence of 
40 to 50% among children in high-income settings may only be reached by  two years of 
age, which is then  followed by a reduction in prevalence of NP colonization around five 
years of age to adult levels of approximately 10% (33). The prevalence of pneumococcal 
colonization may, however, persist at high levels into adulthood in low-income settings, 
e.g. 50% among adults > 40 years in The Gambia (46).  
  
Considering the differences in dynamics of pneumococcal colonization among children 
and adults from high- and low-income countries, it is unclear whether the indirect effects 
on colonization and pneumococcal disease of childhood PCV immunization observed in 
high-income countries will materialize in low-income settings. The high prevalence of 
pneumococcal colonization among adults in low-income countries in general, could serve 
as a source of pneumococcal transmission in the community. This may be even more 
pertinent in settings with a high prevalence of adult HIV-infection, since HIV-infection 
(and particularly among women) is associated with a higher prevalence of PCV7 serotype 
colonization (47). As such, in settings with a high prevalence of adult HIV-infection, 
these individuals could theoretically serve as an additional reservoir of colonization and 
transmission of PCV7 serotypes.  
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1.3 Pneumococcal conjugate vaccines and dosing schedule  
 
Based on the polysaccharide composition of the capsular wall of S. pneumoniae, 42 
serogroups have been characterized, which are further classified  into at least 93 distinct 
serotypes (48). Only a limited number of these 93 serotypes, however, are responsible for 
the majority of IPD cases (49), most of which have been incorporated into PCV 
formulations. The PCV7 was first licensed in 2000 in USA for use in children under two 
years of age. This formulation includes serotypes 4, 6B, 9V, 14, 18C, 19F and 23F. The 
PCV7 serotypes accounted for  80% of IPD in young children in the USA, Canada and 
Australia, at least 50% of IPD in Africa, Europe and Latin America and 30% of IPD in 
Asia prior to the PCV-era (50). Globally, since 2010, PCV7 has been replaced with the 
10-valent PCV (PCV10; which includes serotypes 1, 5 and 7F) and the 13-valent PCV 
(PCV13; which has additional serotypes 3, 6A and 19A). Surveillance data from South 
Africa prior to the PCV-era, reported 70% of IPD were caused by PCV7 serotypes 
+serotype  6A, whereas 77% and 86% of childhood IPD cases were caused by PCV10- 
and PCV13-serotypes, respectively (51).  
 
There has been varying dosing schedules used for PCV childhood immunisation between 
countries. These include two doses during infancy followed by a booster dose in the 
second year of life (2 + 1 schedule), three doses in infancy (3 + 0 schedule), and three 
doses in infancy followed by a booster dose in the second year of life (3 + 1 schedule).  
There has also been variability between national immunization programs as to whether 
PCV vaccine introduction was coupled with a catch up campaign of older children, who 
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would otherwise not be included in the adopted vaccine schedule for younger children. 
The catch-up campaign of older childhood age groups is targeted at providing protection 
to these children, and has also been postulated to accelerate the interruption of 
pneumococcal transmission and hence expedite the time to when indirect protection 
would materialise in communities (52).   
 
The WHO recommends that countries should consider local epidemiological factors 
when deciding on the  PCV schedule, (7) with an implied preference for a 3  dose 
primary series (3+0),without a booster dose (due to cost constrains), premised on the 
efficacy trials undertaken in Africa (53, 54). Alternately, WHO recommends a 2 dose 
primary series followed by a booster dose in the second year of life (2+1) schedule (55). 
The 2+1 dosing schedule has been widely adopted in many European countries (56-59).  
A recent systematic review and meta-analysis, dominated by data from high-income 
countries, suggest there to be little difference in the effectiveness of different dosing 
schedules against vaccine serotype colonization, all-cause pneumonia or vaccine serotype 
IPD (56). Also, there has been similar levels of  indirect protection experienced in 
countries which implemented 2+1 compared to those  with a 3+1 dosing schedules(60-
64).  The relevance of dosing schedules on the long-term and community wide effects of 
pneumococcal transmission dynamics and disease, however, remain to be fully elaborated  
in low-middle income settings (56).  
 
The rationale for South Africa choosing a modified 2+1 dosing schedule (6, 14 and 40 
weeks age), included aiming at improving the persistence of protection among HIV-
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infected children. This was important since waning of vaccine efficacy was observed 
following 5 years of follow-up in HIV-infected children when provided with a 3-dose 
primary series (6, 10 and  14 weeks) without a booster dose of vaccine (65, 66).  The 
public-health relevance of needing to extend the duration of protection against IPD in 
HIV-infected infants (19) was motivated by them contributing to 75% of IPD cases and 
deaths in South Africa, despite only constituting 5-6% of the childhood population (67).  
The 2+1 dosing schedule was demonstrated to have similar immunogenicity one month 
following the primary series of two doses, compared to after the third dose at 14 weeks 
age in a historical cohort who received PCV at 6, 10 and 14 weeks (20). Furthermore, the 
geometric mean concentrations (GMCs) following the third dose at 9 months of age in 
the 2+1 schedule resulted in much higher GMC compared to after the third dose in the 
3+0 schedule (20). This indicates the potential of more prolonged immunity with the 2+1 
compared to 3+0 schedule in South Africa (20). To date, South Africa remains the only 
country to have adopted this dosing schedule (6, 14 and 40 weeks age). Hence, 
delineating the direct and indirect effect of this PCV dosing schedule on pneumococcal 
colonization, IPD and pneumonia, is important to determine the potential utility of such a 
schedule in other low-middle income countries.   
 
1.4 Effect of PCV vaccination on pneumococcal colonization                  
 
PCV vaccination has been shown to be effective in reducing vaccine serotype carriage in 
a variety of settings. A selection of such studies are summarised in Tables 1.1, 1.2 and 
1.3. Early clinical trials, reported that a three-dose PCV primary series reduced vaccine 
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serotype  carriage in vaccinated children compared to controls by 9-12 months of age (8, 
9, 68, 69). Furthermore, there have been randomized trials which reported that household 
contacts of day-care attending PCV-vaccinated children, were less likely to be colonized 
by the vaccine serotypes compared to household members in which the children received 
placebo(8, 33, 70-73) . This included lower prevalence of colonization among older 
unvaccinated siblings and adults sharing household with PCV-vaccinated children. 
Concomitantly, an increase in non-vaccine serotype (NVT) among PCV-vaccinees and 
their PCV-unvaccinated contacts has also been reported (8, 68, 69, 73, 74) .  
 
Following PCV introduction in national immunization programs, population level effects 
on colonization of vaccine introduction have been described in a variety of settings. 
Observational data from several countries, including The Gambia, Kenya, Australia, the 
United Kingdom, The Netherlands, France, the USA and Colombia consistently shows 
decreases in vaccine serotype colonization in PCV-vaccinated and -unvaccinated age-
groups, with varying degrees of non-vaccine serotype replacement (14, 59, 75-84). In the 
USA, whereas vaccine serotype  colonization had decreased by >97% seven years 
following PCV7 introduction, there was a near complete replacement of carriage by non-
vaccine serotypes (85). Various degrees of non-vaccine serotype increases have also been 
observed in various settings from within 2 years of PCV introduction, including in 
Portugal where the PCV was introduced into the private market (14, 59, 75-77, 81-83, 85-
89).  Differences in the extent of non-vaccine serotype replacement between settings may 
vary depending on timing of the survey after vaccine introduction, extent of 
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immunization coverage of targeted age-group, the dosing schedule used and whether 
there was a catch-up campaign of older children.   
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Table 1.1: Randomised Controlled Trials on the effect of PCV on colonization by WHO regions 
Author Study site Study population Vaccine 
formulati
on 
Dose Age when 
colonization 
evaluated 
Vaccine serotypes: 
OR of colonization in 
vaccinees compared to 
controls 
Non-vaccine serotypes: 
OR of colonization in 
vaccinees compared to 
controls 
Africa region 
Matched case control studies 
(Obaro 
1996)(69) 
The Gambia PCV5 recipients matched 
to PCV-unvaccinated 
controls according to age 
and place of residence 
PCV5-
CRM197
1
 
3 doses at 2, 3 and 
4 months,OR two 
doses at 2 and 3 
months followed by 
PPSV23 at 18 
months 
 
24 months 3 dose arm: OR 
0.11(95%CI: 0.04-0.31)  
2 dose arm: OR 0.22 
(95%CI: 0.08-0.61). 
3 dose arm: OR 4.51(95% 
CI:1.62-14.37), 
2 dose group, OR 0.65 (95% 
CI: 0.29-1.42). 
Randomised controlled trials 
Mbelle 1999 
(68) 
South Africa Children enrolled and 
given vaccine at 6, 10 
and 14 weeks 
CRM-9
2 
3 doses at 6, 10 and 
14 weeks 
9 months Decreased among vaccinees, 
18% compared to 36% in 
controls OR: 0.38 (95% CI: 
0.25-0.58) 
Increased among vaccinees 
36% versus 25% in controls 
OR: 1.75 (95% CI: 1.18-
2.60) 
Obaro 2000 
(90) 
The Gambia Children that received 
vaccine or placebo had 
carriage measured at 5 
and 9 months of age 
CRM-9 3 doses at 2, 3 and 
4 months 
5 and 9 
months 
Decreased from 68% in 
controls to 58% in vaccinees 
to  OR 0.84 (95% CI: 0.47 to 
1.50) 
Increased from 35% to 49% 
, OR 1.8 (95% CI: 1.04-3.9) 
Cheung, 
2009 (74) 
The Gambia Vaccine recipients and 
controls enrolled at 6 to 
51 weeks and their 
younger siblings 
CRM-9 3 doses from 6 to 
51 weeks 
9-15 and 21-
27 months 
VT carriage at 9-15 months 
and at 21-27 months  less in 
vaccine recipients , OR 0.44 
(95% CI: 0.36-0.53) and OR 
0.47 (95% CI: 0.39-0.58), 
respectively 
Carriage at 9- 15 months and 
at 21-17 months increased in 
vaccines compared to 
controls, OR 2.03 (95% CI: 
1.69-2.44) and OR 1.92 
(95% CI: 1.57-2.33) 
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respectively 
 
Eastern Mediterranean 
Dagan, 
1996(70) 
Israel Children 12-18 months 
old 
PnCOM
PC-7
3
 
One dose vs two 
doses vs PPSV23 
13-21 
months 
One dose:  OR 0.35 (95% 
CI: 0.16-0.78); 25% to 9% at 
3 months after vaccination 
Decrease  from 25% to 7% , 
OR 0.29 (95% CI: 0.12-
0.74) at 1 month after 
vaccination in two dose arm 
No change in PPSV23 
recipients 
No change 
Dagan 
1997(91) 
Israel Children aged 2, 4 and 6 
months 
Pnc-T
4
 
Or  
Pnc-D
5
 
3 doses at 2, 4 and 
6 months followed 
by PPSV23 at 18 
months 
 Decrease from 27% to 10%, 
OR 0.13 (95% CI: 0.04-
0.49)  for Pnc-D 
Decrease from 27% to 10%, 
OR 0.23 (95% CI: 0.11-
0.74) for Pnc-T 
Non-significant increase  
Dagan 2002 
(8) 
Israel Toddlers attending day 
care age 12-17months 
and 18-35 months 
CRM-9 2 doses at least 2-
3months apart for 
those aged 12-
17months 
1 dose for those 
aged 18-35 months 
24-35 and 
36-47 
months 
Decreases observed among 
children 24-35 months OR 
0.40 (95% CI: 0.26-0.60) 
and among children 36-47 
months OR 0.57 (95% CI: 
0.38-0.87) 
 
 
Increase from 7% to 10% 
among children  ≤ 36months  
Europe 
Kilpi 
2001(72) 
Finland Infants enrolled at 
2months 
PnCOM
PC-7 
2, 4, 6 and 12 
months 
12  and 18 
months 
At 12 months VT declined 
by 17% (95%CI: -9 to 37%) 
At 18 months VT declined 
by 41% (95% CI: 33 to 
Not reported 
14 
 
55%) 
Van Gills 
2009 (63) 
Netherlands Healthy new borns 
followed up to 24 
months of age and their 
parents 
CRM-7
6
 2 doses vs 2+1 
doses vs control 
12, 18 and 
24 months 
At 12months decrease from 
38% to 25% in 2 dose, OR 
0.52 (95% CI, 0.38-0.74) 
and  from 38% to 20% in 
2+1 schedule , OR 0.40 
(95% CI 0.28-0.57),  
Further decreases to 16%   
and 14%  carriage at 18 and 
24 months respectively in 
2+1 schedule 
NVT increased at 12 months 
in 2 dose arm and 2+1 dose 
arm from 29% to 38%, OR 
1.48 (1.07-2.06) 
Similar results at 18 and 24 
months for both groups 
 
 
1
PCV-5 serotypes 6B, 14, 18C, 19F and 23F, 
2 
PCV-9 serotypes 1, 4, 5, 6B, 9V, 14, 18C, 19F and 23F conjugated to CRM, 
3
PnCOMPC-7, serotypes 4, 6B, 9V, 
14, 18C, 19F and 23F conjugated to meningococcal outer membrane protein complex, 
4
Pnc-T: PCV4 serotypes 6B, 14, 19F and 23F conjugated to tetanus toxoid, 
5
Pnc-D: PCV4 serotypes 6B, 14, 19F and 23F conjugated to diphtheria toxoid,
 6
PCV-7 serotypes 4, 6B, 9V, 14, 18C, 19F and 23F conjugated to CRM 
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Table 1.2: Community studies evaluating the impact of childhood PCV immunization on direct and indirect effect 
Author Study site Study population Vaccine 
formulati
on 
Dose Years 
between 
vaccine 
introduction 
and study 
Vaccine serotypes: 
OR of colonization in 
vaccinees compared to 
controls 
Non-vaccine serotypes: 
OR of colonization in 
vaccinees compared to 
controls 
Americas 
O’Brien 
2007 (9) 
Navajo American Indian infants 
and their unvaccinated 
contacts 
CRM-7
1
 3+1 schedule at 2, 4, 
6 and 12-15months  
1month, 6-
9months, 12-
15 months 
At one month post PCV 
vaccination, infants had 
lower odds of carrying 
VT (OR, 0.40: 95% CI: 
0.23-0.67) 
Older siblings in 
vaccinated communities 
had lower  carriage , OR 
0.27 (95% CI: 0.07-1.07) 
Increased 6 months after 
booster dose (OR, 1.67: 95% 
CI: 1.02-2.78) 
 
Millar 2008 
(73) 
Navajo Households of children 
vaccinated with PCV or 
placebo 
CRM-7 3+1 doses at least 
2months apart for 
infant aged 6weeks to 
7 months; 2+1 doses 
for infants aged 
7to11months; 2 doses 
for infants12-
23months  
 
3-15 months 
after 
completion 
of trial 
Vaccinated children and 
adults living in the same 
communities were less 
likely to be colonised,  
OR, 0.57(95% CI: 0.26-
0.96) 
Children living in vaccinated 
communities were more 
likely to be colonized, OR, 
2.26 (95% CI: 1.22-4.20) 
 
Africa 
Roca 2014 
(92) 
The Gambia Infants immunized with 
PCV13 and their mothers 
compared to infants 
immunized with PCV-7 
CRM-7 
vs 
CRM-
13
2
 
Three doses at 2, 3 
and 4 months 
Children aged 2-
11months received 3 
doses one month 
1year Carriage of PCV7 
serotypes lower in 
PCV13 recipients (4.9%) 
compared to PCV7 
recipients (9.4%), 
Significant increase in non-
typable isolates in PCV13 
recipients vs PCV7 
recipients (6.6% vs 0.6%, 
p=0.005) 
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apart 
Children aged 12-30 
months received 2 
doses one months 
apart 
Older than 30 months 
received one dose 
PCV (in vaccinated 
villages) or 
Meningococcal 
vaccine 
(unvaccinated 
villages) 
p=0.025 
Carriage of PCV13 
serotypes was lower in 
PCV13 recipients 
(18.0%) compared to 
PCV7 recipients 
(33.3%), p<0.001 
Carriage prevalence of 
six additional serotypes 
in PCV13 was lower 
(13.4%) in PCV13 
recipients compared to 
PCV7 recipients 
(23.9%), p=0.001 
 
 
Roca 2011 
(79) 
The Gambia Household members in 
vaccinated and 
unvaccinated villages 
Baseline survey: Dec 
2003 to May 2004 
 
CRM-7 Infants received 3 
doses at 2, 3 and 4 
months 
Children aged 2-
11months received 3 
doses one month 
apart 
Children aged 12-30 
months received 2 
doses one months 
apart 
Older than 30 months 
received one dose 
PCV (in vaccinated 
villages) or 
Meningococcal 
CSS
3
1: 4-
6months 
after 
vaccination 
CSS2: 12 
months after 
vaccination 
CSS3: 22 
months after 
vaccination 
Decrease between CSS1 
and CSS2 in vaccinated 
villages   
Among   5 to 15 year 
age-group: OR 0.15 
(95%CI: 0.04-0.57) and 
>15 year age-group: OR 
0.32 (95% CI: 0.10-0.98) 
Decrease between CSS1 
and CSS3 among 5-
15years, OR 0.37: (95% 
CI: 0.15 to 0.90) and 
among >15 years, OR 
0.37 (95% CI: 0.15 to 
0.90) 
  
Transient increase noted at 
CSS1 among vaccinated 
adults, OR 1.50 (95% CI: 
1.03-2.18) 
Decrease at CSS1 in both 
villages among adults , OR 
0.46 (95% CI: 0.26-0.82) 
And at CSS3, OR 0.53 (95% 
CI: 0.31-0.92) 
17 
 
vaccine 
(unvaccinated 
villages) 
1
PCV-7 serotypes 4, 6B, 9V, 14, 18C, 19F and 23F conjugated to CRM  
2
PCV13, serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F conjugated to CRM 
3
CSS, cross sectional survey 
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Table 1.3: Ecological studies evaluating the direct and indirect effect of PCV immunization in different settings by WHO 
regions 
Author Study Site Study Population Vaccine Dose Years 
between 
vaccine 
introduction 
and study 
VT NVT 
Americas 
Huang 
2009 (85) 
Massachuset
ts, USA 
Children 3 months to 
<7 years seen in 
primary care practises 
CRM-7
1
 3+1 schedule at 2, 4, 6 
and 12-15 months in 
national  EPI, from 2000 
, with catch-up 
7 Decreased from 36% in 
2001 to 3% in 2007 , OR 
0.05 (95% CI: 0.03-0.11) 
Increased across the survey 
years from 15% in 2001, 
19% in 2004 and 29% in 
2007, OR 2.3 (95% CI1.8-
3.0) 
Pelton 
2004 (87) 
Massachuset
ts, USA 
Oct 2000-
Sept 2003 
Children aged 2-24 
months presenting for 
well child visits and 
children with acute 
otitis media 
CRM-7 3+1 schedule at 2, 4, 6 
and 12-15 months in 
national EPI, from 2000, 
with catch up 
3 VT decreased from 22% 
to 2%, OR 0.13 (95% CI 
0.03-0.63) 
NVT increased from 7% to 
16%, OR 2.2 (95% CI, 0.63-
7.64) 
Gounder 
2014 (75) 
Alaska Children aged <5 years 
and adults >18 years 
CRM-
13
2
 
3+1 schedule at 2,4 , 6 
months and 12-
15months, introduced 
2010 to replace PCV-7 
2   Among children <5 years 
PCV13 serotypes 
declined to 4% from 
13%, p<0.01 
Among adults >18 years 
VT13 serotypes 
decreased to 1% from 
4%, p<0.01 
Not reported 
Hammitt 
2006 (84) 
Alaska Households in 8 
Alaskan villages 
CRM-7 3+1 schedule at 2, 4, 6 
and 12-15months with 
catch-up 
4 Carriage decreased 
among children <5years 
from 55% to 5% , OR 
0.09 (95% CI: 0.04-
0.16)) 
Increased among adults >18 
from 59.2% to 89.9%, OR 
1.52 (95% CI: 1.37-1.68 
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Among adults carriage 
decreases from 28% to 
4.5%, p<0.001dults  0.16 
(95% CI: 0.10-0.26) 
Europe 
Van Hoek 
2014 (83) 
England Children aged 1-5 
years and their 
household members. 
CRM-13 2+ 1 dose at 2, 4 and 
12/13 months, PCV 7 
introduced in 2006 and 
replaced by PCV13 in 
April 2010 
6 Continued decrease 
PCV-7 serotype  from 
2.9% in 2001/2002 to 
only 0.3% in 2012/2013, 
OR 0.02 (95% CI: 0.00-
0.07 
Decrease in additional 
VT13 serotypes for all 
age group, from 6.3% in 
2001/2 to  0.6%  in 
2012/2013 , OR 0.12 
(0.04-0.34) 
Increase  from 5.2% to 
23.6%, OR 5.37 (95% CI: 
3.78-7.65)  
Flasche 
2011 (59) 
England Households with 
children eligible to 
have received routine 
or catch up PCV 
CRM-7 2 +1 schedule at 2, 4 and 
12-13months, with catch-
up for children up to 2 
years old, since 2006 
2-3 Among children < 5yrs  
decrease from 31.9% to 
3.6%, OR 0.06 (95% CI: 
0.03-0.16) 
Among individuals aged 
5-20 years decrease 9.9% 
to 0% 
Among adults >20 years 
decrease from 4.1% to 
2.3% 
OR for > 5 years, 0.31 
(95% CI: 0.04-2.49) 
Among children < 5 years 
increased from 15.3% to 
45.3%, OR 4.25 (95% CI: 
2.81-6.43) 
Among individuals 5-20 
years  increased from 9.1% 
to 26.3% 
Among adults >20 years 
increased from 3.3% to 7.5% 
OR for >5 years, 5.16 (95% 
CI: 1.95-13.66_ 
Rodrigues 
2009 (88) 
Portugal Children attending day 
care 
CRM-7 2+1 at 2, 4, 12 months of 
age,  Non-universal 
coverage since 2001, 
6  Decreased in children 
with >1 dose of PCV 
from 43.7 % to 13.7%, 
Increased among children 
who received >1 dose  form 
46.5% to 78.2 % < OR 4.13 
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introduced nationally 
2015 
OR 0.20 (95%  CI: 0.11-
0.37) 
(95% CI 2.36-7.23) 
Sa-Leao 
2009 (81) 
Portugal Children in day care 
centre 
CRM-7 2+1 at 2, 4, 12, Non-
universal coverage since 
2001, introduced 
nationally 2015 
5 Decrease from 53.1% to 
11.2% (p<0.001) 
Increased from 46.9% to 
88.8%(p<0.001) 
Cohen 
2010 (14) 
France Children 6 to 24 
months with acute 
otitis media 
CRM-7 3+0 at 2, 4 and 11 
months of age  
3 Decrease from 44.3% to 
17.3%, OR 0.39 (0.32-
0.47) 
Increase from 9.6% to 
23.5%, OR 2.45 (95% CI: 
1.88-3.20) 
Dunais 
2008 (86) 
France Children in day care 
centres 
CRM-7 2+ 1  at 2, 4 and 11 
months of age from 2003 
3 Decreased from 76.5% to 
21.0%, OR 0.08 (95% 
CI, 0.05-0.14) comparing 
between 1999 and 2006 
 
Increased from 9.8% to 
37.4% , OR 2.14 (95% CI, 
1.08-4.26) between 1999 
and 2006 
Spijkerman 
2011 (82) 
Netherlands Children aged 11-24 
months and their 
parents 
CRM-7 3 doses at 11 months and 
4 doses at 24 months 
with no catch up 
3 Children aged 11months: 
decrease from 38% to 
8%, aOR 0.14 (95% CI: 
0.09- 0.23) 
Children aged 24 
months: decrease in VT 
from 36% to 4%, aOR 
0.08 (95% CI: 0.05 -
0.15) 
Parents: decrease in VT 
from 8% to 1%, aOR 
0.06 (95% CI: 0.01-0.26) 
In children aged 11 months 
increase in NVT from 29% 
to 39% , aOR 1.64 (1.15-
2.32) 
In children aged 24 months 
increase in NVT from 30% 
to 45%, aOR 2.01(1.43-
2.84) 
In parents increase in NVT 
from 8% to 15%, aOR 1.98 
(1.16-3.36) 
Steens 
2014(89) 
Norway Children attending day 
care centres 
CRM-7 
introduce
d in 2006  
and 
replaced 
by  
2 + 1 schedule at 3, 5 and 
12 months of age 
2 and 4  
(2006 vs 
2008 vs  
2012) 
Decreased from 54%  
to31.6 %   , OR  0.58 
(95% CI: 0.52-0.65) by 
2008 and further 
declined to 9.3% , OR 
0.17 (95% CI: 0.14-0.21) 
Increased from 33.6% to 60. 
60.6% , OR 1.8 (95% CI: 
1.63-1.99) in 2008 and ti 
56.9% in 2012 , OR 1.69 
(95% CI: 1.53-1.88)  
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CRM-13 
in 2011 
Western Pacific 
Mackenzie 
2007 (78) 
Australia Unimmunised children 
and adults living in 
three remote Australian 
villages 
CRM-7 3 +1 dose schedule at 2, 
4 , 6 months with booster 
dose of PPSV-23 at 23 
months of age, since 
2001 with catch up for 
children up to 23 months 
of age 
12 and 30 
months after 
vaccine 
introduction 
No change at 12 and 30 
months after vaccine 
introduction. 
 
No change at 12 and 30 
months after vaccine 
introduction 
Africa 
Hammit 
2014 (76) 
Kenya Household data PHiD-
CV10
3
 
3 + 0 schedule at 6, 10 
and 14 weeks, also all 
infants catch up, 3 doses 
at least 4 weeks apart 
 Additionally, catch up 
campaign for children 
aged 12-59 months, at 
least 2 doses of vaccine 
2 Decrease in children <5 
years from 34% to 13%. 
Prevalence ratio 0.36 ( 
95% CI, 0.26-0.51) and 
inn individuals > 5 years   
prevalence ratio 0.34 
(0.18-0.62) 
Increased in children < 5 
years from 41% to 57%, 
adjusted prevalence ratio 
1.37 (1.13 to 1.65). 
And among individuals >5 
years NVT were unchanged 
1.13 (0.92 to 1.38) 
Kim 2014 
(77) 
Kenya Children <5 years  PHiD-
CV10 
3+0 schedule at 6, 10 and 
14 weeks of age, 
introduced 2011 with no 
catch-up  
3 
(2009 vs 
2012) 
Among all children  
decrease from 38% in 
2009 to 17% in 2012 
(p<0.001) 
In infants <12 months 
declined by 57%, 
p<0.001 
In children 1to4 years 
old 59% decrease, 
p<0.001 
Also in unvaccinated 
children 1to4years 61% 
decrease, p<0.0001 
Not reported 
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1
PCV7 serotypes 4, 6B, 9V, 14, 18C, 19F and 23F conjugated to diphtheria carrier protein 
2
PCV13, serotypes, 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) which are conjugated to diphtheria carrier protein, 
3
PHiD-CV10 serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F, conjugated to Haemophilus Influenzae protein D. 
 
 
 23 
 
With the exception of the Australian study in a remote region where at 30 months there was 
no change in neither vaccine serotype nor non-vaccine serotype colonization in unimmunised 
children and adults (78) the studies in Table 1.3 above demonstrate varying degrees in 
vaccine and non-vaccine serotype change relative to childhood PCV immunization.  Whilst 
the published studies are informative from a diversity of settings, very few of these studies 
were undertaken at a community-wide level and across a spectrum of age-groups. 
Furthermore, none of the studies were undertaken in a setting with a high prevalence of HIV-
infection.  
In this thesis temporal changes in pneumococcal colonization, following infant PCV-
immunization introduction in South Africa, are described in relation to age-group and HIV 
infections status Chapters 3 and 4.  
 
1.5 Bacterial interactions in the nasopharynx                      
 
Besides S. pneumoniae, the nasopharynx is an ecological niche for other organisms, including 
Haemophilus influenzae and Staphylococcus aureus (22). Changes in pneumococcal 
colonization induced by PCV immunization could theoretically lead to changes in the 
ecology of the nasopharynx and patterns of colonization and disease by other colonizing 
bacteria. Prior to PCV introduction, an inverse associations was shown observed between S. 
pneumoniae and S. aureus colonization  in HIV-uninfected children (65, 93-96) but not in 
HIV-infected children (65, 97). In some studies, this association was strongest for PCV7 
serotypes (94), whereas no such associations were observed by others (98). The negative 
association  between S. aureus and S. pneumoniae colonization (93, 94) is thought to be due 
to inhibition of S. aureus by hydrogen peroxide produced by the pneumococcus (93, 99). 
Failure of the adaptive immunity to develop in HIV-infected children has also been proposed 
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as impacting on this relationship and this is supported by data from studies in HIV-infected 
children which failed to show a negative relationship between S. pneumoniae and S. aureus 
(65, 97).  
 
Conversely, a synergistic association has been observed between H. influenzae and S. 
pneumoniae nasopharyngeal colonization in HIV-uninfected children, (65, 100). This 
synergistic association between H. influenzae and S. pneumoniae also extends to 
nasopharyngeal densities, that is, a high density of H. influenzae is associated with high 
density of S. pneumoniae and similarly, a low density of H. influenzae is associated with a 
low density of S. pneumoniae (96). This equilibrium is, however, disrupted in disease and a 
negative association between H. influenzae and S. pneumoniae has been described in children 
with upper respiratory tract infection (101).  
 
There are limited data on bacterial interactions in adults, among whom prior to the PCV-era 
no association was observed between these bacteria in HIV-uninfected or HIV-infected 
individuals (102-105), An increase in the prevalence of S. aureus colonization has been 
documented  following PCV introduction in some settings among vaccinated children and 
their parents (82, 103). However, this has not been consistently observed (65, 95, 106, 107). 
Bacterial associations in the nasopharynx may be strain/serotype specific (93), for example 
following PCV immunization there was a concomitant increase in non-vaccine serotype and 
H. influenzae colonization in the Netherlands among vaccinated children and their parents at 
11 and 24 months after PCV7 vaccination (108). This is despite a decrease in pneumococcal 
vaccine serotype colonization observed during the same period. 
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There has been no published report on the association of childhood PCV-immunization on 
the nasopharygeal bacterial ecology either at a community level, or specifically in settings 
with a high prevalence of HIV-infection or in HIV-infected individuals. In Chapter, 5 of this 
thesis we describe the temporal association of infant PCV immunization on nasopharyngeal 
ecology of S. pneumoniae, S.aureus and H. influenzae by age-group in a setting with a high 
prevalence of HIV infection among adults.  
 
1.6   Effect of PCV on invasive pneumococcal disease (IPD)              
 
Surveillance data for IPD in the USA indicates that between 1998/99 and 2003 there was a 
75% decline in IPD caused by all serotypes and  a 94% decrease in IPD  PCV7-disease  in the  
general population (10). This reduction  was greatest in children less than two years of age. In 
addition, a notable reduction in IPD was evident among those older than 5 years, and 
particularly among the elderly (>65 years age), supporting an indirect effect of childhood 
PCV-vaccination (10, 11, 73, 109-111). In South Africa, the greatest burden of IPD among 
adults is in HIV-infected adults aged 18-45 years (112). While increased anti-retroviral 
therapy (ART) management showed a clear decrease in IPD among children (113), no change 
was observed among adults in the same period. Demonstration of an indirect protection 
among adults could provide an additional public-health benefit of infant PCV immunization 
in a setting of high HIV prevalence such as ours.  
 
The observed decrease in IPD in  USA was offset by a concomitant increase in non-vaccine 
serotype disease (10). Although non-vaccine serotypes are less commonly associated with 
disease, these serotypes may acquire virulence factors associated with increased invasive 
potential. Also, non-vaccine serotype replacement disease may be of particular concern 
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among immunocompromised individuals, such as those with HIV. In the USA, the incidence 
of IPD due to non-PCV7 serotypes, in particular 19A, increased by 58% among those aged 
less than 2 years and by 135% in those  2 to 4 years of age, within three years of PCV7 
introduction (114, 115). An increase in disease due to non-vaccines serotypes 19A and 7F 
was also described following PCV introduction in Portugal,even though  there was  only 43% 
vaccine  coverage in children at the time (116). Increase in non-vaccine serotype IPD may, 
however, also be independent of PCV-immunization and solely due to natural temporal 
fluctuations (117-120). One such example was from South Korea where the increase in 
serotype 19A IPD  occurred prior to PCV immunization,(117) but concurrently with the 
increase which was being observed in countries where PCV had been introduced (114, 115, 
121).  
    
1.7 Use of IPD or colonization in surveillance                        
 
IPD surveillance may be challenging for countries with poor infrastructure and limited 
resources. Since pneumococcal nasopharyngeal colonization is a precursor for pneumococcal 
disease, the impact of PCV immunization against IPD may be imputable by undertaking 
ecological pre- and PCV-era studies on the changes in serotype-specific colonization (122).  
Since studies on nasopharyngeal colonization are fairly easy to undertake, requiring much 
less infrastructure compared to IPD surveillance, it could be a useful tool to evaluate vaccine 
effectiveness against IPD in low-middle income countries.  Evaluating the effect of new 
formulations of PCV against pneumococcal colonization  is also advocated as an additional  
measure for vaccine licensure as well as post vaccine introduction surveillance (123). An 
improved understanding of the link between colonization and IPD is, however, required to 
help use changes in colonization as a proxy for PCV effect against IPD (124). 
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Theoretically, this could be achieved by incorporating the invasive potential, i.e. measure of 
expected IPD for a given  prevalence of colonization in health and disease by individual 
serotypes (122). Imprecise estimates of IPD post-vaccine introduction were, however, 
obtained when using individual serotype data, compared to a  simplified model that grouped 
PCV-serotypes and non-vaccine serotypes (122). This model was applied to six populations, 
rural Alaska, urban Alaska, England, Massachusetts, the Netherland and the Navajo. With the 
exception of England, the model correctly predicted  within 95% confidence interval the 
measured incidence of  IPD post-PCV introduction (122).  
 
There is limited data from low to middle-income countries to support the use of colonization 
data as a proxy of the direct and indirect effectiveness of PCV against IPD. Furthermore, the 
high HIV prevalence and other concurrent interventions targeted against HIV, which may 
also impact on incidence of IPD, adds a further complexity in using temporal changes in 
PCV-serotype colonization to estimate vaccine effectiveness against IPD (122). In this thesis 
we aim to address this by describing concurrent changes in IPD and NP colonization in 
mother-infant pairs stratified by HIV-status in Chapter 6.  
 
1.8 Study aims and objectives 
 
This study evaluated the effects of the introduction of PCV into the childhood immunization 
program in South Africa on pneumococcal colonization in urban and rural communities with 
a high prevalence of HIV-infection. Furthermore, we explored the association of temporal 
changes in vaccine and non-vaccine serotype colonization and IPD in an urban black-African 
community.  
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The specific objectives of the study included:  
i) To determine the effect of infant PCV-immunization on the epidemiology of 
nasopharyngeal colonization in different age groups in a rural African community with high 
prevalence of HIV-infection; 
ii) To evaluate the effect of routine infant PCV immunization following transitioning from 
PCV7 in 2011 to PCV13 in 2013, on the prevalence of vaccine serotype and non-PCV13 
serotype colonization in HIV-infected and HIV-uninfected mother-child pairs in South Africa 
at a community level;  
iii) To determine the effect of infant PCV7 immunization on the prevalence of 
nasopharyngeal colonization and interaction between S. pneumoniae, S. aureus and H. 
influenzae among children and older individuals in a rural South African community with a 
high prevalence of HIV-infection;  
iv) To analyse the direct and indirect effectiveness of infant PCV immunization on invasive 
pneumococcal disease by HIV-status in Soweto, South Africa;  
v) To evaluate the fitness of a proposed model by Weinberger et al. for predicting the 
changes in IPD from serial colonization studies compared to that observed for vaccine 
serotype and non-vaccine serotype IPD.  
 
The reporting format in this thesis includes: 
i. In chapter 3 we describe the effect of introduction of PCV by age-group on 
nasopharyngeal colonization of S. pneumoniae in a rural community with high 
HIV prevalence.   
ii. In chapter 4, we explore the temporal association of infant PCV immunization on the 
dynamics of pneumococcal colonization in mother-child pairs, and also elucidate 
the effect of HIV on the transmission.  
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iii. In chapter 5, we detail the association of PCV vaccination on colonization 
prevalence by S. aureus and H. influenzae, and whether these interactions differed 
in the pre-PCV compared to the PCV-era.  
iv. In chapter 6 we report on the effect of infant PCV vaccination on trends of IPD in 
children and adults, stratified by HIV-status, in an urban black-African setting.  
Furthermore, we analyzed how changes in PCV-serotype and non-vaccine 
serotype colonization compared to changes in incidence of IPD in the same 
population as well as the robustness of the model proposed by Weinberger et al. in 
our setting. 
 
 
Finally, the results are summarized in chapter 7, and future research work is described. 
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Chapter 2           Methods 
2.1 Study design 
 
The different data sources contributing to the individual study objectives are summarized in 
table 2.1. 
 
 
Table 2.1: Summary of different data collection points and papers in which data is 
reported  
Study site                                                Year Paper 
 2005-2008 2009 2010 2011 2012  
 
 Pre-PCV era PCV7 
introduced 
PCV7-ear PCV-7 
replaced by 
PCV13 
 
 
PCV13-
era 
 
Agincourt  Cross-
sectional 
survey 1: 
Agincourt 
(household 
study) 
 Cross-
sectional 
survey 2: 
Agincourt 
(household 
study) 
 Paper 1 and 2 
Soweto Longitudinal 
carriage 
survey 
among 
mother 
infant pairs 
 Cross-
sectional 
survey 1: 
Soweto 
(mother-
infant 
pairs) 
 Cross-
sectional 
survey 2: 
Soweto 
(mother-
infant 
pairs) 
Paper 3 and 
Paper 4 
Soweto  
Pre-vaccine 
IPD data 
 
IPD data 
 
IPD data 
 
IPD data 
 
IPD data 
 
Paper 4 
 
 
 
 
 
2.2 Study population  
The series of studies were undertaken in two study populations, including a rural community 
in Mpumalanga Province and an urban population in Soweto, Gauteng Province, South 
Africa. The characteristics of these two populations are detailed below. 
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   2.2.1 Agincourt, Mpumalanga, South Africa                   
 
The Agincourt sub-district in Mpumalanga Province, South Africa, has a population of 
approximately 84,000 people in 14,000 households and 26 villages. It covers an approximate 
area of 402 km² in rural northeast South Africa, close to the Mozambique border and a third 
of the population consists of immigrants of Mozambican descent. The Agincourt sub-district 
is one of two socio-demographic surveillance sites in South Africa and has been under 
constant surveillance by the MRC/Wits Rural Public Health and Health Transitions Research 
Unit since 1992 (125).  
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Figure 2.1: Map of Agincourt subdistrict 
 
Despite improvement in electricity and water supply the area has poor infrastructure. It offers 
limited local employment and subsistence farming opportunities. Consequently, most adults 
seek work in industrial, mining or agricultural centers away from home, with 60% of men 
30–54 years age, and 25% of women age 25–49 years being migrant labourers. A health 
center with five satellite clinics services the health care needs of the community. The health 
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center refers complicated cases for further management to one of three district hospitals that 
are 25 to 60 kilometres from Agincourt. Demographic transitions have included sustained 
decrease in fertility since the mid-1970s, which has steadied at near replacement level with 
little recent change in population size. Decreases in mortality rates were ongoing until the 
mid-1990s, following which it increased due to the HIV/AIDS epidemic, with major reversal 
in mortality in young adults and children under-5 years age. By 2005, life expectancy at birth 
had fallen by 12 years for women and by 14 years for men (125). In 2009, females were 
expected to live to 64.4 years while males had a lower life expectancy of 55.7years (126). 
 
2.2.2               Soweto, Johannesburg, South Africa 
 
Soweto is the most populous black township in Johannesburg with an approximate population 
of 1.4 million and a birth cohort of 28 000 per year (127). The community under surveillance 
is a low-income, urbanized black-African community of various tribal ethnicities. The 
prevalence of HIV infection in among adults in Gauteng Province (in which Soweto is based) 
was 16% in 2005 and 30% in pregnant women attending antenatal clinics in Soweto since 
2005 (ANOVA-unpublished data). These prevalences have remained largely unchanged by 
2013 (ANOVA-unpublished data). The vertical mother-to-child transmission (MTCT) rate of 
HIV has, however, declined from 8-12% in 2007 to <2% by 2010 due to more aggressive 
antiretroviral therapy (ART) regimens targeted at pregnant women and aimed at preventing 
vertical HIV transmission (128). HIV-infected adults and children are provided with free 
ART through established HIV clinics in Soweto, including at CHBAH. This includes triple 
ART for all HIV-infected pregnant women irrespective of their CD4+ counts, with a 
coverage rate of approximately 75%. HIV testing of infants born to HIV-infected mothers is 
undertaken through the established MTCT program at 6 weeks of age. HIV testing is also 
undertaken in the majority of children hospitalized in the general wards at Chris Hani 
 34 
 
Baragwanath Academic hospital, the only public facility hospital serving the community of 
Soweto at the time of this study. 
 
Children admitted at CHBAH are provided free state-funded health care, including costs 
related to laboratory investigations and clinical management. Similarly, adults are expected to 
pay a nominal administrative fee which is inclusive of all hospital costs. Patients admitted 
with suspected sepsis and pneumonia have blood cultures undertaken as part of standard of 
care, and similarly lumbar punctures for cerebrospinal fluid microbiologic evaluation are 
undertaken in those suspected to have meningitis. CHBAH has been a sentinel surveillance 
site for IPD surveillance undertaken by the National Institute for Communicable Diseases 
(NICD) since 1999, and the only site able to provide serial measurement of incidence of 
PCV-serotype and non-vaccine serotype IPD stratified by HIV status. It is therefore possible 
to correlate colonization data with IPD data for this population. 
 
2.3 PCV introduction in South Africa 
 
South Africa introduced PCV7 (Prevnar™, Pfizer, New York, US) into the national, public- 
funded childhood immunization program from April 2009. The vaccine is administered in a 
two-dose primary series at ages 6 and 14 weeks, followed by a third dose at age 9 months. No 
catch up campaign of any child older than 6 weeks of age, at the time of initiation of the 
PCV-immunization program, was offered during the course of this study, if they had already 
received any other childhood-vaccine recommended from 6 weeks of age onward. Since May 
2011, PCV7 has replaced by a 13-valent PCV (PCV13; Prevenar-13 ™, Pfizer, Pearl River, 
New York, NY, USA), which was coupled to a limited catch-up campaign targeting children 
up to 3 years of age, and high risk-groups (including HIV-infected children) up to 6 years of 
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age. The immunization coverage for three doses of PCV in Gauteng was reportedly 12.3% in 
2009, 86.3% in 2010 and  99% in 2011 and 2012 (19, 129).  
2.4      Determination of bacterial colonization 
 
Carriage of pneumococcus is more common in the winter months (32). We undertook serial 
cross sectional surveys in the winter months (May to September) each year to account for nay 
seasonal variation.  Sampling of the pharynx was undertaken by trained medical study staff at 
the households. Nasopharyngeal swabs were performed   using an aluminium shafted, Dacron 
swab (MW and E, Medical Wire and Equipment Co. Ltd., Corsham, Wiltshire, England) as 
described (130). Additionally, an oropharyngeal swab was collected in adults. Specimens 
were placed in skimmed milk, tryptose, glycerol and glucose (STGG) broth transport media, 
transported in a cooler box and then stored at -70°C within 6-hours of sampling. Samples 
were shipped intermittently to the Centre for Respiratory Diseases and Meningitis (CRDM) 
laboratory at the National Institute for Communicable Diseases (NICD) in Johannesburg on 
dry ice and stored at -70°C until processed by routine microbiological methodologies. 
Serotyping was undertaken by the Quellung method using serogroup and factor-specific 
antisera (Statens Serum Institute, Copenhagen, Denmark). Presumptive pneumococcal 
isolates which did not exhibit the Quellung reaction with serogroup-specific, factor-specific 
and all-pooled anti-sera were categorized as non-typeable once pneumococcal identification 
was confirmed with lytA PCR.(131) Where >1 distinct morphological colony type was 
present, each colony was serotyped. Serotypes 6A, 6B, 6C and 6D were distinguished only 
using the relevant antisera and without any additional molecular typing. 
 
2.5                                     Ethical issues  
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The colonization studies study protocols were approved by the University of Witwatersrand, 
Human Research Ethics Committee (Medical), Ethics numbers M090015 and M090114. 
Additionally, specific ethics approval for this PhD was also obtained (Reference: M110530).  
 
 
2.6                                 Informed consent 
 
Informed consent was obtained for all adults; and a parent/legal guardian/primary care-giver 
of a child signed consent on behalf of children less than 18 years of age. Also, verbal assent 
was obtained from children older than 8 years of age.  
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Chapter 3: Temporal changes in pneumococcal colonization in a rural 
African community with high HIV-prevalence following routine infant 
pneumococcal immunization 
 
3.1                                               Introduction 
 
Colonization of the nasopharynx by S. pneumoniae, though usually asymptomatic, may be 
associated with pneumococcal disease particularly within the first two months of acquisition 
of new pathogenic serotypes (21). At the time of illness, the same serotype colonizing the 
nasopharynx is identifiable from diseased sites (21, 29). 
 
Immunization of children with PCV, decreases their risk of acquisition of vaccine serotypes, 
particularly serotypes traditionally associated with a high prevalence of asymptomatic NP 
colonization during childhood; i.e. 6A, 6B, 9V, 19A, 19F and 23F (21, 32, 33). Routine 
PCV7 childhood immunization in industrialized settings has been associated with reduced 
NP-acquisition of the vaccine serotypes among vaccinated children, which in-turn has 
resulted in reduced transmission of these serotypes to unvaccinated individuals (8, 9). 
Consequently, reductions in incidence of vaccine serotype IPD among vaccinated and 
unvaccinated individuals have been observed in settings with low prevalence of HIV 
infection (10-12). A decline in vaccine serotype IPD has also been observed among PCV-
unvaccinated HIV-infected adults following childhood PCV7 immunization in USA,(14, 15) 
which has partly been offset by an increase in non-vaccine serotype IPD of greater magnitude 
compared to the general population of  adults (14, 15).  
 
In Africa, a study from The Gambia  reported significant decline in vaccine serotype 
colonization among unvaccinated adolescents and adults following childhood PCV7 
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immunization, which included a targeted catch-up campaign of children aged up to three 
years (80). This study finding may have been confounded by the prolonged time period (3 
years) between when the pre-vaccination survey was undertaken relative to when PCV 
immunization was initiated. Also, the possibility of natural temporal fluctuations of 
circulating pneumococcal serotypes may have contributed to differences in serotype-specific 
pneumococcal colonization, including the lower prevalence of non-vaccine serotype 
colonization, following childhood immunization with PCV (80).  
 
In this study we aimed to determine the effect of infant PCV immunization on the 
epidemiology of nasopharyngeal colonization in different age-groups in a rural African 
community with high prevalence of HIV-infection. 
 
3.2                        Methods 
3.2.1 Study setting and study population 
Two cross-sectional studies, spaced two years apart were undertaken in a rural setting which 
is a health and socio-demographic surveillance site (HDSS), in the Agincourt sub-district in 
Mpumalanga province, northeast South Africa. Details of the Agincourt HDSS have been 
described in Chapter 2. Details of the surveyed population are summarized in Table 3.1.  
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Table 3.1: Characteristics of households and individuals enrolled into the study and 
population characteristics for Agincourt 
 
Characteristic 
 
Period-1 (N=577) 
 
Period-2 (N= 1079) 
 
p value 
 
   Household structure 
Children ≤ 5years (mean ± SD) 1.83 ± 1.0 1.96 ± (1.1) 0.02 
Individuals 6 - 18years (mean ± SD) 2.4 ± 1.8 2.2 ± 1.7 0.03 
Individuals >18 years (mean ± SD)  4.5 ± 2.4 4.7 ± 2.6 0.13 
Individuals in household, (mean ± SD) 8.73 ± 4.1 8.8 ± 4.2 0.74 
Child in house that attends daycare, n/N (%) 164/572 (28.7%) 325/982 (33.1%) 0.07 
Number of rooms used for sleeping, (mean ± SD) 3.15 ± 1.5 3.2 ± 1.7 0.56 
   Fuel used for cooking 
Coal/Wood (%) 394 (68.3) 685 (63.5) 0.11 
Paraffin/Gas (%) 11 (1.9) 17 (1.6) 0.64 
Electricity (%) 168 (29.3) 365 (34.2) 0.03 
   Participants age > 12years 
No of participants 994 1781  
Female 815 (82.1) 1538 (86.3) <0.001 
Mean age ± SD 34.01 ± 16.5 33.4 ± 16.3 0.35 
HIV-infected (self-reporting) 40/505 (7.9) 135/1320 (10.2) 0.11 
   Participants age, ≤ 12 years 
No of participants 1016 1877  
Female 515 (50.7) 964 (51.4) 0.73 
Mean age ± SD 4.32 ± 3.4 3.80 ± 3.4 <.001 
HIV-infected (self-reported) 5/165 (3.0) 20/631 (3.1) 0.93 
 Population characteristics
1
    
Total population 87359 90036  
Percentage <5 years 12.3 11.9  
Percentage < 15 years  22.2 21.8  
Percentage  ≥ 65 years  4.7 4.6  
Life expectancy at birth (females) –years 62 662  
Life expectancy at birth (males)-years 54 56
2
  
Infant mortality rate per 1000 live births 33 35  
Under-5 mortality per 1000 live births (females) 57 41  
HIV prevalence among adults (19-46) Not available 37.4%
3
  
Total number of households 15455 16091  
Mean household size 5.64 5.59  
Percentage using coal/woof for cooking  56.2% 47.2%  
Vaccine coverage in children DPT3 72% Not available  
Vaccine coverage measles 1 (age at PCV3 
vaccination 
85% Not available  
Those characteristics which could have influenced the prevalence of pneumococcal NP-
colonization and which differed between the two sampling periods at a significance level of  
                                                 
1
 Population characteristics calculated as of 1
st
 May 2009 for Period 1 and 1
st
 of May 2011 for Period 2 based 
on data from the Agincourt Health and Demographic Surveillance System (AHDSSS) database. 
2
 Life expectancy for Period 2 based on data for 2010, the most recent complete years data. 
3
 Ref (Gomez-Olive et al, 2012 based on data from an HIV sentinel survey carried out in the Agincourt area in 
2011) 
 40 
 
p-value <0.1 were adjusted when estimating the relative risk of pneumococcal carriage  in 
Period 1 and Period 2. 
 
3.2.2                            Study sampling framework and procedure 
 
The initial survey (Period 1) was undertaken from May to October 2009, i.e. immediately 
upon introduction of PCV into the immunization program. A subsequent (Period 2) survey 
was undertaken between May to October 2011. Based on the annual census update of the 27 
villages in the HDSS, children <2 years of age were identified and linked to their parent 
household for potential study participation in each village. Villages were then randomly 
selected for order of sampling, with the number of villages approached continuing until the 
target sample size was achieved. A household was included if in addition to the listed child 
there was at least one individual older than 12 years who agreed to participate in the study. 
The Agincourt HDSS definition for a household, also used in this study, was “a group of 
people who resided and ate together including temporary migrants, (i.e. a household member 
who is away for more than 6 months per year but retains a significant link to the rural/sending 
household) who ate with them on return”. Meetings were held with community members, 
traditional and civic leaders to explain the study. A questionnaire was administered at the 
time of swab collection. No HIV testing was performed but self-reported HIV infection status 
was collected.   
 
3.2.3     Sample size calculation 
 
Since there were no prior data on the prevalence of pneumococcal NP-colonization in this 
setting, the estimated prevalence of vaccine serotype colonization among adults in 2009 was 
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based on data from Navajo Indian populations (4%) (73) and an African population in 
Malawi (132) in the absence of PCV immunization. Vaccine serotype colonization in South 
African adults was expected to be greater than in Navajo Indians, since a higher prevalence of 
colonization had been reported among HIV-infected Malawian women (11.4% vs. 5.9% in 
HIV-uninfected women) (132). We postulated that the prevalence of vaccine serotype 
colonization would be 10% among adults in 2009. We calculated the need to enrol 611 adults 
in each survey-period to detect at least a 45% reduction in PCV7 serotype colonization 
between Period 1 and Period 2 with 80% power. Based on the actual observed prevalence of 
PCV7 serotype colonization among adults in Period 1 (3.0%), we recalculated the sample 
size for Period 2 and targeted enrolling at least 1783 adults to provide 80% power to detect a 
50% reduction in PCV7 vaccine serotype colonization compared to Period 1.  
 
3.2.4      Determination of bacterial colonization 
 
Sampling procedures and sample processing as described in section 2.4. 
 
3.2.5                   Definitions and statistical analysis 
 
For all statistical analysis, individuals older than 12 years were categorized as 
adolescents/adults and those ≤12 years as children. Multiple, simultaneous serotype 
colonization in the same individual were considered as independent events when measuring 
the prevalence of colonization if they differed in stratification into PCV7 serotype (4, 6B, 9V, 
14, 18C, 19F and 23F), non PCV7 serotype or being non-typeable. Non PCV7 serotypes refer 
to any other pneumococcal serotypes (including serotype 6A) and excluded non-typeable 
isolates. Comparison of the prevalence of pneumococcal NP colonization and serotype 
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distribution between the two periods were performed using chi-squared or Fisher’s exact tests 
where appropriate.  Log binomial regression models were used to estimate the risk ratios for 
pneumococcal carriage in Period 1 versus Period 2, adjusting for potential risk factors for 
colonization including age, gender, fuel used for cooking in the household, presence of a 
child attending day care in the household and household structure, i.e. the presence of any 
child below 5 years and any individual between 6 and 18 years of age in the household. In 
addition, generalized linear mixed models were developed to adjust for potential correlation 
among subjects from the same household plus all the other risk factors used in the log 
binominal regression models. Statistical analyses were performed with STATA 12 (Statacorp, 
Texas, USA) and SAS version 9.2 software (SAS Institute, Inc., NC, USA). 
 
3.3                                   Results 
 
A total of 577 and 1079 households were recruited in Period 1 and Period 2, respectively. 
This included 994 and 1781 adults/adolescents and 1016 and 1877 children, in the two 
respective periods. Characteristics of the sampled households are summarized in Table 3.1. 
Differences between households in the two periods included a higher proportion who used 
electricity for cooking in Period-2 (34.2% vs. 29.3%; p=0.032); higher mean number of 
children <5 years of age within households in Period 2 and consequently an older mean age 
of children enrolled in Period 1(Table 3.1).  
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3.3.1 Temporal changes in prevalence of pneumococcal colonization 
 
In Period 1, 83.0% of children <2 years of age were colonized, including 28 who carried two 
serotypes, resulting in a total of 359 pneumococcal isolates (Table 3.2). The prevalence of 
PCV7 serotype colonization was 45.1% in children age <2 years in Period 1 (Table 3.2). In        
2 to 5 year old children, overall colonization was 80.2%, including 17 children who were 
colonized by two serotypes which resulted in 236 isolates. The prevalence of PCV7 serotype 
and non PCV7 serotype colonization in the 2 to 5 year age-group was 35.5% and 45.8%, 
respectively in Period 1, (Table 3.2).  
Among 6 to 12 year-old children, 60.0% were colonized, including 13 with two serotypes, 
resulting in 199 pneumococcal isolates identified. The prevalence of PCV7 serotype was 
19.0% among the 6 to 12 year age group, which was lower than in the <2 year age-group (p 
<0.0001), while non PCV7 serotype colonization prevalence (42.6%) was similar to that in 
the youngest age group (p=0.32; Table 3.2. Overall, the prevalence of colonization in 
adolescents and adults was 22.8%, 10.7% and 5.1% among the 13-18 years, 19 to 45 years 
and >45 year age groups, respectively; Table 3.2. Additionally, the prevalence of PCV7 
serotype colonization was 5.7%, 3.0% and 1.7% in the respective above specified adolescent 
and adult age groups; Table 3.2. Females who were primary caregivers to the children, had 
similar overall prevalence of pneumococcal colonization (compared to other 
adolescents/adults (10.2% [49/478] vs. 8.4% [19/225; p=0.45) but higher prevalence for 
PCV7 serotypes (3.8% [18/478] vs. 1.3% [3/225]; p=0.06) in Period 1. 
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 Table 3.2 Comparison of prevalence of all pneumococci, PCV7 serotype, non PCV7 serotype and non-typeable serotypes by age and 
gender in Period 1 (2009) and Period 2 (2011). 
 Total per group Overall prevalence colonisation PCV7 serotypes
3
 (VT) Non PCV7 serotypes  Non-typeable serotypes 
  N
1
  n (%)   n (%)   n (%)     
Age group Period 1 Period 2 Period 1 Period 2 p-value Period 1 Period 2 p-value Period 1 Period 2 p-value Period 1 Period 2 p-value 
<2years               
Female 196 456 161(82.1) 336(73.7) 0.02 84(42.9) 111(24.3) <0.0001 76(38.8) 223(48.9) 0.02 7(3.6) 14(3.1) 0.74 
Male 203 452 170(83.7) 330(73.5) 0.003 96(47.3) 102(22.6) <0.0001 79(38.9) 233(51.6) 0.003 5(2.5) 8(1.8) 0.55 
Total (%) 399(19.9) 908(24.8) 331(83.0) 666(73.4) 0.0002 180(45.1) 213(23.5) <0.0001 155(38.9) 456(50.2) 0.0001 12(3.0) 22(2.4) 0.54 
ARR
2
   0.89(0.84,0.94) 0.50(0.42,0.59) 1.35(1.17,1.56) 0.81(0.38,1.72) 
2-5years               
Female 142 209 111(78.2) 147(70.3) 0.10 43(30.3) 55(26.3) 0.42 69(48.6) 92(44.0) 0.40 1(0.7) 2(1.0) - 
Male 131 213 108(82.4) 160(75.1) 0.11 54(41.2) 66(31.0) 0.05 56(42.8) 95(44.6) 0.74 5(3.8) 6(2.8) 0.61 
Total (%) 273(13.6) 422(11.5) 219(80.2) 307(72.8) 0.02 97(35.5) 121(28.7) 0.06 125(45.8) 187(44.3) 0.70 6(2.2) 8(1.9) 0.78 
ARR
2
   0.96(0.88,1.04) 0.79(0.63,0.99) 0.99(0.84,1.18) 0.83(0.29,2.34) 
6-12years               
Female 156 266 95(60.9) 133(50.0) 0.03 31(19.9) 32(12.0) 0.03 65(41.7) 102(38.4) 0.50 2(1.3) 1(0.4) - 
Male 154 218 91(59.1) 109(50.0) 0.08 28(18.2) 29(13.3) 0.20 67(43.5) 80(36.7) 0.19 0(0.0) 3(1.4) - 
Total (%) 310(15.4) 484(13.2) 186(60.0) 242(50.0) 0.006 59(19.0) 61(12.6) 0.01 132(42.6) 182(37.6) 0.16 2(0.7) 4(0.8) 0.77
4
 
ARR
2
   0.83(0.74,0.95) 0.66(0.48,0.92) 0.87(0.73,1.04) 1.40(0.26,7.66) 
13-18years               
Female 92 170 20(21.7) 19(11.2) 0.02 5(5.4) 3(1.8) 0.08
4
 15(16.3) 15(8.8) 0.07 0(0.0) 1(0.6) - 
Male 66 115 16(24.2) 16(13.9) 0.08 4(6.1) 3(2.6) 0.25
4
 13(19.7) 13(11.3) 0.12 0(0.0) 0(0.0) - 
Total (%) 158(7.9) 285(7.8) 36(22.8) 35(12.3) 0.004 9(5.7) 6(2.1) 0.05 28(17.7) 28(9.8) 0.02 0(0.0) 1(0.3) - 
ARR
2
   0.54(0.35,0.81) 0.49(0.17,1.39) 0.55(0.34,0.89) - 
19-45years               
Female 541 1069 63(11.7) 61(5.7) <0.0001 18(3.3) 11(1.0) 0.001 47(8.7) 46(4.3) 0.0004 1(0.2) 7(0.7) - 
Male 92 119 5(5.4) 8(6.7) 0.70 1(1.1) 2(1.7) - 4(4.4) 6(5.0) 0.25
4
 0(0.0) 0(0.0) - 
Total (%) 633(31.5) 1188(32.5) 68(10.7) 69(5.8) 0.0001 19(3.0) 13(1.1) 0.003 51(8.1) 52(4.4) 0.001 1(0.2) 7(0.6) - 
ARR
2
   0.48(0.34,0.67) 0.36(0.18,0.74) 0.46(0.31,0.68) - 
>45years               
Female 195 324 12(6.2) 20(6.2) 0.99 4(2.1) 3(0.9) 0.17
4
 8(4.1) 15(4.6) 0.78 0(0.0) 3(0.9) - 
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Male 42 48 0(0.0) 2(4.2) - 0(0.0) 1(2.1) - 0(0.0) 1(2.1) - 0(0.0) 0(0.0) - 
Total (%) 237(11.8) 372(10.2) 12(5.1) 22(5.9) 0.66 4(1.7) 4(1.1) 0.52
4
 8(3.4) 16(4.3) 0.57 0(0.0) 3(0.8) - 
ARR
2
   1.15(0.55,2.38) 0.63(0.16,2.49) 1.15(0.48,2.72) - 
OVERALL               
Female 1322(65.8) 2494(68.2) 462(35.0) 716(28.7) <0.0001 185(14.0) 215(8.6) <0.0001 280(21.2) 493(19.8) 0.30 11(0.8) 28(1.1) 0.40 
Male 688(34.2) 1165(31.8) 390(56.7) 625(53.7) 0.20 183(26.6) 203(17.4) <0.0001 219(31.8) 428(36.7) 0.03 10(1.5) 17(1.5) 0.99 
Total (%) 2010(100) 3659(100) 852(42.4) 1341(36.7) <0.0001 368(18.3) 418(11.4) <0.0001 499(24.8) 921(25.2) 0.77 21(1.0) 45(1.2) 0.53 
ARR
2
   0.87(0.83,0.91) 0.57(0.51,0.65) 1.03(0.95,1.13) 1.18(0.69,2.03) 
NB: In Period-1, 2010 subjects were enrolled of whom 852 were colonized, including 64 among whom two serotypes were identified. In Period-2, 3659 
participants were enrolled, of whom 1341 were colonized, including   91 with two-serotypes.  In cases of simultaneous detection of multiple serotype 
colonization in the same individual, the serotypes were considered as independent events when measuring the prevalence of colonization if they differed in 
stratification by vaccine serotype, non-vaccine serotype or being non-typeable. 
1
Total number of participants in each age group  
2
ARR (adjusted risk ratio), risk ratio adjusted for age, gender, household structure (i.e. presence of a child less than 5 years and presence of child between 6 
and 18 years), any child attending day care and fuel used for cooking in the household.  
3
 PCV7- serotypes 4, 6B, 9V, 14, 18C, 19F and 23F 
4
 Fisher’s exact test was used to compare the two groups
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In Period 2, 666 (73.4%) children <2 years of age were colonized, including 47 in whom two 
serotypes were identified, which resulted in 713 pneumococcal isolates. The overall 
prevalence of pneumococcal colonization was 11.6% lower in Period 2 compared to Period 1 
(p=0.0002) in the <2 year age-group (Table 3.2). This was dominantly due to a 50.0% 
reduction in PCV7 serotype colonization (ARR 0.50, 95%CI): 0.42-0.59), whilst there was a 
35.0% increase in prevalence of non PCV7 serotype colonization by Period 2; p=0.0001. 
Among 2 to 5 year-old children, although there was a 21% reduction in PCV7 serotype 
colonization, the prevalence of overall and non PCV7 serotype colonization remained 
unchanged in Period 2 compared to Period 1; Table 3.2.  
Among older age groups, lower prevalence of PCV7 serotype colonization in Period 2 
compared to Period 1 were evident in children age 6 to12 years (ARR 0.66, 95%CI: 0.48-
0.92), a similar trend was observed in the 13 to 18 year age-group (ARR 0.49, 95%CI: 0.17-
1.39) and significantly lower prevalence was observed in the 19 to45 year age-group (ARR 
0.36, 95%CI: 0.18-0.74). The prevalence of non PCV7 serotype colonization remained 
unchanged comparing Period 2 to Period 1 in the 6 to 12 year age-group, whereas 45.0% and 
54.0% reduction was observed in the 13 to 18 and 19 to 45 year age-groups, respectively; 
Table 3.2. Overall pneumococcal colonization declined by 17%, 46% and 52% among the 
age-groups 6 to 12 years, 13 to 18 years and 19 to 45 years, respectively. The prevalence of 
pneumococcal colonization among the primary caregivers declined to 5.4% (58/1067; p= 
0.001) overall, 0.94% (10/1067; p=<0.001) for PCV7 serotypes but remained unchanged 
among non-caregivers [8.3% (58/696 overall and 2.01% for PCV7 serotypes in Period 2; 
p=0.9 and 0.4 respectively].  
 Limiting the analysis to those villages only sampled during both periods resulted in similar 
findings compared to when analyzing the entire study cohorts, Table 3.3. Generalized linear 
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mixed models adjusting for potential intra-household clustering had no effect on the observed 
results, Table 3.4 
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Table 3.3 Comparison of prevalence of all pneumococci, PCV7 serotype, non PCV7 serotype and non-typeable serotypes by age and 
gender in Period 1 and Period 2 for nine villages sampled in Period 2 that matched those sampled in Period 1. 
 Total per group Overall prevalence colonisation PCV7 serotypes (VT)
4
 Non PCV7 serotypes  Non-typeable serotypes 
  N
1
  n (%)   n (%)   n (%)     
Age group Period 1 Period 2 Period 1 Period 2 p-value Period 1 Period 2 p-value Period 1 Period 2 p-value Period 1 Period 2 p-value 
<2years               
Female 205 261 170(82.9) 206(78.9) 0.28 85(41.5) 70(26.8) <.001 78(38.1) 126(48.3) 0.03 7(3.4) 10(3.8) 0.81 
Male 222 270 188(84.7) 205(75.9) 0.02 99(44.6) 65(24.1) <.0001 84(37.8) 134(49.6) 0.01 5(2.3) 6(2.2) 0.98 
Total (%) 427(20.6) 531(27.4) 358(83.8) 411(77.4) 0.01 184(43.1) 135(25.4) <.0001 162(37.9) 260(49.0) <.001 12(2.8) 16(3.0) 0.85 
ARR
2
   7.7% (1.6 to 13.6%) 41.0% (27.0 to 54.7%) -29.1% (-45.3 to -12.4 %) -7.2% (-84.9 to 76%) 
2-5years               
Female 150 98 119(79.3) 66(67.4) 0.03 43(28.7) 26(26.5) 0.71 75(50.0) 38(38.8) 0.08 1(0.7) 2(2.0) - 
Male 140 109 117(83.6) 82(75.2) 0.10 55(39.3) 37(33.9) 0.39 57(40.7) 45(41.3) 0.93 5(3.6) 0(0.0) - 
Total (%) 290(14.0) 207(10.7) 236(81.4) 148(71.5) 0.01 98(33.8) 63(30.4) 0.43 132(45.5) 83(40.1) 0.23 6(2.1) 2(1.0) 0.34
5 
ARR
2
   12.1% (2.9 to 21.6%) 9.9% (-14.9 to 34.0%) 11.9% (-7.5 to 30.9%) 53.3% (-78.5 to 1.73%) 
6-12years               
Female 161 130 100(62.1) 73(56.2) 0.30 31(19.3) 15(11.5) 0.07 67(41.6) 57(43.9) 0.70 2(1.2) 1(0.8) - 
Male 162 97 99(61.1) 53(54.6) 0.31 28(17.3) 13(13.4) 0.41 71(43.8) 39(40.2) 0.57 0(0.0) 1(1.0) - 
Total (%) 323(15.6) 227(11.7) 199(61.6) 126(55.5) 0.15 59(18.3) 28(12.3) 0.06 138(42.7) 96(42.3) 0.92 2(0.6) 2(0.9) 0.72
5 
ARR
2
   9.9% (-3.6 to 23.4%) 32.5% (-1.7 to 64.6%) 1.0% (-18.6 to 20.4%) - 
13-18years               
Female 92 83 20(21.7) 7(8.4) 0.02 5(5.4) 0(0.0) - 15(16.3) 7(8.4) 0.12 0(0.0) 0(0.0) - 
Male 67 50 17(25.4) 6(12.0) 0.07 4(6.0) 0(0.0) - 13(19.4) 6(12.0) 0.28 0(0.0) 0(0.0) - 
Total (%) 159(7.7) 133(6.9) 37(23.3) 13(9.8) 0.002 9(5.7) 0(0.0) - 28(17.6) 13(9.8) 0.05 0(0.0) 0(0.0) - 
ARR
2
   58.0% (21.2 to 93.2%) - 44.5% (-1.4 to 88.6%)  
19-45years               
Female 546 579 68(12.5) 37(6.4) 0.001 18(3.3) 9(1.6) 0.06 49(9.0) 24(4.2) 0.001 1(0.2) 4(0.7) 0.20 
Male 92 65 5(5.4) 5(7.7) 0.57 1(1.1) 1(1.5) 0.80 4(4.4) 4(6.3) 0.61 0(0.0) 0(0.0) - 
Total (%) 638(30.8)  644(33.2) 73(11.4) 42(6.5) 0.002 19(2.98) 10(1.6) 0.09 53(8.3) 28(4.4) 0.004 1(0.2) 4(0.6) 0.18
5 
ARR
2
   43.0% (15.7 to 70.7%) 47.9% (-8.1 to 107.4%) 47.7% (15.6 to 80.6%) - 
>45years               
Female 195 175 11(5.6) 13(7.4) 0.49 4(2.1) 2(1.1) 0.49 7(3.6) 11(6.3) 0.23 0(0.0) 0(0.0) - 
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Male 42 24 0(0.0) 1(4.2) - 0(0.0) 1(4.2) - 0(0.0) 0 (0.0) - 0(0.0) 0(0.0) - 
Total (%) 237(11.4) 199(10.3) 11(4.6) 14(7.0) 0.28 4(1.7) 3(1.5) 0.88
5 7(3.0) 11(5.5) 0.18 0(0.0) 0 - 
ARR
2
   -51.6% (-156.5 to 44.6 %) 10.7% (-167.8 to 174.0%) -87.2% (-235.1 to 43.6%)  
OVERALL               
Female 1349 1326 488(36.2) 402(30.3) 0.001 187(13.9) 122(9.2) <.001 291(21.6) 263(19.8) 0.27 11(0.8) 17(1.3) 0.24 
Male 725 615 426(58.8) 352(57.2) 0.57 186(25.7) 117(19.0) 0.004 229(31.6) 228(37.1) 0.03 10(1.4) 7(1.1) 0.69
5 
Total (%) 2074(100) 1941(100) 914(44.1) 754(38.9) <.001 373(18.0) 239(12.3) <.0001 520(25.1) 491(25.3) 0.87 21(1.01) 24(1.2) 0.50 
ARR
2
   11.9% (4.9 to 18.7%) 31.5% (19.2 to 43.8%) -0.9% (-11.6 to 9.8%) -22.1% (-90.4 to 43.8%) 
NB Summary of all pneumococci, vaccine type (VT), non-vaccine type (NVT) and non-typeable pneumococcal colonization by age and gender. 
In Period 1, number of subjects N=2010 of which 852 were colonized and 64 had dual carriage, making a total of 2074 with 916 pneumococcal 
isolates.  Period 2, N=1892 of which 705 were colonized and 49 had dual carriage, making a total of 1941 with 754 positive swabs.   
1
Total number of participants swabbed, if double colonization detected swab was counted twice 
2
Total number of pneumococcal isolates detected 
3
ARR (adjusted risk ratio) 
4
PCV7 serotypes, serotypes 4, 6B, 9V, 14, 18C, 19F and 23F  
5means that Fisher’s exact test was used to compare the two groups
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Table 3.4 Comparison of two models, one that assumes that individuals in the same 
household are independent (logistic) and the second that assumes intra-household 
clustering (random effects or generalized linear mixed model). 
Group Dependant Variable Adjusted odds ratios (Period 1 vs. Period 2) ICC 
  Logistic model1 Random effects model  
<2 years Overall colonization 0.58(0.42-0.78) 0.53(0.37-0.77) 0.23 
 VT2 0.35(0.27-0.46) 0.32(0.23-0.44) 0.11 
 NVT3 1.67(1.30-2.14) 1.73(1.32-2.27) 0.08 
     
2-5years Overall colonization 0.66(0.45-0.96) 0.61(0.38-0.96) 0.21 
 VT 0.71(0.51-0.99) 0.68(0.47-0.99) 0.08 
 NVT 0.97(0.71-1.33) 0.98(0.66-1.45) 0.24 
     
6-12years Overall colonization 0.65(0.48-0.88) 0.63(0.44-0.89) 0.13 
 VT 0.60(0.40-0.90) 0.58(0.13-2.65) 0.98 
 NVT 0.79(0.58-1.07) 0.76(0.53-1.10) 0.18 
     
13-18years Overall colonization 0.46(0.27-0.79) 0.46(0.26-0.81) 0.01 
 VT 0.45(0.15-1.30) 0.31(0.13-0.72) 0.02 
 NVT 0.46(0.25-0.83) 0.40(0.18-0.88) 0.23 
     
19-45years Overall colonization 0.45(0.31-0.64) 0.42(0.27-0.64) 0.21 
 VT 0.36(0.17-0.75) 0.23(0.13-0.40) 0.01 
 NVT 0.43(0.28-0.66) 0.35(0.23-0.55) 0.03 
     
>45years Overall colonization 1.11(0.53-2.35) 0.63(0.32-1.24) 0.01 
 VT 0.70(0.17-2.88) 0.31(0.15-0.64) 0.01 
 NVT 1.14(0.46-2.81) 0.40(0.20-0.79) 0.02 
     
Overall Overall colonization 0.68(0.59-0.78) 0.66(0.56-0.78) 0.13 
 VT 0.52(0.44-0.62) 0.46(0.37-0.57) 0.24 
 NVT 1.01(0.88-1.16) 1.02(0.86-1.22) 0.17 
ICC – intra class correlation coefficient 
1
The logistic model gives the same adjusted relative risks given in Table 3.2 (if the log 
binomial is used) – it assumes that subjects from the same household are independent. The 
hierarchical model aka the random effects model or Generalized Linear Mixed Model 
assumes that subjects from the same household are correlated. The model fitted here is Y_ij = 
b_i + Beta0 + Beta1*Period_ij + other factors such as age, gender, day care attendance, 
where b_i ~ N(0, sigma^2). It is the value of sigma that tells us how much clustering is in the 
data. The Intra-Class Correlation (ICC where class is the household) tells us the amount of 
clustering in the data ICC=sigma^2/(sigma^2+(pi^2)/3). 
2
VT, refers to PCV7 serotypes: 4, 6B, 9V, 14, 18C, 19F and 23F 
3
NVT, excluding PCV7 serotypes  
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3.3.2     Serotype specific colonization by age group over two periods 
Among children aged 0-12 years, the dominant colonizing serotypes in Period 1 were 19F                
(14.2%), 6B (10.2%), 6A (9.3%), 23F (8.9%), 15 (7.6%), 19A (5.0%) and 14 (4.3%) in 
decreasing order of frequency (Table 3.5). The prevalence of colonization was significantly 
lower in Period 2 among children <2 years for serotypes 6B, 18C, 19F and 23F. There were, 
however, no significant changes in prevalence of colonization by individual PCV7 serotype 
in older children and particularly in the 2 to 5 years of age where PCV7 serotypes remained 
dominant (Table 3.5).  
Non PCV7 serotypes which showed significant increase among children age <2 years from 
Period 1 compared to Period 2 included serogroup 15 (i.e. serotypes 15A, 15B, 15C 
combined) which increased from 5.8% to 12.2% (p<0.0001), serotypes 16F and serotypes 
11A; Table 3.5. The dominant serotypes in descending order among colonized children <2 
years in Period 2 included 6A (12.3%), 15B (7.6%), 19A (6.3%), 16F (5.8%), 11A (3.2%) 
and 15A (2.8%). The prevalence of colonization by serotypes 6A and 19A remained 
unchanged between the study-periods in children and adults. Among the individuals >12 
years, a significant increase in serogroup 15 from 3.3% to 10.6% (p=0.02) was also observed 
(Table 3.5).  
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Table 3.5 Serotype distribution by age group in each of the survey Periods.  
 <2 years  
 
2 to 5 years 6  to 12 years All adults (>12years) 
Serotype Period 1 
(N=359) 
Period 2 
(N=713)
2
 
p-value Period 1 
(N=236)
3
 
Period 2 
(N=333)
4
 
p-value Period 1 
(N=199)
5
 
Period 2 
(N=254)
6
 
p-value Period 1 
(N=122)
7
 
Period 2 
(N=132)
8
 
p-value 
PCV7 Serotypes
9
 
4 3 (0.8) 5 (0.7) 0.54 2 (0.8) 5 (1.5) 0.39 9 (4.5) 3 (1.2) 0.03 5 (4.1) 2 (1.5) 0.19 
6B 52 (14.5) 40 (5.6) <0.0001 16 (6.8) 24 (7.2) 0.84 13 (6.5) 10 (3.9) 0.21 5 (4.1) 3 (2.3) 0.32 
9V 7 (1.9) 6 (0.8) 0.12 6 (2.5) 7 (2.1) 0.73 5 (2.5) 5 (2.0) 0.70 3 (2.5) 3 (2.3) 0.62 
14 20 (5.6) 31 (4.3) 0.38 9 (3.8) 11 (3.3) 0.75 4 (2.0) 9 (3.5) 0.25 3 (2.5) 3 (2.3) 0.62 
18C 5 (1.4) 2 (0.3) 0.05 5 (2.1) 3 (0.9) 0.20 1 (0.5) 2 (0.8) 0.59 4 (3.3) 1 (0.8) 0.16 
19F 63 (17.5) 87 (12.2) 0.02 37 (15.7) 47 (14.1) 0.60 13 (6.5) 16 (6.3) 0.92 6 (4.9) 8 (6.1) 0.69 
23F 34 (9.5) 44 (6.2) 0.05 23 (9.7) 28 (8.4) 0.58 14 (7.0) 16 (6.3) 0.76 6 (4.9) 3 (2.3) 0.21 
Subtotal 184 (51.3) 215 (30.2) <0.0001 98 (41.5) 125 (37.5) 0.34 59 (29.6) 61 (24.0) 0.18 32 (26.2) 23 (17.4) 0.09 
Additional serotypes included in PCV10 
10
 
1 1 (0.3) 1 (0.1) 0.56 2 (0.8) 0 - 0 1 (0.4) - 0 0 - 
5 0 0 - 2 (0.8) 0 - 0 0 - 0 0 - 
7 4 (1.1) 7 (1.0) 0.53 2 (0.8) 4 (1.2) 0.51 3 (1.5) 9 (3.5) 0.15 5(4.1) 0 - 
Subtotal 5 (1.4) 8 (1.1) 0.70 6  (2.5) 4 (1.2) 0.19 3 (1.5) 10 (3.9) 0.10 5 (4.1) 0 - 
Additional serotypes included in PCV 13
11
 
3 1 (0.3) 6 (0.8) 0.26 8 (3.4) 7 (2.1) 0.35 12 (6.0) 14 (5.5) 0.82 10 (8.2) 11 (8.3) 0.97 
6A 37 (10.3) 88 (12.3) 0.33 23 (9.7) 42 (12.6) 0.29 14 (7.0) 28 (11.0) 0.15 5 (4.1) 8 (6.1) 0.48 
19A 23 (6.4) 45 (6.3) 0.95 8 (3.4) 16 (4.8) 0.41 9 (4.5) 8 (3.1) 0.45 7  (5.7) 2 (1.5) 0.07 
Subtotal 61  (17.0) 139 (19.5) 0.32 39 (16.5) 65 (19.5) 0.36 35 (17.6) 50 (19.7) 0.60 22 (18.0) 21 (15.9) 0.65 
Dominant non PCV13 serotypes
12
 
15A 2 (0.6) 20 (2.8) 0.01 2 (0.8) 8 (2.4) 0.14 0 5 (2.0) - 1 (0.8) 6 (4.5) 0.07 
15B 13 (3.6) 54 (7.6) 0.01 15 (6.4) 16 (4.8) 0.42 12 (6.0) 3 (1.2) 0.004 1 (0.8) 3 (2.3) 0.34 
15C 6 (1.7) 13 (1.8) 0.86 8 (3.4) 4 (1.2) 0.07 2 (1.0) 7 (2.8) 0.16 2 (1.6) 5 (3.8) 0.26 
Total 
sero-
group 15 
21 (5.8) 87 (12.2) 0.001 25 (10.6) 28 (8.4) 0.38 14 (7.0) 15 (5.9) 0.63 4 (3.3) 14 (10.6) 0.02 
16F 4 (1.1) 41 (5.8) 0.0001 1 (0.4) 13 (3.9) 0.01 8 (4.0) 13 (5.1) 0.58 4 (3.3) 7 (5.3) 0.32 
34 7 (1.9) 29 (4.1) 0.07 11 (4.7) 15 (4.5) 0.93 9 (4.5) 8 (3.1) 0.45 6 (4.9) 5 (3.8) 0.66 
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11A 4 (1.1) 23 (3.2) 0.03 11 (4.7) 5 (1.5) 0.03 10 (5.0) 2 (0.8) 0.01 4 (3.3) 5 (3.8) 0.55 
Other 73 (20.3) 171 (24.0) 0.18 45 (19.1) 78 (23.4) 0.21 61 (30.7) 95 (37.4) 0.13 45 (36.9) 57 (43.2) 0.31 
Subtotal 109 (30.4)  351 (49.2) <0.0001 93 (39.4) 139 (41.7) 0.58 102 (51.3) 133 (52.4) 0.82 63 (51.6) 88 (66.7) 0.02 
Total 359 (100%) 713(100%)  236(100%) 333(100%)  199(100%) 254(100%)  122(100%)  132(100%)  
 
331 children aged < 2years were colonised in Period 1 including 28 with double colonization, 
2
666 children aged < 2years were colonised in 
Period 2 including 47 with double colonization, 
3
219 children aged 2-5 years were colonized in Period 1 including 17 with double colonization 
4
307 children aged 2-5 years were colonized in Period 2 including 26 with double colonization, 
5
199 children aged 6-12 years were colonized in 
Period 1 including 13 with double colonization, 
6
242 children aged 6-12 years were colonized in Period 2 including 12 with double colonization 
7
116 adolescents/adults were colonized in Period 1 including 6 with double colonization, 
8
126 adolescents/adults were colonized in Period 2 
including 6 with double colonization  
9
PCV7 serotypes: serotypes 4, 6B, 9V, 14, 18C, 19F and 23F  
10
Additional PCV10 serotypes: serotypes 1, 5 and 7F 
11
Additional PCV13 serotype: serotypes 3, 6A and 19A 
12
Non-PCV 13 serotypes: excluding serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F
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3.3.3          HIV and pneumococcal colonization 
HIV-infection status in Period 1 and Period 2 was volunteered by 505 and 1320 adults and 
165 and 631 children, respectively, see table 3.6. In Period 1, adolescent/adults who self-
reported as being HIV-infected had a trend towards higher prevalence of overall colonization 
(8/40, 20.0%) compared to HIV-uninfected individuals (55/465, 11.8%; p=0.13). This 
difference was significant in Period 2 when 10.4% (14/135) of self-reported HIV-infected 
individuals were colonized compared to 5.1% (60/1185) of reportedly HIV-uninfected 
adolescents/adults; p=0.01. PCV7 serotype colonization was also greater in 
adolescents/adults reported to be HIV-infected compared to HIV-uninfected individuals in 
Period 1 (10.0% [4/40] vs. 3.2% [15/465]; p=0.054) and Period 2 (3.0% [4/135] vs. 1.0% 
[12/1185], p=0.011). There were no differences in prevalence of overall or PCV7 serotype 
colonization among children aged <12 years in Period 1 or Period 2 when stratified by self-
reporting HIV-status.  
Table 3.6 Prevalence of pneumococcus in adults and children who confirmed their HIV status 
 
 
 
 
 
All 
pneumococci 
 Adults (n/N), % Children (n/N), % 
 HIV positive HIV negative p-
value1 
HIV positive HIV negative p-value1 
Period 1 8/40 
(20%) 
55/467 
(11.8%) 
 
0.13 5/5 
(100%) 
116/160 
(72.5%) 
0.21 
Period 2 14/135 
(10%) 
60/1185 
(5%) 
 
0.011* 15/20 
(75%) 
415/611 
(68%) 
0.50 
p-value2 0.107 <0.0001*  0.29 0.27 
 
 
 Period 1 4/40 
(10%) 
 
15/467 
(3%) 
 
0.05* 2/5 
(40%) 
52/160 
(32.5%) 
0.53 
PCV7 
Serotypes3 
Period 2 4/135 
(3%) 
 
12/1185 
(1%) 
 
0.07 5/20 
(25%) 
140/611 
(22.9%) 
0.79 
 p-value2 0.08 0.001*  0.44 0.013*  
 
1
: comparison between different HIV status in the same Period 
2
: comparison between Periods of same HIV status 
3
PCV7 serotypes: serotypes 4, 6B, 9V, 14, 18C, 19F and 23F 
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3.3.4        Effect of the number of PCV doses received on carriage in 
vaccine recipients 
A total of 386 (51.5%) of 749 children, <2 years of age in Period 2 who had verifiable 
immunisation records at hand, were fully vaccinated.  Fifty percent (347/692) of the children 
age 9 months to 2 years were fully vaccinated with three doses of PCV7, while 31.9% 
(221/692) had received two doses and 17.9% (124/692) had only received a single dose. 
Fully-vaccinated 9 months to 2 year old children had a lower  prevalence of PCV7 serotype 
colonisation (59/347; 17.0%) compared to those who had only received  two (56/221; 25.3%, 
p=0.02) or a single dose  (37/124; 29.8%, p = 0.002).  
Table 3.7 Number of children sampled in period-2 who received PCV7  
  Number of doses, n (%) 
Age group Total 1 2 3 
<3 months 5 5 (100)   
3 – <9 months 52 18 (34.7) 32 (61.5) 2 (3.8) 
9 months- 2 years 692 124 (17.9) 221 (31.9) 347 (50.2) 
Total  749 147 (19.6) 253 (33.8) 349 (46.6) 
 
In 3-9 month old children, there was no difference in PCV7 serotype colonization between 
partially vaccinated (i.e. only received one PCV7 dose; 27.8%) compared to those who had 
received both scheduled PCV7 doses; 28.1%, p=0.979. Overall, in a logistic regression 
model, adjusting for age, there was an inverse relationship between the number of doses of 
PCV7 received and PCV7 serotype colonization [OR 0.69, 95%CI: 0.56-0.87], indicating that 
incompletely vaccinated children were more likely to carry vaccine serotypes compared to 
fully vaccinated children. 
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Table 3.8 Odds ratios for carriage in vaccine recipients with increasing number of 
vaccine doses received. 
 Effects of  the number of doses received  and age on the odds of 
carriage in vaccinee 
Carriage Age Number of doses received 
Any  pneumococci 1.02(0.71-1.46) 0.83(0.67-1.02) 
PCV7
1
 0.97(0.67-1.40) 0.69(0.56-0.87) 
NB: Adjusted odds ratio and 95% confidence intervals are given 
1
PCV7 serotypes: serotypes 4, 6B, 9V, 14, 18C, 19F and 23F 
 
   3.4                            Discussion 
 
We report on the temporal association of infant PCV7 immunization on the epidemiology of 
nasopharyngeal pneumococcal colonization among children and adults in a rural African 
setting with high HIV-prevalence. Our study indicated the prevalence of PCV7 serotype 
colonization in the <2 and 2-5 year age groups were almost similar at the time of initiation of 
the PCV immunization program, nevertheless, a vaccination program limited to 
immunization at 6, 14 weeks and 9 months of age was associated with reduction in vaccine 
serotype colonization in all study age-groups, including the 2 to 5 years old unvaccinated 
children. Notably, the reduction in PCV7 serotype colonization was observed with 51.5% of 
the targeted population having been fully vaccinated based on their age group.  This suggests 
that despite a high prevalence of vaccine serotype colonization among older children in 
resource poor, rural settings, children <2 years of age are likely the primary source of 
transmission of vaccine serotypes in the community, and that an indirect effect of PCV 
immunization can be realized within two years of initiating the PCV immunization program, 
even without a catch-up campaign of older children and with a fairly modest level of vaccine 
coverage of the target population. A higher level of vaccine  coverage, may have been 
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associated with even a greater magnitude of reduction of colonization by vaccine serotypes 
among unvaccinated individuals compared to what was observed in our setting.   
 
The findings of our study corroborate that of clinical trials in which the direct and indirect 
effect of PCV vaccinantion of children reduced colonization among vaccinated and 
unvaccinated individuals (9, 68, 71, 73, 74, 133-135). There are also few observational 
ecological studies where this has now been reported including from The Gambia, (80)  
United Kingdom,(136) The Netherlands,(82) USA among Native Americans, Alaska (84) and 
the general USA population (87, 137) and in Australasia (78). The results of our study, 
nevertheless, are unique in so far as we evaluated a national immunisation program with no 
catch-up campaign of older children as undertaken elsewhere, (78, 80, 82, 87, 136, 137) and 
also it was undertaken in a setting of high underlying HIV-positivity among adults and with 
only modest levels of age-appropraite PCV7 coverage.  
 
Pneumococcal colonization prevalence was generally high in our study population, which is 
similar to that reported from a few other African countries (46, 80). Notably, the prevalence 
of pneumococcal colonization in children <2 years of age (83.8%) was comparable to 3 to 5 
year old children (81.4%) and also high (60%) in the 6 to 12 year age-group at the time of 
PCV7 introduction. In contrast, the prevalence of pneumococcal colonization in children 
from developed countries peaks at 40 to 50% at approximately two years of age and is 
subsequently followed with reduction from  around five years of age to adult levels of 10% or 
less (33). While our study suggests that young infants are the main source of pneumococcal 
transmission to adolescents and older adults, the more modest reduction (21%) in vaccine 
serotype colonization in the 2 to 5 year age group possibly indicates some ongoing 
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transmission of vaccine serotypes among this age group, who are also more likely to 
intermingle in the community and in play groups or day care centres. Although 2 to 5 year 
old children are at lower risk of IPD compared to <2 year old children, (138) they do however 
remain at risk of developing acute otitis media and other mucosal infections which itself may 
warrant catch-up campaigns in this age-group in the presence of only modest reduction in 
PCV7 serotype colonization with immunization only directed at young infants. Our study is 
unable to establish whether there is any added benefit of a PCV catch up campaign of older 
children in accelerating the timing and magnitude of indirect effect as postulated (52). 
Nevertheless, we identified an indirect-effect on PCV7 serotype NP colonization materialized 
within similar timelines and magnitude, in the absence of a catch up campaign, compared to 
settings where catch up campaigns have been implemented (80). 
There is limited information on pneumococcal NP colonization in settings with high 
prevalence of HIV, including conflicting data on whether infants born to HIV-infected 
mothers have higher rates of pneumococcal NP colonization compared to children born to  
HIV-uninfected mothers (139, 140). Also, no difference in prevalence of pneumococcal 
colonization has been observed between HIV-infected compared to HIV-uninfected PCV 
unvaccinated children, (141, 142) similar to that identified in our study. Although limited to 
self reports , the prevalence of HIV-positivity among children in our study (3%) was similar 
to  that recorded in a separate HIV survey undertaken in the  area in 2007 (4.4%; 95% CI 
2.79 to 5.97) (143). HIV-infected women reportedly have a higher prevalence and rate of 
overall and PCV7 serotype pneumococcal colonization, (35, 132, 140) as well as an increased 
risk of PCV7 serotype IPD (33). The heightened risk of PCV7 serotype colonization in HIV-
infected women was partly corroborated by our study. This, despite probable under reporting 
of HIV-positivity status among adults in our study, i.e.10% compared to 23.9% for the 
general adult population in 2011 HIV survey (144). Such under-reporting in our study would 
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have biased our results toward under-estimating the effect of HIV-positivity on the 
prevalence of pneumococcal colonization.  
The likelihood of infant PCV immunization having an indirect protective effect against 
vaccines-serotype IPD among HIV-infected women, including in high HIV prevalence 
settings such as ours, was alluded to by the decrease of PCV7 serotype colonization among 
19-45 year old HIV-infected women which was of a greater magnitude compared to 
reportedly HIV-uninfected individuals. This reduction in PCV7 serotype colonization among 
HIV-infected adults also lessened an earlier theoretical concern of ours, that HIV-infected 
women could remain a potential reservoir for PCV7 serotype colonization and transmission 
in settings such as ours despite PCV vaccination of children. Caregivers, which included 
mothers, had higher PCV7 serotype carriage than non-caregivers in Period 1, which declined 
significantly in Period 2. The close contact between caregivers and young children may 
explain the high carriage among caregivers in Period 1 (38, 40) and the early indirect effect 
among caregivers in Period 2.  
 
While the  increase in non PCV7 serotype colonization was anticipated among the age-group 
eligible to have been vaccinated, i.e. <2 years of age (8, 9, 68, 69) there was an unexpected 
decrease in non PCV7 serotype colonization among age-groups >12 years old. The reasons 
for this decline in non PCV7 serotype colonization following introduction of infant PCV 
immunization remains to be explored further. To our knowledge, there is only one similar 
observation of decline in non PCV serotype and overall colonization among adults which was 
reported from The Gambia (80). The only other studies, to our knowledge, which evaluated 
the effect of childhood PCV immunization on the epidemiology of NP colonization among 
adults was among Navajo Indians in USA,(73, 145) and Alaskan-natives (84). Among 
Navajo Indians, 1 year following implementation of childhood PCV immunization, no 
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changes were observed in non-vaccine serotype colonization among adults post introduction 
of childhood PCV7 immunization, despite an increase among childhood age groups who had 
been targeted for vaccination (73). In contrast among Alaskan natives there was an increase 
in non-vaccine serotype colonization among adults observed within 4 years of childhood 
PCV introduction (84). The lack of an increase in non-vaccine serotype colonization among 
adults in the era of childhood PCV-immunization may relate to most non-vaccine serotype 
strains being less efficient in colonizing healthy adults. Also, there may be a time lag before 
non-vaccine serotype increases are observed among adults as our study was done within 2 
years of vaccine implementation.  
 
Possible reasons as to why non-vaccine serotype colonization may have declined among 
individuals >12 years in our setting remains unclear. This may reflect co-incidental temporal 
changes in circulation of these non-vaccine serotypes, although a similar decline would then 
possibly have been expected among younger children, unless the longer duration of 
pneumococcal colonization in children had masked this (21). A further possible explanation 
for the decline in non PCV7 serotype colonization among adults may include an increase in 
ART coverage in HIV-infected adults with AIDS, which has previously been associated with 
a lower risk of pneumococcal colonization following at least one year of ART (35). Other 
hypothetical reasons include that increased transmission of non-vaccine serotypes to adults 
may result in robust anamnestic responses against the non-vaccine serotypes. This could 
possibly reduce the acquisition and/or duration and subsequently likelihood of detection of 
these non-vaccine serotypes in adults. Despite the decrease in overall non-vaccine serotype 
among adults, serogroup 15 was an exception in having increased in prevalence of 
colonization in children (5.8% vs. 12.2%) as well as in adolescents/adults (3.3% vs. 10.6%). 
This increase in serogroup 15 colonization, dominantly associated with serotype 15B, 
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warrants ongoing monitoring in relation to changes in invasive disease due to this serogroup, 
especially in settings such as ours where serogroup 15 had contributed to 2-3% IPD among 
children and adults prior to PCV-introduction (146-148). Also, a trend toward a higher 
incidence of serotype 15A IPD in placebo-recipients was observed in the phase III efficacy 
trial in South Africa, particularly among HIV-infected children (54). The importance of 
serogroup 15, which is not targeted in either the 10- or 13-valent licensed PCV or a 15-valent 
PCV currently being developed, in causing IPD associated with antibiotic-resistant strains in 
the era of PCV immunization has also been reported in Canada (149).  
 
Other common non PCV7 serotypes in Period 2, which were associated with a high 
proportion of IPD prior to infant PCV immunization in South Africa, were serotypes 6A and 
19A. Although PCV7 has been associated with cross-protection against serotype 6A IPD, 
(150) we did not identify any changes in the overall proportion of individuals colonized by 
serotype 6A  between Period 1 and Period 2 among children or older age groups in our study. 
We also distinguished between serotype 6A and  6C, as cross-protection associated with 6B 
inclusion in PCV has been shown for 6A but not for 6C (150). Decline in serotype 6A 
colonization among children has, however, been reported in Massachusetts-USA, although, 
this was only identified 6 years post PCV7 introduction and was associated with concomitant 
increase in 6C colonization (151).  Serotype 19A colonization (and IPD) which increased in 
the USA and other countries post PCV introduction, (85) did not increase in our setting; and 
is unlikely to increase since the immunization program had subsequently transitioned from 
PCV7 to PCV13 in 2011. Serotype 3 was the only serotype more common among adults than 
children and its prevalence did not change across periods. In South Africa, serotype 3 is an 
important cause of IPD (147, 152) and among HIV-infected patients in Uganda, serotype 3 
was the most prevalent serotype identified from oropharyngeal swabs (153). 
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Limitations specific to this study included the reliance on self-reporting of HIV-infection 
status. This was predicated by resource constraints in undertaking informed testing for all 
study participants, as well as attempting to minimize any stigma being associated with the 
study if perceived to be HIV related. Our study was not powered to detect changes in 
prevalence of individual serotypes. Nevertheless, significant decreases were observed in 
colonization by serotypes 6B, 18C, 19F and 23F among children <2 year old. In addition, our 
study only spanned a two year period, which may under-estimate the longer term effects of 
childhood PCV immunization on the epidemiology of pneumococcal colonization in the 
community. Furthermore, we do not have any data on IPD from the same community, to 
determine what effect the direct and indirect changes associated with vaccine- and non-
vaccine serotype colonization may have had on the incidence of IPD. 
In conclusion, this study demonstrates indirect protection against PCV7 serotype colonisation 
among adolescents and adults in a community with high underlying HIV-infection, which 
was induced by only modest levels of PCV7 immunization coverage that was targeted solely 
at infants as part of a routine immunization program. Although, our study was done within 
two years of implementation of the PCV7-immunization program, the findings are strongly 
suggestive that PCV7 immunization targeted at only infants reduces transmission of the 
targeted vaccine serotypes in high-risk, rural African populations such as ours.  
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Chapter 4: Temporal changes in pneumococcal colonization in HIV-
infected and HIV-uninfected mother-child pairs following 
transitioning from 7-valent to 13-valent pneumococcal conjugate 
vaccine, Soweto, South Africa  
 
4.1           Introduction 
HIV-infected individuals have an 8-40 fold greater risk of developing IPD, including when 
on anti-retroviral treatment (35, 152, 154). Furthermore, HIV-infected women are more 
predisposed to IPD due to “pediatric serotypes” than HIV-infected men (47). A few studies 
have shown that  pneumococcal colonization prevalence is similar between HIV-infected and 
HIV-uninfected children (142, 155). Although there are limited data on the effect of HIV-
infection on pneumococcal colonization in adults (140, 156, 157), HIV-infected women  have 
a higher prevalence of colonization by serotypes commonly associated with IPD in children, 
many of which are included in PCV7 (35, 140, 158). Consequently, the indirect effect of 
infant PCV immunization in the prevention of vaccine serotype pneumococcal disease may 
be attenuated in settings with a high prevalence of HIV among adults, who could serve as an 
additional reservoir of vaccine serotype colonization.  
PCV immunization directly decreases vaccine serotype colonization in the immunized 
children and indirectly in healthy unvaccinated children and adults, however, there are 
limited data on the direct and indirect effect of routine childhood PCV-immunization on 
nasopharyngeal carriage of Streptococcus pneumoniae among HIV-infected children and 
adults (65, 159). An earlier cross-sectional study in our setting reported no difference in 
colonization prevalence by either vaccine serotype or non-vaccine serotypes between 
vaccinated and –unvaccinated HIV-infected children five years following receipt of three 
doses of an investigational 9-valent PCV during infancy, however, that study was performed 
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prior to routine PCV immunization or management of HIV-infected children with 
antiretroviral therapy (65).  
The aim of this  component of the study was to evaluate the effect of routine infant PCV 
immunization, following transitioning from PCV7 in 2011 to PCV13 in 2013, on the 
prevalence of PCV13 additional vaccine serotype and non PCV13 serotype colonization in 
HIV-infected and HIV-uninfected mother-child pairs in South Africa at a community level. 
This evaluation included age groups that would have been eligible for PCV immunization 
and age-groups, including HIV-infected women, who would not have been immunized 
against pneumococcus with any pneumococcal vaccine. 
 
4.2                      Methods 
4.2.1                   Study population 
The study was undertaken in Soweto (Gauteng, South Africa); details of the study population 
are described in Chapter 2. In April 2009, PCV7 was introduced into the national public 
immunization program and was subsequently changed to PCV13 in May 2011, as previously 
described in Chapter 2. 
4.2.2                      Study participants 
We enrolled HIV-infected and HIV-uninfected mother-child dyads between May 2010 and 
February 2011 (early PCV7 era; period 1) and again from May 2012 to April 2013 (PCV13-
era; period 2). Children were aged between 0 and 12 years. In period 1, we targeted enrolling 
700 mother-child pairs with concordant HIV-status in each arm. Individuals were included in 
this study if they had confirmed HIV status and provided written informed consent. HIV 
discordant pairs were excluded from the study. Individuals with a contra-indication to 
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nasopharyngeal swabbing, e.g, bleeding diathesis and current symptomatic disease were also 
excluded from the study. 
Based on the PCV7 serotype colonization prevalence among mothers during period 1, we 
planned on enrolling 602 HIV-infected and 1,234 HIV-uninfected mother-child pairs in 
period 2, to detect at least a 50% reduction in PCV7 serotype colonization in period 2 
compared to period 1 in the women, with 80% power. The study was also sufficiently 
powered (90%) to detect at least a 50% decrease in all PCV13 serotype colonization between 
period 1 and period 2 in both groups of women. Mothers with more than one child were 
evaluated as multiple mother-child pairs. 
HIV-infected mother-child pairs were recruited from two established HIV clinics at Chris 
Hani Baragwanath Academic Hospital, where the majority of HIV-infected children in 
Soweto received their routine care during the study period. HIV-uninfected mother-child 
pairs were recruited from wellness baby clinics. The HIV infection status of women without a 
documented HIV seronegative test in the previous six months was determined, following 
counselling and consenting, using a rapid HIV test (Determine–Alere International Limited, 
Ballybrit, Galway, Ireland). Children of HIV-uninfected women were presumed to be HIV-
uninfected and children of HIV-infected mothers were tested per age-dependent criteria if 
they had not been previously tested. Overall >98% of mothers who were invited to take part 
in the study agreed to participate.   
Demographic and risk factors for colonization were evaluated in participants at the time of 
swab collection. Child’s risk factors assessed included day care attendance, rhinitis at time of 
sampling, breastfeeding history, underlying tuberculosis, hospitalization in preceding 3-
months, current antibiotic treatment, use of anti-retroviral treatment for HIV-infected 
children; and among mothers age, alcohol-intake history, current antibiotic therapy, cigarette 
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smoking, presence of rhinitis,  previous tuberculosis treatment, hospitalization in preceding 3-
months and use of anti-retroviral treatment for HIV-infected mothers. 
4.2.3                      Determination of bacterial colonization 
  
Swab collection and sample collection as described earlier in section 2.4. 
 
4.2.4                   Definitions and statistical analysis assessed the changes of 
all pneumococci, PCV7  
To determine the impact of infant PCV immunization on the prevalence of overall 
pneumococcus, vaccine serotype and non-vaccine serotype colonization, children were 
stratified into four age groups according to the probability of having been vaccinated, i.e. 
children likely to be incompletely vaccinated (<9 months of age), those eligible to have been 
fully vaccinated in both study periods (9 to 24 months of age), those likely to have been fully 
vaccinated only in period 2 (>24 to 48 months of age) and those unlikely to have received 
PCV at all (>48 to 144 months of age).  
We compared colonization prevalence in children and adults between the two study periods, 
including stratification by HIV infection status. Differences in the demographic and clinical 
characteristics between the populations in the two study periods were addressed by 
controlling for possible confounding factors on colonization. Univariate logistic regression 
analysis was conducted and those characteristics with a p-value <0.1 were included in a 
multivariable analysis to calculate adjusted odds ratio (adjusted OR) and corresponding 95% 
confidence intervals (95%CI) for colonization between the study periods.  Similar analyses 
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were implemented for comparison of colonization between HIV-infected and –uninfected 
groups.  
 
Regression analyses 
For the regression analysis we analysed the data by age category as detailed above, HIV-
status and colonization status to reduce the complexity embedded in the data. For each age 
class (HIV-uninfected or HIV-infected or combined), we implemented a model of carriage 
(any pneumococcus or PCV7 serotypes or PCV13 additional 6 serotypes or PCV13 serotypes 
or non-vaccine serotypes) with the independent variable vaccination period (dichotomized: 0 
for period 1 and 1 for period 2), adjusted for other variables that were deemed potential 
determinants for carriage by a univariate analysis. Only variables that produced a p-value of 
<0.1 were used in the multivariate model for pneumococcal carriage. Multivariable analysis 
was necessitated by significant differences in demographic and clinical variables between the 
populations in the two periods to offset possible confounding by these factors.  
We did not include the time from vaccination but only considered the vaccination period, i.e., 
PCV7 era or PCV13 era as we were not aiming for risk factors for carriage but only the 
difference of carriage between two periods.  No weighting of these characteristics included in 
the multivariable analyses was used as sometimes this could potentially increase the random 
error in the estimates. Similarly, for each age strata, we also investigated the association 
between carriage and HIV-infection status, i.e., carriage as a dependent variable, HIV status 
as an explanatory variable plus other factors based on the relative importance in univariate 
analyses, i.e., those with a p-value <0.1 in the univariate analysis. Again no weighting was 
undertaken for the different characteristics. 
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Furthermore, we did not adjust the number of tests, as we undertook a priori planned analysis. 
Nevertheless, we only considered a p-value <0.01 as significant, to offset any chance findings 
based on the multiple comparisons undertaken. Comparison of serotype prevalence between 
period 1 and period 2 was performed using chi-squared or Fisher’s exact tests where 
appropriate. 
 
4.3                       Results 
4.3.1                   Study participants 
We enrolled 1,376 (including 704 HIV-infected) and 1,556 (608 HIV-infected) women in 
period 1 and period 2, respectively, Table 4.1, together with 1,411 (713 HIV-infected) and 
1,649 (616 HIV-infected) of their children in the respectively periods; Table 4.2. This 
included 35 and 93 women in period 1 and period 2, respectively, who had more than one 
child enrolled concurrently. None of the mother-child pairs were enrolled in both study 
periods.   
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Table 4.1 Demographic characteristic of mothers enrolled in 2010 (Period 1; PCV7 era) 
and 2012 (Period 2; PCV13 era) in Soweto, South Africa 
Characteristic  Period 1 (PCV7 era) 
N=1376                     
Period 2 (PCV13 era) 
N=1556 
p-value 
Number of HIV-infected  704 (51.2) 608 (39.1)  
Mean age, years ±SD
1
 30.4±6.50 29.1±6.6 <0.001 
Smoker, n
2
/N
3
(%) 80/1375 (5.8%) 92/1556 (5.9%) 0.91 
Takes snuff, n/N (%) 78/1372 (5.7%)  88/1553 (5.7%) 0.98 
Drinks alcohol, n/N (%) 240/1375 (17.4%) 418/1547 (27.0%) <0.001 
Suffers from a chronic illness, n/N (%) 115/1369 (8.4%) 124/ 1421 (8.0%) 0.76 
HIV-infected and on ART
4
, n/N (%)  299/697(42.9%)  330/608 (54.3%) <0.001 
Currently on TB
5
 treatment, n/N (%) 20/1371 (1.5%) 16/1538 (1.0%) 0.31 
Treated for TB in past year, n/N (%) 80/1357 (5.9%) 83/1532 (5.4%) 0.58 
Currently on antibiotic treatment, n/N (%) 79/1368 (5.8%) 20/1540 (1.3%) <0.001 
Hospitalized in the last 3 months, n/N (%) 25/1369 (1.8%) 19/ 1527 (1.2%) 0.21 
1
standard deviation; 
2
Number of individuals with the investigated outcome; 
3
Total number of individuals with available information on the characteristic; 
4
Anti-retroviral therapy;  
5
Tuberculosis 
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Table 4.2 Demographic characteristics of children enrolled in 2010 (Period 1; PCV7 era) and 2012 (Period 2; PCV13 era) in Soweto, South Africa  
 All children  HIV-infected HIV-uninfected 
Characteristic 
Period 1 
(PCV7 era) 
Period 2 
(PCV13 era) 
p-value Period 1 
(PCV7 era) 
Period 2 
(PCV13 era) 
p-value 
Period  1 
(PCV7 era) 
Period 2 
(PCV13 era) 
p-value 
All children enrolled; n,  mean 
age in years ±SD
1
  
1411;  
2.7 ± 1.98 
1649;  
2.3 ± 2.05 
<0.001 713;  
3.3± 2.1  
616;  
3.8 ± 2.12 
<0.001 698; 
2.03±1.6 
1033;  
1.4 ±1.37 
<0.001 
<9 months; n
2
, mean age (SD) 
months;  
230;  
4.8± 1.8  
 396;  
4.8 ± 2.3 
<0.001 60;  
4.9 ± 2.0 
52;  
5.0 ± 2.0 
0.76 170;  
4.8 ± 1.3 
344;  
4.8 ± 2.2 
0.99 
 9-24 months; n, mean age in 
years ±SD 
 408;  
1.22 ± 0.4 
539;  
1.18 ± 0.34 
0.99 155;  
1.41 ± 0.37 
92;  
1.23 ± 0.39  
<0.001 253;  
1.07 ± 0.35 
447;  
1.16 ± 0.34 
<0.001 
>24- 48 months; n, mean in age 
years ±SD 
449;  
3.2 ±0.55 
348;  
2.9 ± 0.54 
0.10 262;  
3.01 ± 0.60 
182;  
2.98 ± 0.58 
0.60 187;  
3.53 ± 0.25 
166;  
2.87 ± 0.54 
<0.001 
>48-144 months; n, mean in age 
years ±SD 
324;  
5.5 ± 1.43 
366;  
5.6± 1.15 
0.31 236; 
 5.72 ± 1.51 
290;  
5.66 ± 1.14 
0.60 88;  
4.7 ± 0.82 
76;  
5.63 ± 1.14 
<0.001 
Currently breastfed, n/N
3
 (%) 319/1410 
(22.6) 
565/1645  
(34.4) 
<0.001 18/713 
 (2.5) 
45/566 
 (7.5) 
<0.001 301/697  
(43.2) 
501/973 
(51.5) 
0.002 
Ever breastfed, n/N (%) 499/1060 
(47.1) 
628/1056 
 (59.5) 
<0.001 148/665  
(22.3) 
213/549  
(38.8) 
<0.001 337/378 
(89.2) 
389/465  
(83.7) 
0.02 
Attendance at day-care, n/N (%) 623/1410 
(44.2) 
 560/1632 
 (34.3) 
<0.001 379/712  
(53.2) 
325/605  
(53.7) 
0.86 232/678 
(34.2) 
216/969  
(22.3) 
<0.001 
Currently on TB
4
 
treatment/prophylaxis, n/N (%) 
60/1396 
(4.2) 
 67/1643  
(4.1) 
0.76 57/700 
(8.14) 
59/608 
 (9.7) 
0.32 3/676 
(0.44) 
7/975  
(0.7) 
0.36 
Treated for TB in the past year, 
n/N (%) 
116/1349 
(8.6) 
166/1608  
(10.3) 
0.11 122/660  
(17.0) 
150/583 
 (25.7) 
0.002 4/669 
(0.6) 
9/966 
 (0.93) 
0.33 
Currently taking antibiotics, n/N 
(%) 
 120/1396 
(8.6) 
 90/1642  
(5.7) 
0.001 108/704 
(15.3) 
49/609 
 (8.1) 
<0.001 12/672 
 (1.8) 
39/973  
(4.0) 
0.01 
Hospitalized in the last 3 
months, n/N (%) 
 63/1395 
 (4.5) 
109/1634  
(6.7) 
0.01 42/702 
(6.0) 
75/607  
(12.4) 
<0.001 21/673 
(3.1) 
31/968  
(3.2) 
0.93 
Pneumococcal vaccine receipt
5
          
<9 months 
 
at least one 
dose 
196/230 
(85.2) 
320/396 
(80.8) 
0.31 30/60   
(50.0) 
18/52     
(34.6) 
0.10 166/170 
(97.6) 
302/344 
(87.8) 
0.22 
At least 2 
doses 
172/230 
(74.8) 
306/396 
(77.3) 
0.48 16/60    
(26.7) 
11/52    
(21.1) 
0.50 156/170 
(91.8) 
295/344 
(85.8) 
0.05 
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9 -24months At least one 
dose 
259/408 
(63.5) 
400/539 
(74.2) 
<0.001 35/155   
(22.6) 
15/92     
(16.3) 
0.24 224/253 
(88.5) 
385/447 
(86.1) 
0.36 
At least 
2doses 
255/408 
(62.5) 
395/539 
(73.3) 
0.001 34/155    
(21.9) 
15/92     
(16.3) 
0.28 221/253 
(87.4) 
380/447 
(85.0) 
0.39 
At least 3 
doses 
231/408 
(56.6) 
355/539 
(65.9) 
0.004 27/155   
(17.4) 
13/92    
(14.1) 
0.50 204/253 
(80.6) 
342/447 
(76.5) 
0.21 
>24-48 months At least one 
dose 
0/449 145/348 
(41.7) 
NA
6
 0/262 14/182    
(7.7) 
NA 0/187 131/166 
(78.9) 
NA 
At least 2 
doses 
0/449 143/348 
(41.1) 
NA 0/262 14/182    
(7.7) 
NA 0/187 129/166 
(77.7) 
NA 
At least 3 
doses 
8/449    
(1.8) 
135/348 
(38.8) 
<0.001 8/262     
(3.1) 
13/182    
(7.1) 
0.046 0/187 122/166 
(73.5) 
NA 
>48-144months At least one 
dose 
0/324 9/366     (2.5) NA 0/236 3/290      
(0.7) 
NA 0/88 6/76   
(7.9) 
NA 
At least  2 
doses 
0/324 7/366        
(1.9) 
NA 0/236 1/290        
(0.3) 
NA 0/88 6/76   
 (7.9) 
NA 
At least 3 
doses  
15/324 
(11.7) 
6/366        
(1.6) 
0.022 15/236 
(6.4) 
1/290        
(0.3) 
0.005 0/88 5/76    
(6.6) 
NA 
1
Standard deviation 
2
Number of individuals with investigated outcome,  
3
Total number of individuals with available information on the characteristic  
4
Tuberculosis,  
5
only for individuals with available vaccination records at time of interview 
6
NA: Not done due to limited number of observations in one group 
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Generally, there was no difference in the prevalence of PCV13 serotype or non-vaccine 
serotype colonization in HIV-infected individuals on antiretroviral therapy compared to those 
not on antiretroviral therapy among women or children in either study period (Table 4.3). As 
such, no further stratifications were undertaken for antiretroviral therapy usage. 
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Table 4.3 Association of antiretroviral treatment on prevalence of pneumococcal colonization in HIV-infected (HIV+) children and mothers sampled 
in 2010 (Period 1; PCV7 era) and 2012 (Period 2; PCV13 era) in Soweto, South Africa.  
Period  Age group Total All pneumococci PCV7 serotypes
5
 PCV13 serotypes
6
 Non PCV13 serotypes
7
 
  N
1
 n
2
 n n  n 
  ART
3
 No 
ART 
ART No 
ART 
p-value ART No 
ART 
p-value ART No 
ART 
p-value ART No 
ART 
p-value 
Period 1 All HIV+ children 592 59 415 34 0.048 157 12 0.302 232 20 0.426 198 15 0.210 
 %   70.1 57.6  20.3 26.5  39.2 33.9  33.5 25.4  
 <9 months 46 7 23 3 0.774 7 0 NA
4
 7 1 0.949 16 2 0.322 
 %   50.0 42.9  15.2 0.0  15.2 14.3  34.8 28.6  
 9-24 months 126 4 82 2 0.873 40 0 NA 56 0 NA 28 2 0.228 
 %   65.1 50.0  31.7 0.0  44.4 0.0  22.2 50.0  
 >24-48 months 226 20 162 13 0.527 66 6 0.940 94 10 0.466 72 3 0.135 
 %   71.7 65.0  29.2 30.0  41.6 50.0  31.9 15.0  
 >48-144 months 194 28 148 16 0.031 44 6 0.882 75 9 0.506 82 8 0.168 
 %   76.3 57.1  22.7 21.4  38.7 32.1  42.3 28.6  
 HIV+ Mothers 299 398 66 76 0.334 13 19 0.790 28 32 0.537 41 45 0.339 
 %   22.1 19.1  4.4 4.8  9.4 8.0  13.7 11.3  
Period 2 All HIV+ children 518 34 315 19 0.569 57 8 0.028 101 9 0.324 217 10 0.152 
 %   60.8 55.9  11.0 23.5  19.5 26.5  41.9 29.4  
 <9 months 34 10 10 6 0.077 3 3 0.120 3 3 0.120 7 3 0.532 
 %   29.4 60.0  8.8 30.0  8.8 30.0  20.6 30.0  
 9-24 months 73 8 39 4 0.854 10 2 0.338 14 2 0.654 25 2 0.712 
 %   53.4 50.0  13.7 25.0  19.2 25.0  34.3 25.0  
 >24-48 months 154 2 104 1 0.548 17 0 NA 27 0 NA 79 1 0.971 
 %   67.5 50.0  11.0 0.0  17.5 0.0  51.3 50.0  
 >48-144 months 257 14 162 8 0.657 27 3 0.192 57 4 0.577 106 4 0.347 
 %   63.0 57.1  10.5 21.4  22.2 28.6  41.3 28.6  
 HIV+ Mothers 330 279 46 39 0.989 10 3 0.059 19 10 0.210 27 29 0.347 
 %   13.9 14.0  3.0 1.1  5.8 3.6  8.2 10.4  
1
N is the total in the group 
2
n is the number that was colonized;
 3ART: Antiretroviral therapy, 4NA: Not applicable due to limited observations, 5PCV7 serotypes: serotypes 
4, 6B, 9V, 14, 18C, 19F and 23F; 
6
PCV13 serotypes, serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 
7
non-PCV13 serotypes: excluding serotypes in PCV13
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The proportion of mother-child pairs who were concurrently colonized on the day of 
sampling by any  pneumococcus declined from 11.0% (155 of 1411 pairs) in period 1 to 6.8% 
(112 of 1649 pairs) in period 2, p<0.001; Figure 4.1 and  Table 4.4. This was evident among 
HIV-uninfected pairs (declined from 6.7 % (47/698) in period 1 to 4.6% (47/1033) in period 
2, p=0.049); as well as among HIV-infected pairs (declined from 15.2% (108/713) to 10.6% 
(65/616), p=0.013. Similar significant decreases were observed when serotypes were grouped 
as PCV13 serotypes.  
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Table 4.4 The proportion of mother-child pairs sampled in 2010 (Period 1; PCV7 era) and 2012 (Period 2; PCV13 era) from Soweto, 
South Africa who were concurrently colonized by any pneumococcus, same serotype, PCV13 serotype and non-PCV13 serotype 
Age group Total isolates Any pneumococcus Same serotype PCV13 serotypes
2
 Non-PCV13 serotypes
3
 
 Period 1 Period 2 Period 1 Period 2 p-value
1
 Period 1 Period 2 p-value Period 1 Period 2 p-value Period 1 Period 2 p-value 
               
All children 1411 1649 155(11.0) 112(6.8) <0.001 56(4.0) 45(2.7) 0.056 34(2.4) 13(0.8) <0.001 22(1.6) 32(1.9) 0.424 
HIV-uninfected 698 1033 47(6.7) 47(4.6) 0.049 18(2.6) 30(2.9) 0.686 13(1.9) 5(0.5) 0.005 5(0.7) 25(2.4) 0.008 
HIV-infected 713 616 108(15.2) 65(10.6) 0.013 38(5.3) 15(2.4) 0.007 21(3.0) 8(1.3) 0.040 17(2.4) 7(1.1) 0.088 
               
<9 months               
All 230 396 20(8.7) 26(6.6) 0.325 10(4.4) 18(4.6) 0.908 8(3.5) 4(1.0) 0.033 2(0.9) 14(3.5) 0.032 
HIV-uninfected 170 344 11(6.5) 23(6.7) 0.926 6(3.5) 16(4.7) 0.554 6(3.5) 4(1.2) 0.072 0 12(3.5) - 
HIV-infected 60 52 9(15.0) 3(5.8) 0.101 4(6.7) 2(3.9) 0.410 2(3.3) 0 - 2(3.3) 2(3.9) 0.635 
               
9-24 months               
All 408 539 46(11.3) 29(5.4) 0.001 21(5.2) 10(1.9) 0.005 14(3.4) 2(0.4) <0.001 7(1.7) 8(1.5) 0.778 
HIV-uninfected 253 447 23(9.1) 21(4.7) 0.021 10(4.0) 9(2.0) 0.129 6(2.4) 1(0.2) 0.010 0 8(1.8) - 
HIV-infected 155 92 23(14.8) 8(8.7) 0.159 11(7.1) 1(1.1) 0.027 8(5.2) 1(1.1) 0.092 7(4.5) 0 - 
               
>24-48 months               
All 449 348 46(10.2) 28(8.1) 0.289 13(2.9) 9(2.6) 0.792 6(1.3) 2(0.6) 0.243 7(1.6) 7(2.0) 0.630 
HIV-uninfected 187 166 10(5.4) 16(9.6) 0.123 1(0.5) 5(3.0) 0.082 1(0.5) 0 - 0 5(3.0) - 
HIV-infected 262 182 36(13.7) 12(6.6) 0.017 12(4.6) 4(2.2) 0.143 5(1.9) 2(1.1) 0.397 7(2.7) 2(1.1) 0.211 
               
>48-144 months               
All 324 366 43(13.3) 29(7.9) 0.022 12(3.7) 8(2.2) 0.236 6(1.9) 5(1.4) 0.611 6(1.9) 3(0.8) 0.196 
HIV-uninfected 88 76 3(3.4) 5(6.6) 0.282 1(1.1) 0 - 0 0 - 1(1.1) 0 - 
HIV-infected 236 290 40(17.0) 248.3) 0.002 11(4.7) 8(2.8) 0.245 6(2.5) 5(1.7) 0.514 5(2.1) 3(1.0) 0.256 
1
Significant differences, i.e., P <0.05, are in bold type font; 
2
PCV13 serotypes, serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F; 
3
non-PCV13 
serotypes: excluding serotypes in PCV13 
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Figure 4.1: The proportion of mother-child pairs sampled in 2010 (Period-1; PCV7 era) and 2012 (Period-2; PCV13 era) from Soweto, 
South Africa who were concurrently colonized by any pneumococcus, same serotype, PCV13 serotype and non-PCV13 serotype. 
PCV13 serotypes, serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F; non-PCV13 serotypes: excluding serotypes in PCV13
Same serotypes 
PCV13 serotypes Non PCV13 serotypes 
* 
* 
* * 
* 
* * 
* 
* 
* 
* * 
* * 
* * 
* * 
*P<0.05 
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4.3.2    Temporal changes in pneumococcal colonization prevalence in 
children 
 
Overall among children, the prevalence of any pneumococcal serotype, PCV7 serotypes, 
PCV13 additional serotypes and any of the PCV13 serotypes were higher in period 1 
compared to period 2, Figure 4.2 and Table 4.5. In contrast, the prevalence of non-vaccine 
serotype colonization increased in period 2 (30.8% vs. 42.7%, p<0.0001). Reduction in the 
prevalence of PCV13 serotype colonization was evident in all age groups, whilst a 
concomitant  increase in the prevalence of non-vaccine serotype colonization was also 
observed in all age groups, albeit not significant in infants <9 months age. 
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Table 4.5 Comparison of pneumococcal colonization by HIV-status in children and mothers enrolled in 2010 (Period 1; PCV7 era) and 
2012 (Period 2; PCV13 era), in Soweto, South Africa. 
 Total per group All Pneumococci PCV7 serotypes
3
 
Additional PCV13 
serotypes
4
 
PCV13 serotypes
5
 
Non PCV13 
serotypes
6
 
 N n (%) n (%) n (%) n (%) n (%) 
Group Period 1
1
 Period 2
2
 Period 1 Period 2 Period 1 Period 2 Period 1 Period 2 Period 1 Period 2 Period 1 Period 2 
All children             
Total 1411 1649 930(65.9) 966(58.6) 343(24.3) 173(10.5) 187(13.3) 97(5.9) 530(37.6) 270(16.4) 435(30.8) 704(42.7) 
AOR
1
 (95% CI)   0.76(0.65, 0.89) 0.35(0.27, 0.46) 0.43(0.33, 0.57) 0.34(0.28, 0.40) 1.77(1.51, 2.06) 
HIV-uninfected 698 1033 444(63.6) 597(57.8) 159(22.8) 99(9.58) 98(14.0) 49(4.7) 257(36.8) 148(13.3) 206(29.5) 454(44.0) 
AOR (95% CI)   0.85(0.69, 1.04) 0.39(0.29, 0.51) 0.32(0.23, 0.47) 0.32(0.25, 0.40) 1.93(1.56, 2.39) 
HIV-infected 713 616 486(68.2) 369(59.9) 184(25.8) 74(12.0) 89(12.4) 48(7.7) 273(38.3) 122(19.8) 229(32.1) 250(40.6) 
AOR (95% CI)   0.72(0.55, 0.93) 0.38(0.28, 0.52) 0.61(0.42, 0.89) 0.37(0.28, 0.49) 1.55(1.21, 2.00) 
<9months             
Total 230 396 125(54.4) 193(48.7) 38(16.5) 40(10.1) 20 (8.7) 14 (3.5) 58(25.2) 54(13.6) 69(30.0) 140(35.4) 
AOR (95% CI)   0.94(0.47, 1.86) 0.66(0.40, 1.08) 0.40(0.20, 0.82) 0.52(0.34, 0.79) 1.63(0.80, 3.31) 
HIV-uninfected 170 344 98 (57.7) 175(50.9) 31 (18.2) 33(9.6) 18 (10.6) 14 (4.1) 49 (28.8) 47 (13.7) 51 (30.0) 129 (37.5) 
AOR (95% CI)   0.73(0.50, 1.06) 0.57(0.33, 0.99) 0.36(0.17, 0.75) 0.43(0.27, 0.68) 1.29(0.86, 1.94) 
HIV-infected 60 52 27 (45.0) 18 (34.6) 7 (11.7) 7 (13.5) 2 (3.3) 0 (0.0) 9 (15.0) 7 (13.5) 18 (30.0) 11 (21.2) 
AOR (95% CI)   0.78(0.35, 1.73) 0.86(0.19, 3.85) - 0.53(0.13, 2.14) 0.82(0.32, 2.07) 
9-24 months             
Total 408 539 267(65.4) 322(59.7) 116(28.4) 56(10.4) 56 (13.7) 24 (4.5) 172(42.2) 80(14.8) 105(25.7) 245(45.5) 
AOR (95% CI)   0.73(0.55, 0.96) 0.31(0.18,0.53) 0.46(0.23, 0.93) 0.26(0.16, 0.41) 2.02(1.36, 2.99) 
HIV-uninfected 253 447 169(66.8) 273(61.1) 70(27.7) 43(9.62) 39 (15.4) 19 (4.3) 109(43.1) 62(13.9) 68(26.9) 214(47.9) 
AOR (95% CI)   0.74(0.53, 1.03) 0.28(0.18, 0.43) 0.25(0.14, 0.45) 0.23(0.16, 0.33) 2.51(1.79, 3.52) 
HIV-infected 155 92 98(63.2) 49(53.2) 46(29.7) 13(14.1) 17(11.0) 5(5.4) 63(40.7) 18(19.6) 37(23.9) 31(33.7) 
AOR (95% CI)   0.94(0.50, 1.77) 0.35(0.16, 0.80) 0.40(0.11, 1.53) 0.31(0.14, 0.67) 1.85(1.01, 3.37) 
>24-48 months             
Total 449 348 316(70.4) 227(65.2) 123(27.4) 31(8.91) 66 (14.7) 23 (3.5) 189(42.1) 54(15.5) 137(30.5) 175(50.3) 
AOR (95% CI)   0.88(0.64, 1.20) 0.21(0.13, 0.34) 0.42(0.26, 0.69) 0.25(0.17, 0.36) 2.52(1.86, 3.42) 
HIV-uninfected 187 166 131(70.1) 110(66.3) 45(24.1) 12(7.23) 32 (17.1) 11 (6.7) 77(41.2) 23(13.9) 60(32.1) 87(52.4) 
AOR (95% CI)   1.02(0.63, 1.64) 0.24(0.12, 0.49) 0.33(0.16, 0.71) 0.26(0.14, 0.45) 2.37(1.52, 3.69) 
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HIV-infected 262 182 185(70.6) 117(64.3) 78(29.8) 19(10.4) 34 (13.0) 12 (6.6) 112(42.8) 31(17.0) 77(29.4) 88(48.4) 
AOR (95% CI)   0.83(0.54, 1.27) 0.28(0.16, 0.49) 0.48(0.24, 0.96) 0.30(0.19, 0.47) 2.18(1.46, 3.26) 
>48-144 months             
Total 324 366 222(68.5) 224(61.2) 66(20.4) 46(12.6)  45(13.9) 36(9.8) 111(34.3) 82(22.4) 124(38.3) 144(39.3) 
AOR (95% CI)   0.75(0.55, 1.04) 0.53(0.35, 0.81) 0.70(0.43, 1.12) 0.52(0.37, 0.75) 1.12(0.82, 1.54) 
HIV-uninfected 88 76 46(52.3) 39(51.3) 13(14.8) 11(14.5) 9 (10.2) 5 (6.5) 22(25.0) 16(21.1) 27(30.7) 24(31.6) 
AOR (95% CI)   0.96(0.52, 1.78) 0.98(0.41, 2.33) 0.62(0.20, 1.93) 0.80(0.38, 1.66) 1.05(0.53, 2.08 
HIV-infected 236 290 176(74.6) 185(63.8) 53(22.5) 35(12.1) 36 (15.3) 31(10.7) 89(37.7) 66(22.8) 97(41.1) 120(41.4) 
AOR (95% CI)   0.62(0.42, 0.91) 0.43(0.26, 0.70) 0.70(0.41, 1.18) 0.45(0.29,0.71) 0.97(0.66, 1.42) 
Mothers             
Total 1376 1556 209(15.2) 176(11.3) 52(3.78) 18(1.15) 45(3.3) 30(1.9) 97(7.05) 48(3.08) 117(8.50) 128(8.21) 
AOR (95% CI)   0.71(0.57, 0.89) 0.38(0.21, 0.68) 0.69(0.42, 1.13) 0.53(0.36, 0.78) 0.83(0.63, 1.09) 
HIV-uninfected 672 948 65(9.67) 92(9.67) 20(2.98) 5(0.53) 16(2.3) 14(1.5) 36(5.36) 19(2.00) 30(4.46) 73(7.68) 
AOR (95% CI)   1.02(0.73, 1.43) 0.22(0.07, 0.68) 0.65(0.30, 1.42) 0.44(0.23, 0.81) 1.58(1.00, 2.49) 
HIV-infected 704 608 144(20.5) 84(13.8) 32(4.55) 13(2.13) 29(4.1) 16(0.2) 61(8.66) 29(4.76) 87(12.4) 55(9.03) 
AOR (95% CI)   0.61(0.45, 0.82) 0.56(0.28, 1.11) 0.72(0.38, 1.37) 0.63(0.39, 1.02) 0.69(0.48, 0.99) 
1
PCV7 era; 
2
PCV13 era 
3
PCV7 serotypes: serotypes included in the seven-valent pneumococcal conjugate vaccine, i.e. 4, 6B, 9V, 14, 18C, 19F, 23F;  
4
Additional PCV13 serotypes: serotypes 1, 3, 5, 6A, 7F and 19A; 
5
PCV13-serotypes: combination of PCV7 and additional PCV13-serotypes; 
6
Non 
PCV13serotypes: serotypes not included in the PCV13 including the non-typeable serotypes. AOR: adjusted odds ratio; 95% CI: 95% Confidence Interval;  
 
In children, variables considered in the models are: child attending day care, child having a running nose, mother being colonized, whether the child was ever 
breast fed, whether the child was infected with tuberculosis, child ever hospitalized and child on antibiotics. In HIV-infected children, we also included the 
use of antiretroviral therapy (ART). In women, we considered characteristics such as whether the mother was a smoker, mother drinks alcohol, mother with a 
running nose; mother takes snuff, mother ever hospitalized and whether the child was colonized. In addition, in HIV-infected mothers, in the multivariate 
model, we included the use of ART, antibiotics use and whether the mother was previously treated for tuberculosis. All the variables were modelled as 
categorical  variables.  
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Figure 4.2 Comparison of pneumococcal colonization by HIV-status in children and mothers enrolled in 2010 (Period 1; PCV7 era) and 
2012 (Period 2; PCV13 era), in Soweto, South Africa. PCV7 serotypes: serotypes 4, 6B, 9V, 14, 18C, 19F, 23F; Additional PCV13 
PCV7 
Additional PCV13 PCV13 
Non PCV13 
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serotypes: serotypes 1, 3, 5, 6A, 7F and 19A; PCV13 serotypes: combination of PCV7 and additional PCV13 serotypes; Non PCV13 
serotypes: serotypes not include in the PCV-13 including the non-typeable serotypes
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Among HIV-uninfected children, reductions in PCV7 serotype colonization from period 1 to period 2 
was evident among all age groups except those >48 months age. A similar trend for lower prevalence 
of PCV13 additional serotypes colonization was observed in these age groups; Figure 2. On the other 
hand, the prevalence of non PCV13 serotype colonization was greater in period-2 (44.0%) than 
period-1 (29.5%), p<0.0001. This was evident in children age 9-24 months and >24-48 months, with 
a similar trend also observed among infants <9 months age, whereas it remained unchanged among 
those >48 months age.  
 
Overall among HIV-infected children, the prevalence of overall pneumococcal colonization trended 
to being higher in period 1 compared to period 2 (68.2 vs 59.9%, respectively; p=0.012); including 
for PCV7 serotypes (25.8 vs 12.0%; p<0.0001 and any PCV13 serotype (38.3 vs 19.8%; p<0.0001). 
Conversely, there was a higher prevalence of non PCV13 serotype colonization in period 2 (40.6%) 
compared to period 1 (32.1%; p=0.001). The decline in prevalence of PCV13 serotype colonization 
was detected among all HIV-infected age groups >9 months old, whilst there was a limited number of 
evaluable children <9 months old; Table 4.5. An increase in prevalence of non PCV13 serotype 
colonization between period 1 to period 2 among HIV-infected children was only apparent in in the 
age group >24-48 months (29.4 vs 48.4%; p=0.0001). 
The prevalence of individual serotype colonization in period 1 and period 2 among all the children 
and when stratified by age group are reported in Figure 4.3. Overall, declines in colonization were 
observed for serotypes 3 (3.3% to 0.8% (p=0.03), 6A (6.0% vs. 1.9%, p<0.001), 6B (5.2% vs. 1.7%, 
p<0.001), 14 (3.1% vs. 0.9%, p<0.001), 19A (5.0% vs. 2.7%, p=0.001), 19F (8.0% vs. 4.5%, 
p<0.001) and 23F (6.2% vs. 2.2%, p<0.001); Figure 4.3a.  
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Figure 4.3 Prevalence of common serotypes in all children (A), HIV-uninfected children (B) and 
HIV-infected children (C) observed in 2010 (Period 1; PCV7 [serotypes 4, 6B, 9V, 14, 18C, 19F, 
23F] era)  and 2012 (Period 2; PCV13 [serotypes 1, 3, 4, 5, 6A, 6B,7F, 9V, 14, 18C, 19A, 19F, 
23F] era).  
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Decline in prevalence of colonization by all these serotypes were evident in both HIV-
infected and HIV-uninfected children, albeit not significant for serotype 3 in both groups and 
for 19A among the HIV-infected children (Figure 4.3b and 4.3c). Serotypes 1, 4, 5, 7F, 9V 
and 18C were uncommon (≤2%) in both periods.  
Overall, the most common non PCV13 serotypes in period 2 included 11A (3.5%, n=58), 
15A (3.0%, n=49), 15B (4.2%, n=69), 16F (3.6%, n=59), 34 (2.6%, n=43) and 35B (2.1%, 
n=34); Figure 4.3. The prevalence of colonization by each of the above serotypes increased 
between period 1 to period 2, except for 16F and 34. Among HIV-uninfected children, an 
increase in non-vaccine serotype colonization was observed specifically for serotypes 11A 
(2.0 vs 3.9%; p=0.04), 15A (1.0 vs 3.4%; p=0.002), 15B (2.4 vs 3.8%; p<0.0001) and 34 (1.4 
vs 3.0%, p=0.04). Although similar trends were evident in HIV-infected children, this was 
only significant for serotype 35B (0.3% to 2.3%; p=0.01).  
4.3.3    Temporal changes in pneumococcal colonization prevalence in 
women  
Among women, there was a decline in overall pneumococcal colonization prevalence from 
period 1 (15.2%) to period 2 (11.3%; p=0.003), including PCV7 serotype (3.8% vs 1.2%; 
p=0.001) and PCV13 serotype (7.1% vs 3.1%; p=0.001) colonization; Figure 4.2. The decline 
in PCV13 serotype colonization between period 1 and period 2 was significant among HIV-
uninfected women with a similar trend observed in HIV-infected women. Similar findings 
were observed when analyses were limited to the PCV7 serotypes.  
The overall prevalence of pneumococcal colonization remained unchanged among HIV-
uninfected women, with a non-significant increase in non-vaccine serotype colonization in 
period 2 compared to period 1 (4.5 vs 7.7%; p=0.05). In contrast, there was a reduction in 
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colonization by any serotype among HIV-infected women between period 1 (20.5%) and 
period 2 (13.8%; p=0.001), due to the lower PCV13 serotype colonization. 
Among women, the most frequently colonizing vaccine serotypes in period 1, were 19F 
(1.3%, n=18), 23F (0.9%, n=13), 6A (0.8%, n=11) and 6B (0.5%, n=7), the prevalence of 
which declined to 0.4 % (p=0.006), 0.2% (p=0.005), 0.3% (p=0.04) and 0.1% (p=0.05) in 
period 2, respectively; Figure 4.4a. Serotype 3 colonization was more prevalent in HIV-
infected (2.0%) than HIV-uninfected women (0.6%; p=0.02) in period 1, with a non-
significant decrease observed between period 1 and period 2 in HIV-infected women (2.0% 
vs 1.2%; p=0.23); Figure 4.4b and 4.4c.  
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Figure 4.4 Prevalence of common serotypes in all women (A), HIV-uninfected women 
(B) and HIV-infected women (C) observed in 2010 (Period 1) and 2012 (Period 2)  
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4.3.4   Differences in carriage between HIV-infected and HIV-
uninfected groups 
The demographic characteristics differed significantly between HIV-infected and HIV-
uninfected children in both study periods; Table 4.6. After adjusting for these differences, no 
differences in carriage of overall pneumococcus and PCV13 serotypes were observed in 
either study period between HIV-uninfected and HIV-infected children; Figure 4.5 and Table 
4.7.  
 
 88 
 
 
 
   
  
  
Figure 4.5 Comparison of pneumococcal colonization in HIV-uninfected and HIV infected children (mothers) sampled in 2010 (Period 
1; PCV7 era) and 2012 (Period 2; PCV13 era) in Soweto, South Africa. 
PCV7 
Additional PCV13 
PCV13 
Non PCV13 
All pneumococcus 
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Table 4.6 Comparison of demographic characteristics between HIV-infected and HIV-uninfected children enrolled in 2010 (Period 1; 
PCV era) and 2012 (Period 2; PCV13 era) in Soweto, South Africa  
 Period 1 (PCV7 era) Period 2 (PCV13 era) 
Characteristic HIV-infected HIV-uninfected  p-value HIV-infected HIV-uninfected 
 
p-value 
All children enrolled; N,  mean age in years ±SD
1
  713, 3.3± 2.1  698,2.03±1.6 <0.001 616, 3.8±2.12 1033,1.4 ±1.37 <0.001 
<9 months; 
2
n, mean age (SD) months;  60, 0.41 ± 0.17 170,0.40 ± 0.11 0.60 52, 0.42± 0.17 344,0.40 ± 0.18 0.26 
 9-24 months; n, mean age in years ±SD 155, 1.41 ± 0.37 253, 1.07 ± 0.35 <0.001 92, 1.23±0.39 447,1.16 ± 0.34 0.08 
24.1- 48 months; n, mean in age years ±SD 262, 3.01 ± 0.60 187, 3.53 ± 0.25 <0.001 182, 2.98±0.58 166,2.87 ± 0.54 0.07 
48.1-144 months; n, mean in age years ±SD 236,  5.72 ± 1.51 88, 4.7 ± 0.82 <0.001 29, 5.66±1.14 76,5.63 ± 1.14 0.83 
Currently breastfed, n/N
3
 (%) 18/713  (2.5) 301/697 (43.2) <0.001 45/566 (7.5) 501/973(51.5) <0.001 
Ever breastfed, n/N (%) 148/665 (22.3) 337/378(89.2) <0.001 213/549 (38.8) 389/465(83.7) <0.001 
Attendance at day-care, n/N (%) 379/712 (53.2) 232/678(34.2) <0.001 325/605 (53.7) 216/969(22.3) <0.001 
Currently on TB
4
 treatment/prophylaxis, n/N (%) 57/700(8.14) 3/676(0.44) <0.001 59/608 (9.7) 7/975 (0.7) <0.001 
Treated for TB in the past year, n/N (%) 122/660 (17.0) 4/669(0.6) <0.001 150/583 (25.7) 9/966 (0.93) <0.001 
Currently taking antibiotics, n/N (%) 108/704(15.3) 12/672 (1.8) <0.001 49/609 (8.1) 39/973 (4.0) 0.001 
Hospitalized in the last 3 months, n/N (%) 42/702(6.0) 21/673(3.1) 0.011 75/607 (12.4) 31/968 (3.2) <0.001 
Pneumococcal vaccine receipt
5
       
<9 months 
 
At least one dose 30/60 (50.0) 166/170  (97.6) <0.001 18/52 (34.6) 302/344 (87.8) <0.001 
At least 2 doses 16/60 (26.7) 156/170 (91.8) <0.001 11/52 (21.1) 295/344 (85.8) <0.001 
9 -24months At least one dose 35/155 (22.6) 224/253 (88.5) <0.001 15/92 (16.3) 385/447 (86.1) <0.001 
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At least 2 doses 34/155 (21.9) 221/253 (87.4) <0.001 15/92 (16.3) 380/447 (85.0) <0.001 
At least 3 doses 27/155  (17.4) 204/253 (80.6) <0.001 13/92 (14.1) 342/447 (76.5) <0.001 
>24-48 months At least one dose 0/262 0/187 NA
6
 14/182(7.7) 131/166 (78.9) <0.001 
At least 2 doses 0/262 0/187 NA 14/182(7.7) 129/166 (77.7) <0.001 
At least 3 doses 8/262    (3.1) 0/187 NA 13/182(7.1) 122/166 (73.5) <0.001 
>48-144 months At least one dose 0/236 0/88 NA 3/290 (0.7) 6/76  (7.9) 0.003 
At least  2 doses 0/236 0/88 NA 1/290 (0.3) 6/76   (7.9) <0.001 
At least 3 doses  15/236 (6.4) 0/88 NA 1/290 (0.3) 5/76  (7.9) 0.002 
1
Standard deviation;  
2
Number of individuals with investigated outcome 
3
Total number of individuals with available information on the characteristic 
4
Tuberculosis; 
5
only for children with available vaccination records at time of interview 
6
NA: Not done due to limited number of observations in one group 
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Table 4.7 Comparison of pneumococcal colonization in HIV-uninfected (HIV-) and HIV-infected (HIV+) children (mothers) sampled in 
2010 (Period 1; PCV7 era) and 2012 (Period 2; PCV13 era) in Soweto, South Africa. 
 
 Total per group All Pneumococci PCV7 serotypes
1
 
Additional PCV13 
serotypes
2
 
PCV13 serotypes
3
 
Non PCV13 
serotypes
4
 
 N n (%) n (%) n (%) n (%) n (%) 
Group HIV- HIV+ HIV- HIV+ HIV- HIV+ HIV- HIV+ HIV- HIV+ HIV- HIV+ 
All children             
Period 1 698 713 444(63.6) 486(68.2) 159(22.8) 184(25.8) 98(14.0) 89(12.4) 257(36.8) 273(38.3) 206(29.5) 229(32.1) 
AOR
5
 (95% CI)
6
   1.22(0.98,1.53) 1.11(0.85,1.45) 0.84(0.61,1.18) 1.06(0.78,1.27) 1.00(0.79,1.27) 
Period 2 1033 616 597(57.8) 369(59.9) 99(9.58) 74(12.0) 49(4.7) 48(7.7) 148(13.3) 122(19.8) 454(44.0) 250(40.6) 
AOR (95% CI)   1.20(0.95, 1.50) 0.66(0.14, 3.09) 1.32(0.79, 2.19) 1.38(1.02, 1.86) 0.90(0.71, 1.13) 
<9months             
Period 1 170 60 98 (57.7) 27 (45.0) 31 (18.2) 7 (11.7) 18 (10.6) 2 (3.3) 49 (28.8) 9 (15.0) 51 (30.0) 18 (30.0) 
AOR (95% CI)   0.60(0.33, 1.09) 0.60(0.24, 1.49) 0.29(0.06, 1.31) 0.49(0.22, 1.10) 0.76(0.38, 1.52) 
Period 2 344 52 175(50.9) 18 (34.6) 33(9.6) 7 (13.5) 14 (4.1) 0 (0.0) 47 (13.7) 7 (13.5) 129 (37.5) 11 (21.2) 
AOR (95% CI)   0.51(0.28, 0.94) 1.27(0.51, 3.16) - 0.94(0.39, 2.23) 0.56(0.25, 1.27) 
9-24 months             
Period 1 253 155 169(66.8) 98(63.2) 70(27.7) 46(29.7) 39 (15.4) 17(11.0) 109(43.1) 63(40.7) 68(26.9) 37(23.9) 
AOR (95% CI)   0.98(0.64, 1.51) 1.07(0.66, 1.73) 0.63(0.34, 1.17) 0.94(0.61, 1.44) 0.83(0.51, 1.37) 
Period 2 447 92 273(61.1) 49(53.2) 43(9.62) 13(14.1) 19 (4.3) 5(5.4) 62(13.9) 18(19.6) 214(47.9) 31(33.7) 
AOR (95% CI)   0.93(0.57, 1.51) 1.43(0.71, 2.85) 0.13(0.01, 1.29) 0.98(0.45, 2.13) 0.69(0.42, 1.14) 
>24-48 months             
Period 1 187 262 131(70.1) 185(70.6) 45(24.1) 78(29.8) 32 (17.1) 34 (13.0) 77(41.2) 112(42.8) 60(32.1) 77(29.4) 
AOR (95% CI)   1.29(0.83, 1.99) 1.14(0.72, 1.81) 0.69(0.41, 1.18) 0.95(0.63, 1.42) 1.15(0.73, 1.81) 
Period 2 166 182 110(66.3) 117(64.3) 12(7.23) 19(10.4) 11 (6.7) 12 (6.6) 23(13.9) 31(17.0) 87(52.4) 88(48.4) 
AOR (95% CI)   1.07(0.67, 1.71) 1.51(0.71, 3.20) 0.72(0.25, 2.04) 1.28(0.72, 2.31) 0.91(0.59, 1.40) 
>48-144 months             
Period 1 88 236 46(52.3) 176(74.6) 13(14.8) 53(22.5)  9 (10.2) 36 (15.3) 22(25.0) 89(37.7) 27(30.7) 97(41.1) 
AOR (95% CI)   2.68(1.61, 4.46) 1.67(0.86, 3.24) 1.51(0.68, 3.31) 1.68(0.94, 2.99) 1.11(0.57, 2.17) 
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Period 2 76 290 39(51.3) 185(63.8) 11(14.5) 35(12.1) 5 (6.5) 31(10.7) 16(21.1) 66(22.8) 24(31.6) 120(41.4) 
AOR (95% CI)   1.77(1.06, 2.97) 0.81(0.39, 1.68) 1.75(0.64, 4.75) 1.04(0.55, 1.98) 1.53(0.89, 2.62) 
Mothers             
Period 1 672 704 65(9.67) 144(20.5) 20(2.98) 32(4.55) 16(2.3) 29(4.1) 36(5.36) 61(8.66) 30(4.46) 87(12.4) 
AOR (95% CI)   2.27(1.64, 3.15) 1.40(0.79, 2.51) 1.71(0.89, 3.27) 1.63(1.05, 2.51) 2.99(1.93, 4.64) 
Period 2 948 608 92(9.67) 84(13.8) 5(0.53) 13(2.13) 14(1.5) 16(0.2) 19(2.00) 29(4.76) 73(7.68) 55(9.03) 
AOR (95% CI)   1.46(1.06, 2.02) 4.37(1.39,13.7) 1.90(0.88, 4.09) 2.59(1.38, 4.85) 1.12(0.77, 1.63) 
1
PCV7 serotypes: serotypes: 4, 6B, 9V, 14, 18C, 19F, 23F;  
2
Additional PCV13 serotypes: serotypes 1, 3, 5, 6A, 7F and 19A  
3
PCV13 serotypes: combination of PCV7 and additional PCV13-serotypes;  
4
Non PCV13 serotypes: serotypes not included in the PCV13 including the non-typeable serotypes. 
5
AOR: adjusted odds ratio; 
6
95% CI: 95% Confidence Interval;  
 
In children, variables included in the models include child attending day care, child having a running nose, mother being colonized, whether the child was 
ever breast fed, whether the child was infected with tuberculosis, child ever hospitalized and child on antibiotics. In women, included characteristics such as 
whether the mother was a smoker, mother drinks alcohol, mother with a running nose, mother takes snuff, mother ever hospitalized and whether the child was 
colonized. All the variables were modelled as categorical variables.  
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There were more HIV-infected women who had suffered a chronic illness, were currently on 
tuberculosis treatment, who had been treated for tuberculosis in the previous year, or were 
currently on antibiotics than  HIV-uninfected women in both study periods;  see Table 4.8. 
HIV-infected women compared to HIV-uninfected individuals had higher prevalence of any-
serotype colonization in period-1 (20.5% vs. 9.7%, p<0.001) as well as PCV13-serotype 
colonization (4.8% vs. 2.0% in period-2; p=0.003),  Table 4.7.  
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Table 4.7 Comparison of demographic characteristics between HIV-infected and HIV-uninfected women in Period 1 and Period 2, in 
Soweto, South Africa 
Characteristic  Period 1  
N=1376 
                 
  Period 2  
N=1556 
 p-value 
 HIV-infected HIV-
uninfected 
p-value HIV-infected HIV-uninfected p-value 
Number enrolled  704 (51.2) 672 (48.8)  608 (39.1) 948 (60.9)  
Smoker, n
1
/N
2
 (%) 40/704 (5.7) 38/672 (5.7) 0.938 45/608 (7.4) 46/948 (4.9) 0.037 
Takes snuff, n/N (%)  50/704 (7.1) 27/672 (4.0) 0.013 61/608 (10.0) 26/948 (2.7) <0.001 
Drinks alcohol, n/N (%) 110/704 (15.6) 127/672 (18.9) 0.108 159/608(26.2) 250/948 (26.4) 0.923 
Suffers from a chronic illness, n/N (%) 70/704 (9.9) 60/672 (8.9) 0.212 59/608 (9.7) 55/948 (5.8) 0.004 
Currently on TB
3
 treatment, n/N (%) 17/704 (2.4) 3/672 (0.4) 0.002 15/608 (2.5) 1/948 (0.1) <0.001 
Treated for TB in past year, n/N (%) 76/704 (10.8) 4/672 (0.6) <0.001 74/608 (12.2) 7/948 (0.7) <0.001 
Currently on antibiotic treatment, n/N (%) 76/704 (10.8) 3/672 (0.4) <0.001 12/608 (2.0) 8/948 (0.8) 0.054 
Hospitalized in the last 3 months, n/N (%) 12/704 (1.7) 13/672 (1.9) 0.750 8/608 (1.3) 10/948 (1.1) 0.639 
1Number of individuals with investigated outcome 
2Total number of individuals with available information on the characteristic 
3
Tuberculosis
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4.4                             Discussion 
The targeted immunization of young South African infants with three doses of PCV at 6, 4 
and 40 weeks of life was temporally associated with a decline in vaccine serotype 
colonization among HIV-infected and HIV-uninfected individuals, including among 
individuals such as HIV-infected  women who were not targeted for immunization. This was 
observed during a period of time when the immunization program transitioned from use of 
PCV7 since April 2009 to PCV13 in May 2011, and in the absence of any substantive catch-
up campaign of older children. 
Similar to previous reports, HIV-infected adults in our study, even in the presence of infant 
PCV immunization, had a higher prevalence of overall and PCV13 serotype colonization than 
HIV-uninfected adults (47, 140, 153, 159, 160), implying that HIV-infected adults are still at 
increased risk of IPD due to these serotypes.   Recently, it has been shown that the indirect 
effects of childhood PCV immunization in South Africa on adult IPD were similar in HIV-
infected and in HIV-uninfected adults, nonetheless incidence of IPD remained 36-fold higher 
in HIV-infected adults in the PCV era (112). Specifically, post PCV introduction, HIV-
infected adults aged 25-44 years had a higher incidence of overall, PCV7 serotype, 6A, 
PCV13 serotype and non-vaccine serotype IPD compared to HIV-uninfected adults (112). 
Despite the heightened IPD risk, currently there is no national recommendation to vaccinate 
HIV-infected adults with PCV, although the PCV has been shown to be 75% efficacious 
against vaccine serotype IPD in HIV-infected adults for a limited period of time (161). As 
such, the indirect effect realised from vaccinating infants in South Africa is likely to have 
contributed to the indirect effect of protection against vaccine serotype IPD even in HIV-
infected individuals (112). This likely culminated through reduced community transmission 
of these vaccine serotypes from young children to older unvaccinated individuals, including 
HIV-infected children.   
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In partially vaccinated HIV-infected children, i.e. age group 0-9 months, no change was 
observed from Period 1 to Period 2 in vaccine serotype or non-vaccine serotype colonization. 
This may be attributable to the small numbers of children in this age group or may suggest 
that two doses of PCV given at 6 and 14 weeks are inadequate to protect against vaccine 
serotype colonization (162), especially among HIV-infected children at these early stages of 
the PCV immunization program. We expect a reduced risk of exposure to vaccine serotypes 
over time which will likely result in reduction of vaccine serotype colonization among this 
age group (13). An indirect effect against vaccine serotype colonization has also been 
reported among young children not yet eligible for PCV vaccination in The Gambia, 
following vaccination of individuals across all age groups in selected villages (163).The 
decrease in PCV7 serotypes, but not in the PCV13 additional serotypes in HIV-uninfected 
children <9 months is an encouraging evidence that younger children are also benefitting 
from indirect protection as the immunization programme continues. This is also corroborated 
by decreases in PCV7 serotype IPD of 78%, among children younger than 10 weeks of age in 
South Africa (112). 
The reduction in vaccine serotype colonization from period 1 to period 2 in fully vaccinated 
children was, however, partially offset by the increase in non PV13 serotype colonization that 
resulted in the overall pneumococcal colonization remaining unchanged among this group. 
On the other hand, non PCV13 serotype colonization among HIV-infected women did not 
differ significantly between the two study periods, which was also corroborated by no 
increase in non PCV13 serotype IPD among HIV-infected adults since the introduction of 
PCV into the South African immunization program (112).  
Among children >48 months of age, the overall prevalence of pneumococcal colonization 
remained unchanged in HIV-uninfected children in period 2 compared to period 1, although a 
decline in PCV13 serotype colonization was detected among HIV-infected children. 
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Similarly, in a rural South African community with high HIV-prevalence, there was no 
change in colonization among children aged >3 to 12 years, two years post PCV7 
introduction (162). Although unlikely, the decrease in PCV13 serotype colonization in older 
HIV-infected children might have been due to the catch up immunization campaign targeted 
at this age-group at the time of PCV13 introduction. In The Gambia, decreases in 
colonization among older children were observed in villages that had additional catch up 
vaccination 12 months after catch up was initiated (80). The high colonization prevalence 
among older children in settings such as ours and other low-middle income countries, 
suggests that catch up campaigns aimed at older children, could possibly accelerate and 
improve the indirect effects of PCV immunization compared to only targeting young infants 
for immunization (52). Nevertheless, even with no initial catch up campaign in our setting, an 
indirect effect was detected within three years of PCV introduction into our public 
immunization program, indicating young children likely to have been the most important 
source of transmission of these vaccine serotypes prior to the PCV immunization program. 
The reduction in vaccine serotype colonization among HIV-infected children in the era of 
PCV immunization, is in contrast to our earlier randomized controlled trial of an 
investigational 9 valent PCV, in which no difference was observed in prevalence of vaccine 
serotype colonization between PCV vaccinated and unvaccinated HIV-infected children at 5 
years post vaccination (65). This earlier study only measured direct protection at the 
individual level, whereas the current study is evaluating the community wide effect of the 
infant PCV immunization program, and measures the composite of the direct and indirect 
effects among vaccinated and indirect effect among unvaccinated age groups.  
Our study was not powered to detect changes in individual serotypes, especially when 
stratifying by HIV-status or age groups, nevertheless, decreases in individual vaccine 
serotypes were observed among fully vaccinated children for serotypes 6A, 6B, 19F and 23F. 
 98 
 
 
 
Furthermore, largely due to the success of the prevention of mother-to-child transmission 
program in South Africa, we were unable to recruit similar numbers of young HIV-infected 
and HIV-uninfected children; however, statistical power was achieved to demonstrate 
changes in older age-groups. Another limitation of our study is that it is cross-sectional and 
we cannot exclude the fact that the observed changes can be purely temporally driven.  
In conclusion, our study suggests that PCV13 immunization of infants, vaccinated at 6, 10 
and 40 weeks of age,  was associated with a reduction in vaccine serotype colonization 
among HIV-infected and HIV-uninfected individuals, including among age groups not 
targeted for vaccination. Although HIV-infected women are disproportionately affected by 
disease caused by predominantly “pediatric-serotypes” included in PCV7, in whom the 
burden remains 40-fold greater than the general adult population even in the presence of 
antiretroviral therapy (15), the indirect effect against PCV13 serotype colonization in HIV-
infected women is likely to reduce the burden of vaccine serotype IPD in this group. 
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Chapter 5: Temporal association of infant immunization with 
pneumococcal conjugate vaccine on the ecology of Streptococcus 
pneumoniae, Haemophilus influenzae and Staphylococcus aureus 
nasopharyngeal colonization in a rural South African community 
  
5. 1                                          Introduction 
The nasopharynx is an ecological niche for pathogens, including bacteria such as 
Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus. Typically 
these bacteria exist in a commensal state of equilibrium with other nasopharyngeal flora, but 
may occasionally cause respiratory mucosal and invasive diseases(164). Pneumococcal and 
H. influenzae type b polysaccharide protein conjugate vaccines have been introduced into 
childhood immunization programmes in many countries.  
Pneumococcal conjugate vaccines (PCV) are directed against a limited number of 
pneumococcal serotypes, and reduce nasopharyngeal acquisition of the vaccine serotypes in 
immunized children, (8, 68, 69, 71) which could affect the equilibrium of colonization by 
other bacteria (103, 104). Furthermore, reduced nasopharyngeal colonization by pneumococci 
in young children may interrupt the transmission thereof to older PCV unvaccinated 
community members (73), and this  may consequently alter the nasopharyngeal flora of the 
community in general. The decline in colonization by PCV serotypes has, however, generally 
been associated with a concomitant increase in non-vaccine serotypes colonization, resulting 
in the overall prevalence of pneumococcal colonization remaining unchanged among PCV 
vaccinated and unvaccinated individuals (68, 69, 71, 74, 133, 135). 
In addition to changes in pneumococcal colonization due to childhood PCV immunization, it 
has been hypothesised that nasopharyngeal colonization by bacteria such as H. influenzae and 
S. aureus could also be affected (165-167). Interactions of non-vaccine serotype 
pneumococci with either H. influenzae or S. aureus in children and adults are largely 
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unknown. Previously described associations in PCV unvaccinated populations include an 
inverse relationship between S. pneumoniae colonization, particularly by those serotypes 
included in PCV7 and S. aureus (93, 94). This raised a theoretical concern that PCV 
immunization could increase the prevalence of colonization by S. aureus, which may lead to 
an increase in S. aureus disease (93, 168). Conversely, a synergistic association has been 
observed between H. influenzae and S. pneumoniae nasopharyngeal colonization in HIV-
uninfected children, (65, 100) suggesting that reduction in colonization by one may reduce 
colonization and consequently disease by the other.  
The aim of this component of my studies was to determine the effect of infant PCV7 
immunization on the prevalence of nasopharyngeal colonization and interaction between S. 
pneumoniae, S. aureus and H. influenzae among children and older individuals in a rural 
South African community with a high prevalence of HIV-infection. This analysis expands on 
our previous analysis of the same study cohort in which we described the effect of PCV7 
immunization on pneumococcal colonization in different child and adult age groups as 
described in Chapter 3 (162).  
 
5.2                                           Methods  
Detailed methods of the study and the study population have previously been published(162). 
Briefly, two cross sectional surveys were conducted in rural Mpumalanga province (in the 
Agincourt Health Socio-Demographic Survelliance Site- Agincourt HDSS) from May to 
October in 2009 (Period-1) and May to October in 2011 (Period-2), in which nasopharyngeal 
swabs were collected from children (≤12 years) and adolescents/adults (>12 years). S. 
pneumoniae, H. influenzae and S. aureus were isolated from nasopharyngeal swabs and 
processed by standard microbiologic methods as previously described (65). PCV7 was 
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introduced in to the national immunization program from May 2009 and substituted with 
PCV13 in May 2011 at 6 and 14 weeks of age, followed by a booster dose at 9 months. 
 
5.2.1 Definitions and statistical analyses 
PCV7serotypes included serotypes 4, 6B, 9V, 14, 18C, 19F and 23F. All other serotypes were 
classified as non PCV7 serotypes. Comparison of the prevalence of S. pneumoniae, S. aureus 
and H. influenzae nasopharyngeal colonization between the two study periods and bacterial 
interactions were analysed using repeated measures multivariate logistic regression models. 
Other risk factors for colonization such as attendance at day care center, fossil fuel usage for 
cooking and/or heating, age of participant and household structure, were added to the models 
to adjust for possible confounding. To explore the effects of covariates on each of the 3 
pathogens, colonization of each pathogen was modelled separately by using the remaining 2 
pathogens as predictors including an interaction term and other covariates. All statistical 
analyses were performed with STATA 12 (Statacorp, Texas, USA) and SAS version 9.2 
software (SAS Institute, Inc., NC, USA).  
 
5.3                                                      Results  
In period 1 and period 2, 1016 and 1877 children and 994 and 1781 adolescents/adults from 
577 and 1079 households respectively, were enrolled. Detailed demographic characteristics 
of the participants and households sampled are presented in section 3.1. Differences observed 
in period 1 compared to period 2 among study participants included older median age for 
children and higher proportion of children who were breastfed, these and other characteristics 
are shown in Table 3.1.  
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5.3.1 Temporal changes in prevalence of nasopharyngeal bacterial 
colonization 
 
In period 1, the prevalence of colonization among children was 74.9% for S. pneumoniae, 
compared to 55.7% for H. influenzae (p<0.0001) and 12.3% for S. aureus (p<0.0001); Table 
5.1 . Among adults sampled in period 1, colonization by S. aureus (31.2%) was more 
common than by H. influenzae (16.7%, p<0.0001) or by S. pneumoniae (11.2%, p<0.0001), 
similar trends were observed in period 2. The frequency of individuals who were not 
colonized by any of the three bacteria increased significantly in both children (13.8% vs. 
19.2%; p<0.0001) and adolescents/adults (51.3% vs. 67.0%; p<0.0001) from period 1 
compared to period 2, respectively; Table 5.1. 
 Details of S. pneumoniae colonization prevalence have been outlined in section 3.3.1 (162). 
Stratifying children by age group (0 to 2; 3 to 5 and 6 to 12 years) and comparing 
colonization patterns between period 1 and period 2, there was a decrease across all age 
groups for S. pneumoniae colonization. Colonization by S. pneumoniae decreased among 
adolescents (13-18 years) from 21.4% in period 1 to 12.3% in period 2 (p=0.0015) and 
among adults 19 to 45 years from 10.7% to 5.8% (p=0.0002); Table 5.1.  
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Table 5.1 Prevalence of bacterial pathogens in children and adults in Period 1 and Period 2 
Pathogen Period Population age group 
  0-2 years 3-5years 6-12years 13-18years 19-45years >45years 
Overall 
children 
Overall 
adults 
Overall 
OVERALL COLONIZATION 
1
SP 
Period 1
11
 331 (82.9) 219 (80.2) 186 (60.0) 36 (21.4) 68 (10.7) 12 (5.1) 736 (74.9) 116 (11.2) 852 (42.4) 
Period 2
12
 666 (73.3) 307 (72.2) 242 (50.0) 35 (12.3) 69 (5.8) 22 (5.9) 1215 (67.0) 126 (6.8) 1341 (36.7) 
AOR10 0.57 (0.41,0.76) 0.65(0.45,0.96) 0.63(0.47,0.85) 0.42(0.25,0.72) 0.51(0.36,0.73) 1.27(0.61,2.64) 0.60(0.50,0.72) 0.57(0.44,0.75) 0.63(0.55,0.73) 
 p-value 0.0002 0.0282 0.0022 0.0015 0.0002 0.5225 <.0001 <.0001 <.0001 
PCV7 
serotypes 
Period 1 180(45.1) 97(35.5) 59(19.0) 9(5.7) 19(3.0) 4(1.7) 336(34.2) 32(3.1) 368(18.3) 
Period 2 213(23.5) 121(28.7) 61(12.6) 6(2.1) 13(1.1) 4(1.1) 395(21.8) 23(1.2) 418(11.4) 
AOR 0.37(0.29,0.48) 0.76(0.54,1.05) 0.58(0.39,0.87) 0.38(0.13,1.10) 0.35(0.17,0.71) 0.63(0.15,2.58) 0.49(0.41,0.58) 0.39(0.22,0.67) 0.49(0.42,0.58) 
 p-value <0.0001 0.0986 0.0083 0.0752 0.0038 0.5204 <.0001 0.0006 <.0001 
Non PCV7 
serotypes 
Period 1 155(38.9) 125 (45.8) 132 (42.6) 28 (17.7) 51 (8.1) 8 (3.4) 412 (42.0) 87 (8.5) 499 (24.8) 
Period 2 456 (50.2) 187 (44.3) 182 (37.6) 28 (9.8) 52 (4.4) 16 (4.3) 825 (45.6) 96 (5.2) 921 (25.2) 
AOR 1.65(1.29,2.11) 0.95(0.69,1.31) 0.84(0.62,1.13) 0.47(0.26,0.84) 0.60(0.40,0.89) 1.59(0.67,3.75) 1.17(1.00,1.38) 0.66(0.49,0.90) 1.02(0.89,1.17) 
 p-value <.0001 0.7607 0.2468 0.0115 0.0111 0.2947 0.0515 0.0075 0.7627 
2
HI 
Period 1 226 (56.6) 174 (63.7) 147 (47.4) 30 (17.8) 111 (17.5) 32 (13.5) 547 (55.7) 173 (16.7) 720 (35.8) 
Period 2 490 (54.0) 233(55.2) 178 (36.8) 34 (11.9) 99 (8.3) 29 (7.8) 901 (49.7) 162 (8.8) 1063(29.1) 
AOR 0.88(0.69,1.12) 0.72(0.52,0.99) 0.60(0.45,0.81) 0.53(0.31,0.93) 0.44(0.33,0.59) 0.55(0.32,0.94) 0.73(0.62,0.86) 0.48(0.38,0.60) 0.66(0.58,0.75) 
 p-value 0.3088 0.0445 0.0009 0.0257 <0.0001 0.0285 0.0001 <0.0001 <0.0001 
3
SA 
Period 1 34 (8.5) 27 (9.9) 60 (19.4) 56 (33.3) 213 (33.6) 55 (23.2) 121 (12.3) 324 (31.2) 445 (22.1) 
Period 2 81 (8.9) 43 (10.2) 76 (15.7) 67 (23.5) 313 (26.3) 58 (15.6) 200 (11.0) 438 (23.7) 638 (17.4) 
AOR 1.03(0.67,1.57) 1.09(0.65,1.82) 0.79(0.54,1.16) 0.53(0.34,0.81) 0.70(0.56,0.86) 0.59(0.39,0.89) 0.94(0.74,1.20) 0.66(0.56,0.79) 0.75(0.65,0.86) 
 p-value 0.9015 0.7482 0.2333 0.0039 0.0008 0.0127 0.6346 <0.0001 <0.0001 
SINGLE PATHOGEN COLONIZATION 
Any SP 
serotype 
only 
Period 1 127  (31.8) 59 (21.6) 56 (18.0) 19 (12.0) 30 (4.7) 7 (3.0) 242 (24.6) 56 (5.4) 298 (14.8) 
Period 2 249 (27.4) 98 (23.2) 96 (19.8) 15 (5.3) 37 (3.1) 11 (3.0) 443 (24.4) 63 (3.4) 506 (13.8) 
AOR 0.81(0.62,1.05) 1.04(0.72,1.52) 1.14(0.79,1.64) 0.39(0.19,0.81) 0.62(0.38,1.03) 1.03(0.39,2.71) 0.96(0.80,1.15) 0.60(0.41,0.87) 0.88(0.74,1.03) 
 p-value 0.1137 0.8235 0.4871 0.011 0.0628 0.9567 0.6496 0.0066 0.1118 
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PCV7 
serotype 
only 
Period 1 68 (17.0) 28 (10.3) 12 (3.9) 7 (4.4) 5 (0.8) 2 (0.8) 108 (11.0) 14 (1.4) 122 (6.1) 
Period 2 79 (8.7) 43 (10.2) 21 (4.3) 4 (1.4) 8 (0.7) 2 (0.5) 143 (7.8) 14 (0.8) 157 (4.3) 
AOR 0.47(0.33,0.67) 0.98(0.59,1.63) 1.17(0.56,2.45) 0.33(0.09,1.15) 0.80(0.26,2.50) 0.58(0.08,4.21) 0.65(0.50,0.85) 0.55(0.26,1.16) 0.65(0.51,0.84) 
 p-value <0.0001 0.9279 0.6668 0.0821 0.7063 0.5877 0.0016 0.1151 0.0008 
HI only 
Period 1 28 (7.0) 20 (7.3) 20 (6.5) 13 (8.2) 57 (9.0) 28 (11.8) 68 (6.9) 98 (9.5) 166 (8.3) 
Period 2 90 (10.0) 31 (7.3) 38 (7.9) 13 (4.6) 43 (3.6) 19 (5.1) 159 (8.8) 75 (4.1) 234 (6.4) 
AOR 1.42(0.90,2.22) 1.02(0.56,1.85) 1.25(0.71,2.20) 0.51(0.23,1.15) 0.39(0.26,0.58) 0.40(0.21,0.74) 1.26(0.94,1.70) 0.40(0.29,0.55) 0.75(0.61,0.92) 
 p-value 0.1286 0.9569 0.4468 0.1029 <0.0001 0.0033 0.1288 <0.0001 0.0061 
SA only 
Period 1 2 (0.5) 4 (1.5) 23 (7.4) 43 (27.2) 154 (24.3) 46 (19.4) 29 (3.0) 243 (23.6) 272 (13.5) 
Period 2 16 (1.8) 10 (2.4) 50 (10.3) 50 (17.5) 266 (22.4) 50 (13.4) 76 (4.2) 366 (19.8) 442 (12.1) 
AOR 3.46(0.78,15.3) 1.61(0.49,5.27) 1.68(0.98,2.88) 0.55(0.34,0.88) 0.87(0.69,1.09) 0.60(0.39,0.94) 1.85(1.17,2.91) 0.78(0.64,0.93) 0.88(0.75,1.04) 
 p-value 0.1014 0.4337 0.0582 0.0132 0.2267 0.0266 0.0082 0.0074 0.1429 
CO-COLONIZATION 
4
SP + HI 
Period 1 176 (44.1) 138 (50.5) 101 (32.6) 9 (5.7) 14 (2.2) 0 415 (42.3) 23 (2.2) 438 (21.8) 
Period 2 360 (39.7) 180 (42.7) 124 (25.6) 10 (3.5) 17 (1.4) 6 (1.6) 664 (36.6) 33 (1.8) 697 (19.0) 
AOR 0.83(0.65,1.06) 0.74(0.54,1.02) 0.67(0.49,0.93) 0.50(0.19,1.36) 0.61(0.30,1.26) - 0.74(0.63,0.87) 0.80(0.47,1.38) 0.74(0.63,0.86) 
 p-value 0.1349 0.0629 0.0161 0.1752 0.1835 - 0.0003 0.4308 0.0001 
5
PCV7 + HI 
Period 1 97 (24.3) 63 (23.1) 32 (10.3) 2 (1.3) 6 (0.9) 0 192 (19.5) 8 (0.8) 200 (10.0) 
Period 2 116 (12.8) 65 (15.4) 29 (6.0) 0 5 (0.4) 1 210 (11.6) 6 (0.3) 216 (5.9) 
AOR 0.44(0.33,0.60) 0.62(0.42,0.92) 0.50(0.29,0.85) - 0.40(0.12,1.35) - 0.49(0.39,0.61) 0.37(0.13,1.10) 0.49(0.39,0.60) 
 p-value <0.0001 0.0178 0.0108 - 0.1391 - <0.0001 0.0742 <0.0001 
6
SP + SA 
Period 1 10 (2.5) 7 (2.6) 11 (3.5) 5 (3.2) 19 (3.0) 5 (2.1) 28 (2.9) 29 (2.8) 57 (2.8) 
Period 2 25 (2.8) 11 (2.6) 10 (2.1) 6 (2.1) 8 (0.7) 4 (1.1) 46 (2.5) 18 (1.0) 64 (1.7) 
AOR 1.10(0.52,2.33) 1.17(0.44,3.11) 0.51(0.21,1.25) 0.57(0.17,1.95) 0.24(0.10,0.55) 0.57(0.15,2.18) 0.90(0.55,1.45) 0.35(0.19,0.63) 0.61(0.43,0.89) 
 p-value 0.809 0.7498 0.1411 0.3729 0.0008 0.4106 0.6538 0.0005 0.0089 
7
PCV7 + 
SA 
Period 1 6 (1.5) 3 (1.1) 3 (1.0) 0 5 (0.8) 2 (0.8) 12 (1.2) 7 (0.7) 19 (0.9) 
Period 2 7 (0.7) 4 (0.9) 4 (0.8) 2 (0.7) 0 0 15 (0.8) 2 (0.1) 17 (0.5) 
AOR 0.53(0.17,1.61) 1.02(0.22,4.72) 0.88(0.19,4.00) - - - 0.73(0.34,1.57) 0.17(0.03,0.82) 0.50(0.26,0.97) 
 p-value 0.2638 0.9832 0.8684 - - - 0.4154 0.0271 0.0416 
8
HI + SA Period 1 4 (1.0) 1 (0.4) 8 (2.6) 5 (3.2) 35 (5.5) 4 (1.7) 13 (1.3) 44 (4.3) 57 (2.8) 
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Period 2 8 (0.8) 4 (0.9) 4 (0.8) 7 (2.5) 32 (2.7) 3 (0.8) 16 (0.9) 42 (2.3) 58 (1.6) 
AOR 0.71(0.20,2.49) 2.64(0.29,24.3) 0.29(0.09,0.99) 0.76(0.23,2.48) 0.50(0.30,0.81) 0.51(0.11,2.33) 0.64(0.31,1.35) 0.53(0.34,0.81) 0.56(0.39,0.82) 
 p-value 0.5977 0.3925 0.0483 0.6522 0.0054 0.3857 0.2456 0.0036 0.0025 
9
SP + HI + 
SA 
Period 1 18 (4.5) 15 (5.5) 18 (5.8) 3 (1.8) 5 (0.8) 0 51 (5.2) 8 (0.7) 59 (2.9) 
Period 2 32 (3.5) 18 (4.3) 12 (2.5) 4 (1.4) 7 (0.6) 1 (0.3) 62 (3.4) 12  (0.7) 74 (2.0) 
AOR 0.77(0.42,1.41) 0.77(0.38,1.58) 0.39(0.19,0.84) 0.60(0.13,2.86) 0.83(0.26,2.64) - 0.64(0.43,0.94) 0.83(0.33,2.04) 0.66(0.46,0.93) 
 p-value 0.402 0.4821 0.0154 0.5242 0.7469 - 0.0215 0.6772 0.0187 
Non-
Colonized 
Period 1 34 (8.5) 29 (10.6) 73 (22.6) 61 (38.6) 319 (50.4) 147 (62.0) 136 (13.8) 527 (51.3) 663 (33.0) 
Period 2 128 (14.1) 70 (16.6) 150 (31.0) 180 (63.2) 778 (65.4) 278 (74.7) 348 (19.2) 1236 (67.0) 1584 (43.2) 
AOR 1.85(1.23,2.79) 1.65(1.03,2.66) 1.50(1.08,2.09) 2.98(1.97,4.51) 1.90(1.56,2.32) 1.85(1.30,2.64) 1.64(1.31,2.05) 1.98(1.69,2.32) 1.80(1.58,2.04) 
 p-value 0.0033 0.0381 0.0156 <0.0001 <0.0001 0.0007 <0.0001 <0.0001 <0.0001 
Total Period 1 399 273 310 158 633 237 982 1028 2010 
 Period 2 908 422 484 285 1188 372 1814 1845 3659 
1
SP – Streptococcus pneumoniae, 2HI – Haemophilus influenzae, 3SA – Staphylococcus aureus, 4SP + HI – dual carriage of Streptococcus 
pneumoniae and Haemophilus influenzae, 
5
PCV7 + HI - dual carriage of PCV7 serotypes and Haemophilus influenzae, 
6
SP + SA – dual carriage 
of Streptococcus pneumoniae and Staphylococcus aureus, 
7
PCV7 + SA – dual carriage of PCV7 serotypes and Staphylococcus aureus, 8HI + SA 
– dual carriage of Haemophilus influenzae and Staphylococcus aureus, 9SP + HI + SA – triple carriage of Streptococcus pneumoniae, 
Haemophilus influenzae and Staphylococcus aureus. 
10
 Number of individuals carrying a particular pathogen and percentage are given in parenthesis. We also present the adjusted odds ratios (AOR) 
derived from multivariate regression models that included other confounders such as the age of the subject, fuel used for cooking or heating, any 
child attending day care in the household, the number of people living in the same household and the number of children below the age of 5 
years living in the household (significant p-values are in bold) 
11
Period-1 (2009, pre-PCV introduction), 
12
Period-2 (2011-post-PCV introduction)
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The prevalence of H. influenzae colonization decreased with increasing age in both periods, 
(chi square for trend p<0.001. Comparing period 1 to period 2, there was a decline in H. 
influenzae colonization in the age groups 3 to 5 years (63.7% vs. 55.2%; p=0.04) and 6-12 
years (47.4% vs. 36.8%; p<0.001), but not among those 0 to2 years (56.6% vs. 54.0%; 
p=0.31); Table 2. Among adolescents/adults, colonization of H. influenzae decreased from 
16.7% in period 1 to 8.8% in period 2 (p<0.0001); Table 2. This inlcuded  a decrease in the 
prevalence in colonization among adults 19 to 45 years (17.5% vs. 8.3%; p<0.001) and 
among those older than 45 years (13.5% vs. 7.8%; p=0.029). A declining trend was also 
observed among adolescents (17.8% vs. 11.9%, p= 0.026).  
The prevalence of S. aureus colonization tended to be higher among older children and adults 
than in young children in both periods; Table 5.1. In all age-groups in children there was no 
change in prevalence of S. aureus colonization between the two periods, while overall S. 
aureus colonization decreased from 31.2% to  23.7% (p<0.0001) among adults/adolescents; 
Table 5.1. 
Co-colonization by at least two pathogens was higher in period 1 compared to period 2. A 
decrease in co-colonization from period 1 to period 2 was observed for S. pneumoniae and 
H.influenzae among children 3 to 5 years  (50.5% vs. 42.7%; p=0.07) and 6 to 12 years 
(32.6% vs. 25.6%; p=0.016); but not among children 0 to 2 years (44.1% vs. 39.7%; p=0.14); 
Table 2. PCV7 serotypes and H. influenzae co-colonization decreased in children (19.5% vs. 
11.6; p<0.0001), while H. influenzae and S. aureus co-colonization also declined in children 
6 to12 years (2.6% vs. 0.8%; p=0.0483). No change was, however, observed for co-
colonization between S. aureus and overall S. pneumoniae among  children (2.9% vs. 2.5%; 
p=0.6538), nor specifically S. aureus and PCV7 serotype colonization (1.2% vs. 0.8%, 
p=0.4154); Table 5.1. Concurrent colonization by all three bacteria declined from 5.8% in 
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Period-1 to 2.5% in Period-2 among children 6 to 12 years (p=0.0154), but remained 
unchanged in the other age-groups; Table 5.1. 
 
5.3.2                               Bacterial associations   in children 
 
S. pneumoniae was positively associated with H. influenzae colonization in period 1 in 
children aged 3 to 5 years and 6 to 12 years (adjusted odds ratio [AOR] 3.49, 95% CI 1.79-
6.83 and AOR 7.50, 95% CI 3.95-14.3, respectively); Table 5.2, and in all childhood age-
groups in period 2 (AOR 2.05, 95% CI 1.45-2.90 in 0 to 2 years; AOR 4.26, 95% CI 2.47-
7.35 in 3-5 years and AOR 4.78, 95% CI 2.93–7.78 in 6 to 12 years); Table 5.2. In addition,  
a negative association between pneumococcal and S. aureus colonization was observed only 
among children 6 to 12 years in period 2 (AOR 0.36, 95% CI 0.17-0.80); Table 5.2.  
H. influenzae colonization was positively associated with S. pneumoniae colonization in both 
period 1 and period 2 for children 3 to 5 years (AOR 3.50, 95% CI 1.79-6.86 and AOR 4.26, 
95% CI 2.46–7.37, respectively) and 6 to12 years (AOR 8.02, 95% CI 4.18–15.4 and AOR 
4.74, 95% CI 2.92–7.71, respectively), but only in period 2 for children 0 to 2 years (AOR 
2.01, 95% CI 1.42–2.86); Table 5.2.  
S. aureus was negatively associated with both S. pneumoniae (AOR 0.45, 95% CI 0.21-0.97) 
and H. influenzae (AOR 0.36, 95% CI 0.16-0.80) in period 2 in children 6 to 12 years, with  
similar trends observed in other childhood age groups; Table 5.2. A negative association was 
also detected betweeen  S. aureus and non PCV13 serotypes in children aged 6 to 12 years in 
period 2. (AOR 0.32, 95% CI 0.13-0.80), Table 5.3. 
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Table 5.2 Effects of PCV7 serotype carriage on other bacterial carriage in children (stratified by age group) and adults  
Investigated risk 
factors for bacterial 
carriage in children 
Carriage of H. influenzae 
Period 1                               Period 2
 
OR
2
 (95% CI)
4
                   OR (95% CI) 
AOR
3
 (95% CI)                 AOR (95% 
CI) 
Carriage of S. aureus 
Period 1                              Period 2
 
OR (95% CI)                    OR (95% CI) 
AOR (95% CI)              AOR (95% CI)          
Carriage of S. pneumoniae 
Period 1                             Period 2
 
OR (95% CI)                 OR (95% CI) 
AOR (95% CI)              AOR (95% CI)          
Carriage of PCV7 serotypes 
Period 1                                  Period 2
 
OR (95% CI)                      OR (95% CI) 
AOR (95% CI)                 AOR (95% CI) 
0-2 years     
Child carrying S. 
pneumoniae (yes/no)? 
1.60(0.95,2.71)                2.13(1.58, 2.88)  
1.53(0.86, 2.70)               2.05(1.45, 2.90) 
0.95(0.38, 2.40)            0.85(0.51, 1.40) 
1.20(0.25, 5.81)            0.76(0.37, 1.55) 
  
Child carrying PCV7 
serotypes (yes/no)? 
1.15(0.77, 1.71)               1.34(0.98, 1.83)     
1.09(0.71, 1.68)              1.24( 0.86, 1.79) 
0.96(0.47, 1.94)            0.93(0.54, 1.60) 
1.39(0.42, 4.65)            0.61(0.23, 1.65)  
  
Child carrying H. 
influenzae (yes/no)? 
 1.44(0.69, 2.99)            0.85(0.53, 1.35) 
2.42(0.40, 14.6)            0.66(0.25, 1.72)    
1.60(0.95, 2.71)            2.13(1.58, 2.88) 
1.56(0.88, 2.77)            2.01(1.42, 2.86) 
1.15(0.77, 1.71)               1.34(0.98, 1.83) 
1.09(0.71, 1.69)               1.22(0.85, 1.76)     
Child carrying S. aureus 
(yes/no)? 
1.44 (0.69, 2.99)              0.85(0.53, 1.35) 
2.53(0.43, 15.0)               0.81(0.31, 2.14) 
 0.95(0.38, 2.40)            0.85(0.51, 1.40) 
1.36(0.27, 6.79)            0.81(0.39, 1.66) 
0.96(0.47, 1.94)               0.93(0.54, 1.60) 
1.39(0.42, 4.58)               0.62(0.23, 1.66) 
Child carrying both S. 
pneumoniae and H. 
influenzae (yes/no)? 
 1.20(0.59, 2.43)            0.87(0.55, 1.40)     
0.53(0.07, 3.80)            1.32(0.43, 4.07)   
  
Child carrying both 
PCV7 serotypes and H. 
influenzae (yes/no)? 
 1.00(0.45, 2.23)            0.98(0.51, 1.92) 
0.58( 0.13, 2.62)           2.01(0.57, 7.07) 
  
Child carrying both S. 
pneumoniae and 
S.aureus (yes/no)? 
1.40(0.63, 3.12)               1.13(0.65, 1.95) 
0.52(0.07, 3.70)               0.99(0.32, 3.10) 
   
Child carrying both 
PCV7 serotypes and 
S.aureus (yes/no)? 
1.15(0.40, 3.29)               1.55(0.57, 4.23) 
0.61(0.14, 2.70)               1.63(0.45, 5.85)  
   
Child carrying both H. 
influenzae and S.aureus 
(yes/no)? 
  0.92(0.30, 2.82)            1.48(0.67, 3.27) 
0.44(0.06, 3.27)            1.17(0.38, 3.66) 
0.84(0.35, 2.01)               1.25(0.61, 2.54) 
0.57(0.13, 2.54)               1.99(0.57, 6.99) 
3-5 years     
Child carrying S. 
pneumoniae (yes/no)? 
3.64(1.96, 6.76)               4.12(2.60, 6.55)    
3.49(1.79, 6.83)               4.26(2.47, 7.35) 
1.09(0.39, 3.04)            0.75(0.38, 1.48) 
0.77(0.20, 2.95)            0.74(0.27, 1.99) 
  
Child carrying PCV7 
serotypes (yes/no)? 
1.34(0.79, 2.26)               1.41(0.91, 2.17) 
1.44(0.81, 2.55)               1.29(0.77, 2.16) 
0.49(0.19, 1.25)            1.09(0.55, 2.16) 
0.75(0.18, 3.18)            0.79(0.24, 2.63) 
  
Child carrying H. 
influenzae (yes/no)? 
 0.81(0.36, 1.82)            0.81(0.43, 1.53)   
0.27(0.03, 2.71)            0.63(0.15, 2.60) 
3.64(1.96, 6.76)           4.12(2.60, 6.55) 
3.50(1.79, 6.86)           4.26(2.46, 7.37) 
1.34(0.79, 2.26)               1.41(0.91, 2.17) 
1.48(0.84, 2.64)               1.30(0.78, 2.17) 
Child carrying S. aureus 0.81(0.36, 1.82)               0.81(0.43, 1.53)  1.09(0.39, 3.04)            0.75(0.38, 1.48) 0.49(0.19, 1.25)               1.09(0.55, 2.16) 
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(yes/no)? 0.39(0.04, 3.85)               0.66(0.16, 2.65) 0.96(0.26, 3.60)            0.76(0.28, 2.08)  0.88(0.21, 3.64)               0.72(0.22, 2.35) 
Child carrying both S. 
pneumoniae and H. 
influenzae (yes/no)? 
 0.98(0.44, 2.18)            0.78(0.41, 1.48) 
3.15(0.26, 39.0)            1.15(0.22, 5.87) 
  
Child carrying both 
PCV7 serotypes and H. 
influenzae (yes/no)? 
 0.36(0.11, 1.25)            1.26(0.58, 2.76) 
0.54(0.08, 3.82)            2.00(0.44, 9.21) 
  
Child carrying both S. 
pneumoniae and 
S.aureus (yes/no)? 
1.24(0.49, 3.15)               1.32(0.61, 2.88) 
2.00(0.17, 24.2)               1.05(0.21, 5.32)  
   
Child carrying both 
PCV7 serotypes and 
S.aureus (yes/no)? 
0.56(0.11, 2.84)               1.82(0.55, 6.00) 
0.57(0.08, 4.17)               2.56(0.56, 11.7) 
   
Child carrying both H. 
influenzae and S.aureus 
(yes/no)? 
  3.90(0.50, 30.2)            1.71(0.57, 5.16)   
2.11(0.17, 25.7)            1.10(0.21, 5.78) 
0.40(0.11, 1.44)               1.78(0.74, 4.28) 
0.41(0.06, 2.95)               2.39(0.54, 10.7)  
6-12 years     
Child carrying S. 
pneumoniae (yes/no)? 
6.09(3.63, 10.2)               6.14(4.04, 9.33) 
7.50(3.95, 14.3)               4.78(2.93, 7.78)  
0.55(0.31, 0.98)            0.35(0.20, 0.59) 
0.59(0.25, 1.39)            0.36(0.17, 0.80)  
  
Child carrying PCV7 
serotypes (yes/no)? 
4.21(2.23, 7.98)               2.83(1.63, 4.90) 
4.42(1.99, 9.81)               2.34(1.22, 4.50) 
1.56(0.80, 3.05)            1.21(0.60, 2.45) 
1.71(0.42, 7.01)            1.00(0.31, 3.20) 
  
Child carrying H. 
influenzae (yes/no)? 
 0.82(0.46, 1.44)            0.40(0.22, 0.72) 
1.23(0.43, 3.51)            0.46(0.15, 1.41) 
6.09(3.63, 10.2)            6.14(4.04, 9.33) 
8.02(4.18, 15.4)            4.74(2.92, 7.71) 
4.21(2.23, 7.98)               2.83(1.63, 4.90) 
4.62(2.10, 10.2)               2.31(1.20, 4.44)   
Child carrying S. aureus 
(yes/no)? 
0.82(0.46, 1.44)               0.40(0.22, 0.72) 
1.27(0.46, 3.52)               0.45(0.21, 0.97)  
 0.55(0.31, 0.98)            0.35(0.20, 0.59)  
0.65(0.28, 1.54)            0.36(0.16, 0.80) 
1.56(0.80, 3.05)               1.21(0.60, 2.45) 
1.30(0.32, 5.18)               1.01(0.32, 3.23) 
Child carrying both S. 
pneumoniae and H. 
influenzae (yes/no)? 
 0.63(0.34, 1.16)            0.43(0.22, 0.82) 
0.74(0.19, 2.90)            0.42(0.20, 0.92)  
  
Child carrying both 
PCV7 serotypes and H. 
influenzae (yes/no)? 
 1.70(0.82, 3.55)            1.32(0.56, 3.13)   
1.47(0.27, 7.91)            2.49(0.47, 13.3)  
  
Child carrying both S. 
pneumoniae and 
S.aureus (yes/no)? 
1.93(0.88, 4.23)               2.13(0.90, 5.02)  
0.74(0.19, 2.81)               2.02(0.46, 8.79) 
   
Child carrying both 
PCV7 serotypes and 
S.aureus (yes/no)? 
4.74(1.31, 17.2)               3.07(0.89, 10.6) 
2.76(0.52, 14.6)               2.12(0.40, 11.2)  
   
Child carrying both H. 
influenzae and S.aureus 
  1.55(0.65, 3.69)            3.10(0.99, 9.77) 
0.56(0.15, 2.09)            2.07(0.48, 8.96)  
4.32(1.88, 9.93)               5.93(2.12, 16.6) 
2.17(0.42, 11.3)               2.17(0.40, 11.8)  
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(yes/no)? 
Children (≤ 12 years)     
Child carrying S. 
pneumoniae (yes/no)? 
3.83 (2.84, 3.16)             3.89 (3.16, 4.78)  
3.35 (2.41, 4.65)             2.82 (2.16, 3.69)                
0.54 (0.36, 0.79)          0.50 (0.38, 0.66)                
0.68 (0.45, 1.04)          0.59 (0.39, 0.89) 
 
Child carrying H. 
influenzae (yes/no)? 
 0.79 (0.55, 1.15)          0.58 (0.43, 0.78) 
                                     0.59 (0.33, 1.04)                
3.83 (2.84, 5.16)          3.89 (3.16, 4.78)  
3.87 (2.71, 5.54)          3.36 (2.45, 4.62)               
1.15 (0.77, 1.71)             1.77 (1.41, 2.21) 
1.10 (0.73, 1.66)             1.25 (0.96, 1.64)  
Child carrying S. aureus 
(yes/no)? 
0.79 (0.55, 1.15)            0.58 (0.43, 0.78)  
                                       0.50 (0.25, 1.00)                
 0.54 (0.36, 0.79)          0.50 (0.38, 0.66) 
0.65 (0.40, 1.04)          0.56 (0.33, 0.94)                
0.96 (0.47, 1.94)             0.92 (0.64, 1.30) 
Child carrying both S. 
pneumoniae and H. 
influenzae (yes/no)? 
 0.72 (0.50,  1.05)         0.60 (0.40, 0.82)               
                                     1.43 (0.71, 2.89) 
 
Child carrying both S. 
pneumoniae and S. 
aureus (yes/no)? 
1.50 (0.94, 2.41)             1.45 (0.98, 2.15) 
1.13 (0.67, 1.89)             1.67 (0.72, 3.89)                  
   
Child carrying both H. 
influenzae and S. aureus 
(yes/no)? 
  1.44 (0.77, 2.69)          2.02 (1.17, 3.48)  
                                     1.99 (0.74, 5.29)               
0.84 (0.35, 2.01)             1.97 (1.22, 3.17) 
                                        1.78 (1.01, 3.11) 
Adults (> 12 years)     
Adult carrying S. 
pneumoniae (yes/no)? 
1.70 (1.04, 2.75)            6.83 (4.41, 10.6)  
1.71 (1.05, 2.79)            7.34 (4.22, 13.1)                
1.15 (0.75, 1.77)          1.07 (0.69, 1.66)                
                                          
 
Adult carrying H. 
influenzae (yes/no)? 
 0.98 (0.69, 1.41)          1.86 (1.30, 2.65) 
                                     1.90 (1.30, 2.77)                
1.70 (1.04, 2.75)     6.83 (4.41, 10.6)  
1.62 (0.99, 2.65)      7.34 (4.05, 13.1)               
2.33 (1.04, 5.22)             5.36 (2.15, 13.4) 
                                  6.48 (4.10, 10.3) 
Adult carrying S. aureus 
(yes/no)? 
0.98 (0.69, 1.41)             1.86 (1.30, 2.65)  
                                       2.04 (1.33, 3.12)                
 1.15 (0.75, 1.77)      1.07 (0.69, 1.66) 
                                        
1.13 (0.52, 2.47)             0.32 (0.07, 1.37) 
Adult carrying both S. 
pneumoniae and H. 
influenzae (yes/no)? 
 1.01 (0.43,  2.37)         1.38 (0.67, 2.81)               
                                         
 
Adult carrying both S. 
pneumoniae and 
S.aureus (yes/no)? 
1.46 (0.65, 3.26)             7.63 (3.51, 16.6) 
                                       0.82 (0.29, 2.32)                  
   
Adult carrying both H. 
influenzae and S.aureus 
(yes/no)? 
  1.60 (0.73, 3.50)          4.28 (2.14, 8.57)  
                                     0.76 (0.31, 1.85)               
2.16 (0.63, 7.37)              1.59(0.21, 12.1) 
1 For the multivariate model, we included other variables such as any sibling attending of day care, fossil fuel used for cooking or heating, age of 
the study participant and the number of people in the household, number of children below <5 years. 
2OR: odds ratio; 3AOR: adjusted OR; 4CI: confidence interval (multivariate Generalized Estimate Equation models);   
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Table 5.3 Effects of non PCV7 serotype carriage on other bacterial carriage in children (stratified by age group) and adults 
Investigated risk factors for 
bacterial carriage in children 
Carriage of H. influenzae 
Period 1
6 
                                   Period 2
7 
OR
2
 (95% CI)
4
                       OR (95% CI) 
AOR
3
 (95% CI)                   AOR (95% CI) 
Carriage of S. aureus 
Period 1                                            Period 2
 
OR (95% CI)                               OR (95% CI) 
AOR (95% CI)                            OR (95% CI)          
Carriage of NVT7
5
-serotypes 
Period 1                                       Period 2
 
OR (95% CI)                           OR (95% CI) 
AOR (95% CI)                      AOR (95% CI) 
0-2 years    
Child carrying NVT7-serotypes 
(yes/no)? 
1.17 (0.78,1.75)                  1.53 (1.17,1.99) 
1.18 (0.76,1.82)                  1.57 (1.16,2.14) 
0.86 (0.42,1.77)                        0.89 (0.56,1.40) 
0.68 (0.19,2.42)                        1.09 (0.54,2.19) 
 
Child carrying H. influenzae 
(yes/no)? 
  1.17 (0.78,1.75)                    1.53 (1.17,1.99) 
1.19 (0.76,1.84)                    1.58 (1.16,2.15) 
Child carrying S. aureus (yes/no)? 
  0.86 (0.42,1.77)                    0.89 (0.56,1.40) 
0.75 (0.21,2.69)                    1.15 (0.57,2.30) 
Child carrying both NVT7-
serotypes and H. influenzae 
(yes/no)? 
   
Child carrying both NVT7-
serotypes and S.aureus (yes/no)? 
1.74 (0.53,5.75)                  0.92 (0.49,1.74) 
1.13 (0.24,5.34)                  0.65 (0.24,1.76) 
  
Child carrying both H. influenzae 
and S.aureus (yes/no)? 
  0.97 (0.40,2.31)                    1.02 (0.54,1.93) 
1.02 (0.21,4.88)                    0.62 (0.23,1.67) 
3-5 years    
Child carrying NVT7-serotypes 
(yes/no)? 
2.01 (1.21,3.33)                  2.44 (1.64,3.64) 
1.88 (1.08,3.27)                  2.63 (1.64,4.22) 
1.71 (0.76,3.84)                         0.75(0.39,1.42) 
0.94 (0.25,3.58)                         0.82(0.29,2.30) 
 
Child carrying H. influenzae 
(yes/no)? 
  2.01 (1.21,3.33)                    2.44 (1.64,3.64) 
1.83 (1.05,3.20)                    2.61 (1.63,4.20) 
Child carrying S. aureus (yes/no)? 
  1.71 (0.76,3.84)                    0.75 (0.39,1.42) 
1.00 (0.27,3.72)                    0.97 (0.35,2.69) 
Child carrying both NVT7-
serotypes and H. influenzae 
(yes/no)? 
 1.63 (0.73,3.64)                        0.64 (0.31,1.35) 
2.86 (0.47,17.3)                        0.81 (0.20,3.21) 
 
Child carrying both NVT7-
serotypes and S.aureus (yes/no)? 
1.76 (0.55,5.61)                  1.14 (0.43,3.06) 
2.10 (0.34,12.9)                  0.55 (0.14,2.15) 
  
Child carrying both H. influenzae 
and S.aureus (yes/no)? 
  3.59 (1.13,11.43)                  0.97(0.41,2.30) 
2.68 (0.44,16.25)                  0.59(0.15,2.34) 
6-12 years    
Child carrying NVT7-serotypes 
(yes/no)? 
2.41 (1.52,3.82)                  3.87 (2.61,5.72) 
2.72 (1.58,4.66)                  3.17 (2.01,5.00) 
0.41 (0.22,0.76)                         0.31(0.17,0.57) 
0.53 (0.21,1.33)                         0.33(0.13,0.82) 
 
Child carrying H. influenzae 
(yes/no)? 
  2.41 (1.52,3.82)                    3.87 (2.61,5.72) 
2.74 (1.59,4.72)                    3.13 (1.99,4.92) 
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Child carrying S. aureus (yes/no)? 
  0.41 (0.22,0.76)                    0.31 (0.17,0.57) 
0.65 (0.26,1.61)                    0.32 (0.13,0.80) 
Child carrying both NVT7-
serotypes and H. influenzae 
(yes/no)? 
 0.32 (0.14,0.74)                        0.32 (0.14,0.73) 
0.49 (0.12,1.93)                        1.22 (0.28,5.35)    
 
Child carrying both NVT7-
serotypes and S.aureus (yes/no)? 
0.86 (0.31,2.36)                  1.74 (0.60,5.04) 
0.30 (0.08,1.19)                  1.16 (0.26,5.19) 
  
Child carrying both H. influenzae 
and S.aureus (yes/no)? 
  0.46 (0.19,1.12)                    1.26 (0.46,3.44) 
0.31 (0.08,1.20)                    1.25 (0.29,5.43) 
Children (≤ 12 years)    
Child carrying NVT7-serotypes 
(yes/no)? 
1.80 (1.40, 2.32)                 2.38 (1.98,2.87) 
1.79 (1.34,2.37)                  2.15 (1.72,2.67) 
0.70 (0.47,1.02)                        0.54 (0.40,0.73) 
0.67 (0.36,1.23)                        0.68 (0.43,1.07) 
 
Child carrying H. influenzae 
(yes/no)? 
  1.80 (1.40,2.32)                    2.38 (1.98,2.87) 
1.75 (1.32,2.32)                    2.12 (1.70,2.63) 
Child carrying S. aureus (yes/no)? 
  
 
0.70 (0.47,1.02)                    0.54 (0.40,0.73) 
0.68 (0.37,1.25)                    0.67 (0.43,1.05) 
Child carrying both NVT7-
serotypes and H. influenzae 
(yes/no)? 
 0.71 (0.46,1.11)                        0.54 (0.37,0.77) 
1.05 (0.46,2.40)                        0.93 (0.48,1.79) 
 
Child carrying both NVT7-
serotypes and S. aureus (yes/no)? 
1.30 (0.71,2.39)                  1.24 (0.77,1.98) 
0.84 (0.37,1.92)                  0.80 (0.41,1.58) 
  
Child carrying both H. influenzae 
and S. aureus (yes/no)? 
  1.02 (0.61,1.70)                    1.12 (0.72,1.76) 
1.01 (0.45,2.26)                    0.92 (0.47,1.79) 
Adults (> 12 years)    
Adult carrying NVT7-serotypes 
(yes/no)? 
1.33 (0.75,2.37)                 6.99 (4.38,11.1) 
1.42 (0.70,2.90)                 8.35 (4.51,15.4) 
1.15 (0.71,1.87)                         1.25(0.78,1.99) 
1.08 (0.62,1.87)                         1.22(0.63,2.34) 
 
Adult carrying H. influenzae 
(yes/no)? 
  1.33 (0.75,2.37)                    6.99 (4.38,11.1) 
1.47 (0.72,3.00)                    8.32 (4.48,5.47) 
Adult carrying S. aureus (yes/no)? 
  1.15 (0.71,1.87)                    1.25 (0.78,1.99) 
1.09 (0.63,1.90)                    1.25 (0.65,2.40) 
Adult carrying both NVT7-
serotypes and H. influenzae 
(yes/no)? 
 0.97 (0.34,2.83)                        1.48 (0.70,3.15) 
0.83 (0.24,2.90)                        0.75 (0.25,2.22) 
 
Adult carrying both NVT7-
serotypes and S.aureus (yes/no)? 
1.15 (0.43,3.07)                7.32 (3.26,16. 5) 
0.76 (0.22,2.65)                 0.65 (0.22,1.93) 
  
Adult carrying both H. influenzae 
and S.aureus (yes/no)? 
  1.27 (0.49,3.28)                    4.66 (2.26,9.61) 
0.71 (0.20,2.47)                    0.67 (0.22,1.99) 
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1 For the multivariate model, we included other variables such as any sibling attending of day care, fossil fuel used for cooking or heating, age of 
the study participant and the number of people in the household, number of children below <5 years. 
2OR: odds ratio; 3AOR: adjusted OR; 4CI: confidence interval (multivariate Generalized Estimate Equation models); 5NVT7-serotypes: serotypes not included 
in the seven-valent vaccine6Period 1 (2009, pre-PCV introduction), 7Period 2 (2011, post-PCV introduction) 
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5.3.3                                      Bacterial associations  in adults 
S. pneumoniae colonization was positively associated with  H. influenzae  colonization in 
period 1 (AOR 1.71, 95% CI 1.05-2.79) and period 2 (AOR 7.34, 95% CI 4.22-13.1); Table 
5.2, including a positive association between non PCV13 serotypes and H. influenzae 
colonization in period 2 (AOR 8.35, 95% CI 4.51-15.4), Table 4. H. influenzae colonization 
was also positively associated with S. aureus colonization  in period 2 (AOR 1.90, 95% CI 
1.30-2.77) but not in period 1; Table 5.2. 
 
5.4                                            Discussion  
 
To date there is a paucity of data regarding the effect of PCV7 vaccination on bacterial 
nasopharyngeal ecology across different age-groups from the same population. Our study 
showed, that there was a decrease in S. pneumoniae colonization among  children <2 years of 
age who had been targeted for PCV immunization, while the prevalence of H. influenzae and 
S. aureus colonization remained unchanged in this age group following PCV7 introduction. 
Among adolescents/adults from the same population, however, there were temporal declines 
in S. pneumoniae, H. influenzae and S. aureus colonization following infant PCV7 
immunization. The decrease in S. pneumoniae vaccine serotypes colonization prevalence 
among the adolescents/adults, (162) may have resulted from PCV vaccination of young 
children reducing transmission of pneumococci to these older unvaccinated age groups. This 
decrease in vaccine serotype colonization was larger than the increase in non-vaccine 
serotype colonization in children resulting in a net decrease in overall pneumococcal 
colonization. Non-vaccine serotypes may be less efficient colonizers as demonstrated by an 
increase in prevalence of colonization in PCV vaccinated but not among unvaccinated 
children. Also, a decrease in non-vaccine pneumococcal serotypes colonization was observed 
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in adults, we have previously alluded this decrease to be possibly due to increased 
antiretroviral therapy coverage in adults (162). This may again be a plausible explanation for 
the decline observed in the prevalence of H. influenzae and S. aureus colonization among 
adults/adolescents. 
The prevalence  of H. influenzae colonization among children in our study (55%) was higher 
than observed among Kenyan children aged 0 to 5 years (26%) and 5 to 9 years (24%), (169) 
but lower than that reported among infants in The Gambia (70% compared to 52% among 
infants in our study) (100). Our study, however, observed a decline in H. influenzae 
nasopharyngeal colonization among older children 3 to 12 years but not among PCV 
vaccinated children <2 years of age, following the implementation of the PCV immunization 
program. This is in contrast to the increase in  prevalence of H. influenzae colonization which 
was observed among vaccinated children in The Netherlands, following a  booster dose of 
PCV at 11 months of age after a three dose primary series schedule (108). However, an 
earlier study also from The Netherlands, in which children were vaccinated with a two dose 
primary series and a booster dose of PCV, did not demonstrate an  increase in H. influenzae 
colonization at 11 months of age (104). In our population there was no change in H. 
influenzae colonization after the booster dose at 9 months. This supports data from a study in 
Fiji where there was no change in H. influenzae in vaccinated children younger than 2 years 
(95). 
Decreases in H. influenzae colonization were noted in the unvaccinated age-groups in our 
study. Studies in neonatal rats show that when H. influenzae is inoculated first in the 
respiratory tract followed by S. pneumoniae, there is an increase in H. influenzae density, 
however, when the order of inoculation is reversed competition between the two species was 
observed (170). This observation was found to be strain specific (170). In our study we 
demonstrated a positive association between non-vaccine serotype and H. influenzae carriage 
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in all age-groups. This may explain the decrease in H. influenzae carriage in unvaccinated 
age-groups which may have been caused by a decrease in non-vaccine pneumococcal 
serotype carriage observed in these age-groups (162). Our study was, however, done within 
two years of PCV7 implementation, and the full effects of vaccination may not be evident 
and established in the population and our results may reflect short term shifts in the 
nasopharyngeal microbiome associated with vaccination or temporal variation in colonization 
prevalence. 
The inhibition of S. aureus by hydrogen peroxide produced by the pneumococcus results in a 
negative relationship between S. aureus and S. pneumoniae (93, 94). Also, it  is thought to be 
immune mediated, specifically CD4+ T-lymphocyte mediated (102) and due to a decrease in 
mucosal immunity (65). This is supported by the absence of this relationship among HIV-
infected children (65, 97) and HIV-infected adults (102). Our study was carried out in a 
setting with high prevalence (23.9%) of HIV-infection among adults (162). We observed a 
reduction in S. aureus prevalence among adolescents and adults but not among children. 
Most of the studies that investigated the effect of PCV on S. aureus colonization among 
children have also failed to detect an increase in prevalence of S. aureus colonization in the 
PCV era (65, 95, 106, 107). An exception was a  study in The  Netherlands where an increase 
in the prevalence of S. aureus colonization was observed in children aged 11-12 months 
following 3 doses of PCV7 and at three years of age (103, 108). We did not observe any 
increase in S. aureus colonization post PCV7 booster among vaccine recipients (data not 
shown).  In South Africa, PCV was administered with a modified 2+1 dose schedule versus 
the 3+1 in The Netherlands, which may impact on the time it takes to realise shifts in 
bacterial interactions. In the USA, however, as part of a S. aureus surveillance program 
between 2001 and 2004, decrease in S. aureus colonization was observed among children and 
adults following the introduction of a 3+1 PCV7 immunization into the national 
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immunization program in 2000 (171). This decrease may, however, have been a transient 
early effect of PCV vaccination, since nine years later the prevalence of  S. aureus 
colonization among children was similar to pre-vaccination levels (107). A South African 
study on the long-term effects of PCV in the context of a randomised placebo trial found no 
differences in S. aureus and H. influenzae colonization after 5 years of vaccination between 
vaccinees and placebo-recipients (65).  
Colonization by multiple pathogens is common in African children, in part due to host and 
environmental factors (100). The synergism between S. pneumoniae and influenza virus has 
been well described (172) as well as other interactions between bacteria and viruses, 
including respiratory syncytial virus, rhinovirus, adenoviruses, to mention but a few (173). 
We did not isolate respiratory viruses from our samples and are therefore unable to deduce 
the effect of seasonal respiratory viruses on colonization. However, co-carriage of multiple 
pathogens is also supported by data among adolescents/adults, where H. influenzae 
colonization was positively associated with both S. aureus and S. pneumoniae. It has been 
demonstrated that among PCV naïve children S. pneumoniae colonization, mainly by vaccine 
serotypes, is negatively associated with S. aureus carriage and positively associated with H. 
influenzae carriage (93, 94). The studies that reported on the same paradigm following 
pneumococcal vaccination show that such associations are probably maintained (65, 103, 
104). In our study population the previously established positive association in period 1 
between S. pneumoniae and H. influenzae as well as the negative association between H. 
influenzae and S. aureus were observed in children also in period 2.  
Limitations of our study include that it was cross-sectional rather than longitudinal, which 
could have provided greater insight into the timing of acquisition of the different bacteria and 
their interactions in colonization. Also, we only sampled the nasopharynx rather than the 
anterior nares for S aureus, however, swabs from the nasopharynx have been used before for 
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detection of multiple respiratory pathogens (103, 104). All nasopharyngeal samples were 
processed by means of culture-based techniques, which are inferior to molecular detection 
methods for the identification of multiple carriages. Additionally, we do not have H. 
influenzae typing data to determine the serotypes associated with colonization. Moreover, we 
did not look for other pathogens, for example Moraxella catarrhalis and respiratory viruses 
which could have helped us to better understand the dynamics of colonization. We sampled 
more females than males in either study period limiting the generalizability of our study 
findings. Lastly, due to uncertainty over self-reported HIV status we did not stratify our 
analysis by HIV status among adults. 
Our results on early changes in the interactions between S. pneumoniae, H. influenzae and S. 
aureus suggest that the S. aureus carriage in children was not affected by PCV7 
immunization and that there was a decrease in colonization in the adult population. It is 
therefore, unlikely that disease due to S. aureus would increase in our population. Continued 
surveillance is however, needed to monitor changes with vaccination in later years. 
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Chapter 6: Trends in community-wide effect on invasive 
pneumococcal disease and associations with colonization, Soweto, 
South Africa following infant pneumococcal conjugate vaccination 
 
6.1 Introduction 
 
Pneumococcal nasopharyngeal colonization precedes pneumococcal disease, hence, serotypes 
identified in invasive disease isolates are also identified in the nasopharynx at the time of 
illness (21, 30, 31). PCV vaccinated compared to unvaccinated children have an 
approximately 50% reduced risk of vaccine serotype nasopharyngeal colonization acquisition 
(174). Since young children are the main source of transmission of pneumococci in 
communities (21), targeted PCV immunization of children has interrupted transmission of 
vaccine serotypes within the communities (73). Consequently, reduction in prevalence of 
vaccine serotype colonisation has also been observed among PCV unvaccinated individuals 
at the household and community level  (9, 71, 73, 80, 84, 162).  
Concurrently, a decline in the incidence of vaccine serotype IPD among PCV vaccinated and 
unvaccinated individuals has been observed, (7, 10, 11). In the USA, the indirect effect of 
childhood PCV immunization has resulted in 2.2-fold greater number of IPD cases prevented  
among PCV unvaccinated adults compared to that prevented among age-groups targeted for 
PCV vaccination (10). There is a paucity of data from low and middle income countries on 
the  effectiveness of childhood PCV immunization in protecting against IPD among PCV 
unvaccinated age groups, which would be essential to  fully evaluate the public health impact 
and cost-effectiveness of this intervention (123).    
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Weinberger et al. propose that ecological nasopharyngeal vaccine serotype and non-vaccine 
serotype colonization studies prior and  following childhood PCV immunization can be used 
to impute the direct and indirect effectiveness of childhood PCV immunization against IPD 
(122). This would be pertinent to most low and middle income countries, where high-quality 
surveillance systems to directly monitor the impact of PCV against IPD are generally lacking. 
The aim of this study was to analyse the direct and indirect effectiveness of infant PCV 
immunization among HIV-infected and HIV-uninfected children and their mothers in 
Soweto, South Africa. Furthermore, we evaluated the fit of the proposed model by 
Weinberger et al,(122) to determine whether temporal changes in vaccine serotype 
colonization relative to childhood PCV immunization was predictive of the direct and indirect 
effect of PCV against IPD (122).     
 
6.2 Methods  
6.2.1 Study population  
A series of pneumococcal colonization studies were undertaken in mother-child pairs in 
Soweto (Gauteng, South Africa), which has a population of 1.4 million of whom 125,000 are 
under five years  age (175). We enrolled HIV-infected and HIV-uninfected children >3 
months to 5 years age and their mothers aged >18-45 years age. We specifically targeted 
enrolling mothers of the children, since women in our setting have greater contact with 
children than men, which possibly also contributes to them having a higher incidence of IPD 
than men (47).  
The majority of the Soweto population seeks medical care from 23 primary health care 
centres and a single public-hospital (Chris Hani Baragwanath Academic Hospital; CHBAH) 
where approximately 90% of all hospitalizations from the community occur.  The  
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effectiveness of infant PCV-immunization against IPD in this community was included as 
part of a recent national analysis on the direct and indirect effect against IPD in South Africa 
(112). The current analysis on IPD expands on the previous report by providing temporal 
changes in incidence of IPD in children and women from Soweto (112).     
Details of vaccine introduction into the national immunization program were previously 
described, in section 2.3. 
 
6.2.2 Pneumococcal colonization studies in Soweto (2007 to 2012)   
 
Prior to PCV7 introduction into the national immunization program, we undertook a 
longitudinal cohort study to investigate the dynamics of pneumococcal transmission in HIV-
uninfected mother-child pairs between January 2007 and April 2009 (pre-PCV era) as 
reported (158). This survey was not designed as part of this study. Since the use of 
longitudinal data could overestimate colonization prevalence, to transform the data into cross-
sectional data, a single randomly selected visit for each mother-child pair was used. Briefly, 
the study showed an association of vaccine serotype acquisition between young children and 
their mothers (140), and that children transmitted PCV7 serotypes more often to their mothers 
than vice-versa (105). Subsequently, two cross-sectional colonization prevalence surveys 
were undertaken in the same population in 2010 (PCV7 era) and 2012 (PCV13 era) as 
described (176). This study showed a significant reduction of PCV7 serotype colonization in 
both HIV-infected and HIV-uninfected mothers and their children; and an increase of non-
vaccine serotype colonization in children but not in the mothers (176). 
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In all the colonization studies, nasopharyngeal swabs were collected in children and 
nasopharyngeal and oropharyngeal swabs from the mothers. Samples were kept on ice for a 
maximum of 6 hours and stored at -70
o
C until processing. The methods of sample collection, 
culture and serotyping are detailed in section 2.4 (162).  
 
6.2.3 Invasive pneumococcal disease surveillance (2005 -2012)  
 
Laboratory-based surveillance for IPD in South Africa has been ongoing since 1999 by the 
National Institute for Communicable Diseases (NICD) (177). Since 2003, this included an 
enhanced component at twenty-four sentinel hospitals, including CHBAH, in which detailed 
individual case-level demographic and clinical data are collected. IPD cases were defined as 
isolation of S. pneumoniae from normally sterile sites including cerebrospinal fluid (CSF), 
blood and joint fluid. Recurrent IPD episodes at least 21 days apart in the same individual 
were considered as new cases.  
The standard culture method at CHBAH for blood uses the BacT/Alert microbial detection 
system (Organon Teknika, Durham, North Carolina, USA). Autolysed blood culture 
specimens, macroscopically chocolate-colored with or without pleomorphic Gram-positive 
cocci on microscopy, were tested with a latex agglutination kit (Wellcogen Bacterial Antigen 
Kit, Remel Europe Ltd, Dartford, UK). Viable pneumococcal isolates were serotyped by 
Quellung method using specific antisera (Statens Serum Institute, Copenhagen, Denmark). 
Serotype 6A was distinguished from 6C by Quellung (162).  
Both IPD and colonizing pneumococcal isolates were serotyped at the Centre for Respiratory 
and Meningitis Diseases at NICD as described in section 2.4.  
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6.2.4 Statistical analysis 
 
PCV7 serotypes were defined as any of the 7 valent vaccine serotypes (i.e. 4, 6B, 9V, 14, 
18C, 19F and 23F). Furthermore, since antibody to serotype 6B confers cross-protection 
against serotype 6A, the latter was analysed separately (150). The additional serotypes 
included in PCV13 (i.e. 1, 3, 5, 7F and 19A) were categorised as PCV13 additional serotypes; 
whereas all non PCV13 serotypes and non-typeable strains were categorized as non-vaccine 
serotypes. Non viable isolates were prorated based on identified serotypes as its been shown 
that the distribution of serotypes among viable isolates determined by culture and among 
non-viable isolates determined by PCR is similar (178).  
Incidence of IPD for children, 0 to 3 months, >3 months to 24 months and >24 to 60 months, 
5 to 18 years of age, and adults 18 to 45 years and >45years of age were calculated using the 
annual number of IPD cases identified by mid-year population estimates for Soweto. The 
population denominators were available through Statistics South Africa [25]. The average of 
the IPD incidence between 2005 and 2008 represented the pre PCV rate. We then compared 
this pre PCV era incidence to that in 2010 (PCV7 era) and 2012 (PCV13 era) and calculated 
the percent change in the rate of IPD, as well as the absolute difference between the pre PCV 
era and PCV7 era and PCV13 era. Differences in the rates including the 95% confidence 
interval were used to evaluate the significance of observed changes in IPD. The Chi-square 
test was used to assess differences in proportions with a p-value of <0.05 considered as a 
statistically significant result. Since the HIV prevalence among IPD cases in years prior to 
2008 could have been overestimated because of a lower proportion (70% in 2005 vs >88% in 
2012) of cases having had an HIV test done, we used a previously developed methodology to 
account for this potential bias (112).  
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For colonization data we compared colonization prevalence in the different study period 
stratified by HIV-status. Both colonization and IPD data were imputed into a  theoretical 
model (Model 1) proposed by Weinberger et al. (122) to calculate the expected IPD 
incidence post PCV introduction and compared model-predicted values to the observed IPD 
incidence changes, for age groups, >3 to 24 months, >24 to 60 months and women 18-45 
years old. The model assumes that the ratio of IPD incidence to carrier prevalence for any 
serotype is constant, such that a change in carriage prevalence will result in a proportional 
change in IPD incidence. 
 
6.3 Results 
6.3.1 Temporal changes in pneumococcal colonization 
Compared to the pre PCV era there was a reduction in PCV7 serotype colonization 
prevalence in the 2010 survey; and reduction in the additional PCV13 serotypes in the 2012 
survey, Fig 6.1 and Table 6.1. 
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Figure 6.1 Comparison of carriage prevalence by age group between baseline year 2007-
2009 and 2010 (1) or baseline year and 2012 (2). A, HIV-uninfected children >3months 
to 5 years, B, HIV-uninfected women 18-45 years, C, HIV-infected women 18-45 years. 
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Table 6.1 Comparison of pneumococcal colonization by HIV-status in children and mothers enrolled in 2007-2009 (Pre-PCV era); 2010 (PCV7- era) 
and 2012 (PCV13-era), in Soweto, South Africa. 
Group    All 
HIV-
uninfected  HIV-infected   
Children >3 to 24months          
   
Total OR (95%CI) 
 
OR (95%CI) 
  
OR (95%CI) 
Total per group 2007-2009 251 
  
125 
  
- 
  
 
2010 
 
638 
  
423 
  
215 
  
 
2012 
 
935 
  
791 
  
144 
  
All serotypes 2007-2009 158 (62.9) 
  
83 (66.4) 
  
- 
  
 
2010 
 
392 (61.4) 0.93 (0.69-1.27) 267(63.1) 0.87 (0.57-1.32) 125 (58.1) 
  
 
2012 
 
515 (55.1) 0.72 (0.54-0.96 )  448(56.6) 0.66 (0.44-0.98) 67 (46.5) 0.63 (0.41-0.96)* 
PCV7 serotypes 2007-2009 83 (33.1) 
  
38 (30.4) 
  
- 
  
 
2010 
 
154 (24.1) 0.64 (0.47-0.89) 101(23.9) 0.72 (0.46-1.12) 53 (24.7) 
  
 
2012 
 
96 (10.3) 0.23 (0.17-0.32) 76 (9.6) 0.24 (0.16 - 0.38) 20 (13.9) 0.49 (0.28-0.87)* 
Additional-PCV13 serotypes 2007-2009 24 (9.6) 
  
13 (10.4) 
  
- 
  
 
2010 
 
76 (11.9) 1.27 (0.79-2.08) 57 (13.5) 1.34 (0.71-2.54) 19 (8.8) 
  
 
2012 
 
38 (4.1) 0.40 (0.24-0.68) 33 (4.2) 0.38 (0.19-0.73) 5 (3.5) 0.37  (0.14-1.02)* 
Non-PCV13 serotypes 2007-2009 51 (20.3) 
  
32 (25.6) 
  
- 
  
 
2010 
 
174 (27.3) 1.47 (1.03-2.09) 119(28.1) 1.14 (0.72-1.79) 55 (25.6) 
   2012  381 (40.7)    2.70    (1.93-3.77) 339(42.9)            2.18    (1.42-3.34) 42 (29.2)            1.20      (0.75-1.92)* 
Mothers 
 
Total per group 2007-2009 251 
  
125 
  
126 
  
 
2010 
 
1376 
  
672 
  
704 
  
 
2012 
 
1556 
  
948 
  
608 
  All serotypes 2007-2009 50   (19.9) 
  
28(22.4) 
  
22 (17.5) 
  
 
2010 
 
209 (15.2) 0.72 (0.51-1.01) 65 (9.7) 0.37  (0.23-0.61) 144 (20.5) 1.22  (0.74-1.99) 
 
2012 
 
176 (11.3) 0.51 (0.36-0.73) 92 (9.7) 0.37 (0.23-0.60) 84 (13.9) 0.76 (0.45-1.27) 
PCV7 serotypes 2007-2009 18 (7.2) 
  
5 (4.0) 
  
13 (10.3) 
  
 
2010 
 
63 (4.6) 0.62 (0.36-1.07) 26 (3.9) 0.97 (0.36-2.57) 37(5.3) 0.48 (0.25-0.94) 
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2012 
 
22 (1.4) 0.19 (0.10-0.35) 7 (0.7) 0.18 (0.06-0.57) 15 (2.5) 0.22 (0.10-0.47) 
Additional-PCV13 serotypes 2007-2009 7 (2.8) 
  
4 (3.2) 
  
3 (2.4) 
  
 
2010 
 
33 (2.4) 0.86 (0.37-1.96) 10(1.5) 0.46 (0.14-1.48) 23 (3.3) 1.38      (0.41-4.68) 
 
2012 
 
26 (1.7) 0.59 (0.25-1.38) 12(1.3) 0.39  (0.12-1.22) 14 (2.3) 0.97      (0.27-3.41) 
Non-PCV13 serotypes 2007-2009 25 (10.0) 
  
19(15.2) 
  
6  (4.8) 
  
 
2010 
 
117 (8.6) 0.84 (0.53-1.32) 29 (4.3) 0.25 (0.14-0.46) 84 (11.9) 2.71 (1.16-6.35) 
 
2012 
 
128 (8.2) 0.81 (0.52-1.27) 73 (7.7) 0.47 (0.27-0.80) 55 (9.0) 1.99 (0.84-4.73) 
 Data on comparison of carriage prevalence in 2010 compared to 2012 has been described in Chapter 4. 
*Comparison between carriage in 2010 and 2012, no data for baseline year (2007-2009) 
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6.3.2 Temporal changes in pneumococcal colonization among 
children 
Compared to the pre PCV era, there was a reduction in PCV7 serotype colonization 
prevalence among HIV-uninfected children by 2010; and reduction in the PCV13 additional 
serotypes by 2012, Figures 6.1a, 6.1b, 6.1c and Table 6.1. The change was evident among 
children aged <3 months-24 months, among whom the overall colonization prevalence 
decreased from 62.9% to 55.1% (p=0.025), PCV7 serotype from 33.1% to 10.3% (p<0.001) 
and PCV13 additional serotypes from 9.6% to 4.1% (p=0.001) between the pre PCV era and 
2012. During the same period, non-vaccine serotype colonization increased from 20.3% to 
40.7% (p<0.001), Figure 6.1a and Table 6.1. Notably, the reduction in PCV7 serotype 
colonization was already evident within one year of PCV7 introduction (OR: 0.64; p=0.007); 
which declined further by 2012 (OR: 0.23; p<0.001). In contrast, colonization prevalence due 
to PCV13 additional serotypes between the pre PCV era and 2010 was similar (9.6% vs 
11.9%; p=0.32; whilst decreasing to 4.1% one year following PCV13 introduction (OR: 0.40 
p<0.001); Figure 6.1a and Table 6.1. Compared to the pre PCV era, the prevalence of non-
vaccine serotype colonization increased from 20.3% to 40.7% by 2012 (OR: 2 .70; p<0.001); 
Figure 6.1a and Table 6.1.  
Similar pre-PCV era data were unavailable for HIV-infected children, with the observed 
changes in colonization prevalence between 2010 and 2012 being previously described in 
section 4.3.2; and Table 6.1 [28].  
 
6.3.3 Pneumococcal colonization in women aged 18-45 years 
 
Overall, the prevalence of pneumococcal colonization in women was 19.9% in the pre PCV 
era, which decreased to 15.2% (p=0.06) and then 11.3% (p<0.001) by 2010 and 2012, 
respectively. Stratifying by HIV-infection status, overall pneumococcal prevalence declined 
 129 
 
from 22% in the pre PCV area compared to 9.7% in 2010 (p<0.001) and 9.7 in 2012 
(p<0.001) among HIV-uninfected women; whilst it remained unchanged in HIV-infected 
women (range: 17.5% to 13.9%); Figures 6.1b, 6.1c and Table 6.1. PCV7 serotype 
colonization remained unchanged between the pre PCV era and 2010 (4.0% vs 3.9%) but 
declined to 0.7% by 2012 (p=<0.001) among HIV-uninfected women whilst in HIV-infected 
women it decreased from 10.3% in the pre-PCV era to 5.3% by 2010 (p<0.001) and 2.5% by 
2012 (p<0.001).  PCV13 additional serotypes trended to also decrease from 3.2% in the pre 
PCV era to 1.5% in 2010 (p=0.181) and 1.3% by 2012 (p=0.094) in  HIV-uninfected women; 
but remained unchanged in HIV-infected women (2.4% to 3.3% in 2010 and 2.3% in 2012) 
.There was also a decline in non-PCV13 serotype colonization among HIV-uninfected 
women between the pre PCV era (15.2%) compared to 2012 (7.7%; p=0.005), whereas this 
trended to being higher among HIV-infected women (4.8% in pre PCV era vs 9.0% in 2012; 
p=0.113);  Table 6.1. 
           
6.3.2 Invasive pneumococcal disease  
 
We identified 4,144 IPD cases between 2005 and 2012 at CHBAH of which 2,533 (61%) had 
viable isolates for further characterization. The overall IPD rate decreased from 55.5 per 
100,000 to 18.0 per 100,000 in 2012 among all ages; Figure 6.2A. Although the incidence of 
IPD was highest in children ≤2 years throughout, the magnitude of this difference compared 
to other age-groups narrowed over time; Figure 6.2B. HIV-infected individuals had higher 
IPD rates compared to HIV-uninfected, regardless of the age of the individual, a difference 
which persisted even in 2012 (  Figures 6.3 and 6.4).  
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Figure 6.2: IPD trends in Soweto, South Africa, 2005-2012, A, Overall IPD by vaccine 
serotype, B by age group. Arrows indicate introduction of PCV7 in 2009 and PCV13 in 
2011 
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Figure 6.3 Invasive pneumococcal disease incidence in children >3 months to 5 years and adults aged >18 to 45 years by sero-group over 
time (2005-2012). A, HIV-uninfected children >3months to 2 years, B, HIV-infected children >3 months to 2 years, C.HIV –uninfected 
children >2 to 5 years, D, HIV-infected children >2 to 4 years, E, HIV-uninfected   adults >18 to 45years, F. HIV-infected adults >18 to 
45 years 
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Figure 6.4 Invasive pneumococcal disease incidence in children 0 to 3 months, 5- 18 years and adults aged >45 years by sero-group over 
time (2005-2012). A, HIV-uninfected children 0 to 3months, B, HIV-infected children 0 to 3 months, C.HIV –uninfected children 5 to 18 
years, D, HIV-infected children 5 to 18 years, E, HIV-uninfected   adults >45years, F. HIV-infected adults >45 years
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6.3.4 Changes in Invasive Pneumococcal Disease 
            In children >3-24 months of age, the annual overall incidence of IPD (per 100,000) in the 
pre-PCV era was 214.7, including an incidence of 137.3, 19.5 and 26.4, respectively for 
PCV7 serotype, serotype 6A and PCV13 additional serotypes (Table 6.2). By 2012 the 
overall IPD incidence in the >3-24 month age group had declined by 72.4% (95% CI; 58.5 to 
82.4%). This included reductions in PCV7 serotype (-93.1%), serotype-6A (-87.9%) and 
PCV13 additional serotype IPD (-82.1%; p<0.05 for all observations); Table 6.2. No 
significant changes were observed in the incidence of non PCV13 serotype IPD between the 
pre-PCV era and 2012 (Table 6.2).  
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Table 6.2 Rate changes of invasive pneumococcal disease cases among children  3months to <2 years of age, and 2 to 5 years of age by year and 
serotype group, South Africa, 2010 and 2012 compared with baseline pre-PCV years 2005-2008.  
 
Number and rate (cases per 100,000) Change in rate 
 
2005-2008 2010 2012 2010 vs baseline 2012 vs baseline 
Serotypes N Rate
1
 n Rate n Rate 
Rate difference
2
 
(95% CI
3
) 
% change 
(95% CI) 
Rate difference
2
 
(95% CI) 
% change 
(95% CI) 
3 months to <2 years of age 
All serotypes 341 214.7 28 69.6 25 59.3 -145.1 (-179.5 to -110.8) -67.6 (-78.8 to -52.3) -155.4 (-188.0 to -122.9) -72.4 (-82.4 to -58.5) 
PCV7 serotypes 218 137.3 12 29.8 4 9.5 -107.5 (-132.3 to -82.6) -78.3 (-88.9 to -61.3) -127.8 (-148.2 to -107.3) -93.1 (-98.1 to -82.1) 
6A 31 19.5 3 7.5 1 2.4 -12.1 (-22.9 to -1.2) -61.8 (-92.5 to +22.4) -17.2 (-25.4 to -8.9) -87.9 (-99.7 to -27.1 ) 
PCV13-additional 
serotypes 
42 26.4 5 12.4 2 4.7 -14.0 (-27.5 to -0.05) -53.0 (-85.5 to +18.6) -21.7 (-32.1 to -11.4) -82.1 (-97.9 to -31.1) 
Non-PCV13 
serotypes 
50 31.5 8 19.8 18 42.7 -11.6 (-27.9 to +4.7) -36.9 (-74.2 to +34.2) +11.2 (-10.4 to +32.8) +35.6 (-25.6 to +136.5) 
HIV-uninfected           
All 174 115.8 16 41.4 14 34.5 -74.4 (-101.0 to -47.8) -64.3 (-80.0 to -40.3) -81.3 (-106.3 to -56.4) -70.2 (-84.1 to -48.7) 
PCV7 serotypes 103 68.6 4 10.3 1 2.5 -58.2 (-74.9 to -41.5) -84.9 (-96.0 to -60.2) -66.1 (-80.2 to -52.0) -96.4 (-99.9 to -79.5) 
6A 20 133.1 3 7.8 1 2.5 -5.6 (-16.1 to +5.0) -41.7 (-88.9 to +96.5) -10.9 (-18.4 to -3.3) -81.5 (-99.6 to +15.7) 
PCV13-additional  21 14.0 4 10.3 2 4.9 -3.6 (-15.4 to +0.8) -26.0 (-81.5 to +119.4) -9.1 (-18.1 to +0.02) -64.8 (-96.0 to +44.2) 
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serotypes 
Non-PCV13 
serotypes 
28 18.6 5 12.9 10 24.6 -5.7 (-18.9 to +7.6) -30.6 (-79.1 to +82.0) +6.0 (-10.8 to +22.7) +32.2 (-42.7 to +180.3) 
HIV-infected           
All 167 1947.3 12 757.1 11 676.1 -1190.2 (-1710.5 to -669.9) -61.1 (-80.3 to -30.3) -1271.2 (-1768.1 to -774.4) -64.9 (-82.2 to -35.6) 
PCV7 serotypes 115 1341.0 8 504.7 3 184.4 -836.2 (-1263.3 to -409.1) -62.4 (-84.1 to -23.3) -1156.6 (-1478.4 to -834.7) -86.1 (-97.2 to -58.4) 
6A 11 128.3 0 - 0 0 -128.3 (-204.1 to -52.5) - -128.3 (-204.1 to -52.5) - 
PCV13-additional 
serotypes 
23 268.2 1 63.1 0 0 -205.1 (-370.3 to -39.9) -76.5 (-99.4 to +44.9) -268.2 (-377.8 to -158.6) - 
Non-PCV13 
serotypes 
19 221.6 3 189.3 8 496.6 -322.7 (-268.5 to +203.9) -14.6 (-83.8 to +190.2) +270.2 (-84.8 to +625.1) +124.1 (-15.1 to +436.2) 
2-5yrs           
All serotypes 130 44.6 19 26.2 8 11.0 -18.4 (-32.5 to -4.3) -41.2 (65.7to -4.4) -33.6 (-44.4 to -22.8) -75.3 (-89.6 to -49.9) 
PCV7 serotypes 72 24.7 8 11.0 1 1.4 -13.7 (-23.2 to -4.1) -55.3 (-81.4 to -7.1) -23.3 (-29.7 to -17.0) -94.4 (-99.9 to -67.9) 
6A 16 5.5 4 5.5 1 1.4 +0.03 (-6.0 to +6.1) +0.6 (-75.5 to +211.7) -4.1 (-7.9 to -0.3) -74.9 (-99.4 to +61.5) 
PCV13-additional 
serotypes 
25 8.6 6 8.2 3 4.1 -0.3 (-7.7 to +7.1) -3.5 (-67.6 to +141.1) -4.5 (-10.2 to +1.3) -51.8 (-90.7 to +57.9) 
Non-PCV13 
serotypes 
17 5.8 1 1.4 3 4.1 -4.5 (-8.3 to -0.6) -76.3 (-99.4 to +51.1) -1.7 (-7.1 to +3.7) -29.2 (-86.7 to +145.0) 
HIV-infected           
 138 
 
All serotypes 57 20.4 4 5.8 3 4.3 -14.7 (-22.4 to -6.9) -71.9 (-92.6 to -23.9) -16.1 (-23.3 to -9.0) -79.0 (-95.8 to -35.5) 
PCV7 serotypes 24 8.6 1 1.4 0 - -7.2 (-11.6 to -2.7) -83.3 (-99.6 to +2.5) -8.6 (-12.0 to -5.2) - 
6A 8 2.9 0 - 0 - -2.9 (-4.9 to -0.9) - -2.9 (-4.9 to -0.9) - 
PCV13-additional 
serotypes 
17 6.1 3 4.3 2 2.9 -1.8 (-7.5 to +3.9) -29.2 (-86.7 to +144.7) -3.2 (-8.1 to +1.7) -53.1 (-94.7 to +97.6) 
Non-PCV13 
serotypes 
5 1.8 - - 1 1.4 -1.8 (-3.4 to -0.2) - -0.4 (-0.4 to +2.9) -20.3 (-98.3 to +612.4) 
HIV-infected           
All serotypes 73 591.6 15 542.3 5 194.6 -67.3 (-365.4 to -230.7) -11.4 (-52.8 to +55.9) -397.0 (-615.0 to -179.0) -67.1 (-89.6  to -19.7) 
PCV7 serotypes 48 389.0 7 244.7 1 38.9 -144.3 (-356.4 to +67.7) -37.1 (-75.0 to +39.8) -350.1 (-484.0 to -216.2) -90.0 (-99.8 to -41.5) 
6A 8 64.8 4 139.8 1 38.9 +74.9 (-69.2 to +219.2) +115.6 (-52.5 to +704.9) -25.9 (-114.5 to +62.6) -40.0 (-98.7 to +347.8) 
PCV13-additional 
serotypes 
8 64.8 3 104.9 1 38.9 +40.0 (-86.9 to +166.9) +61.7 (-72.4 to +573.8) -25.9 (-114.5 to +62.6) -40.0 (-98.7 to +347.8) 
Non-PCV13 
serotypes 
12 97.3 1 34.9 2 77.9 -62.3 (-150.2 to +25.6) -64.1 (-99.2 to +142.9) -19.4 (-140.5 to +101.7) -20.0 (-91.3 to +259.6) 
1 average rate for period 2005-2008, 2 cases per 100,000 population; 3CI, confidence interval;  
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In children >24-60 months age, the annual overall incidence (per 100,000) of IPD decreased 
by 75.3% (95%CI: 49.9% to 89.6%) from the pre-PCV era, (44.6) compared to 2012 (11.0). 
This included a decline in incidence of PCV7 serotype IPD from 24.7 to 11.0 by 2010 (-
55.3%; 95%CI: -7.1% to -81.4%), which declined even further to 1.4 by 2012 (-94.4%; 
95%CI: -67.9% to -99.9%). In contrast, IPD due to PCV13 additional and non-vaccine 
serotypes remained unchanged over this period. 
 
Among HIV-uninfected children 3-24 months age, the incidence (per 100,000) of PCV7 
serotype IPD compared to the pre-PCV era (68.6) decreased by 84.9% by 2010 (10.3; 
p<0.001) and by 96.4% in 2012 (2.5; p<0.001), Figure 6.3a and Table 6.2. Similarly, among 
HIV-uninfected children >24-60 months age, the incidence of PCV7 serotype IPD declined 
by 83.3% from 8.6 in the pre-PCV era to 1.4 by 2010 (p=0.016), whilst no PCV7 serotype 
cases were recorded in 2012 (100% reduction; p<0.001); Figure 6.3c and Table 2.  The 
incidence of   PCV13 additional and non-vaccine serotypes remained unchanged for both 
childhood age groups between the pre-PCV era up until 2012.  
 
Among HIV-infected children >3-24 months age, the incidence of PCV7 serotype IPD 
declined by 62.4% from the pre-PCV7 era (1,341) compared to 2010 (504.7; p=0.001) and by 
86.1% compared to 2012 (184.4; p<0.001), Figure 6.3b and Table 6.2. Furthermore, the 
incidence of PCV13 additional serotypes declined from 268.2 in the pre-PCV era to 63.1, by 
2010 (p=0.05); whilst no cases were observed in 2012 (100% reduction; p=0.009). The 
incidence of non-vaccine serotype IPD remained unchanged among the >3-24 month age-
group of HIV-infected between the pre-PCV era and 2012.  
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Among HIV-infected children >24-60 months age, the incidence of PCV7 serotype IPD 
trended to decline from 389.0 in the pre-PCV era to 244.7 by 2010 (-37.1%; p=0.124), and 
38.9 in 2012 (-90%; p=0.061); Figure 6.3d and Table 6.2. Similar to HIV-uninfected 
children, the incidence of PCV13 additional serotypes and non-vaccine serotype IPD was 
unchanged between the pre-PCV era until 2012.    
 
Among adults 18-45 years of age, overall serotype, PCV7 serotype, PCV13 additional 
serotypes and non PCV13 serotype IPD incidence (per 100,000) were 57.5, 18.6, 20.6 and 
15.3, respectively in the pre-PCV era; Table 6.3. By 2010, we observed reductions in the 
incidence of overall serotype (-29.3%; p<0.001), PCV7 serotype (-44.1%; p<0.001) and 
PCV13 serotype IPD (-28.2%; p=0.002). Non-vaccine serotype IPD was unchanged in 2010 
(-8.7%; p=0.23). By 2012, further declines were observed in overall IPD (-64.4%: p<0.001), 
PCV7 serotype (-84.9%; p<0.001), and PCV13 additional serotype IPD (-69.5%; p<0.001. 
Furthermore, we also observed a reduction in incidence of non PCV13 of -31.9% between the 
pre-PCV era (15.3) and 2012 (10.4; p=0.002).  
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Table 6.3 Rate changes of invasive pneumococcal disease cases among adults 18 to 45 years of age, by year and serotype group, South Africa, 2010 
and 2012 compared with baseline pre-PCV years 2005-2008.  
 
Number and rate (cases per 100,000) Change in rate 
 
2005-2008 2010 2012 2010 vs baseline 2012 vs baseline 
Serotypes N Rate n Rate n Rate 
Rate difference 
(95% CI) 
% change 
(95% CI) 
Rate difference# 
(95% CI) 
% change 
(95% CI) 
 
          
All serotypes 1330 57.5 242 40.6 124 20.5 -16.9 (-22.9 to -10.9 ) -29.3 (-38.6 to -18.9) -37.0 (-41.8 to -32.3) -64.4 (-70.4 to -57.2) 
PCV7 serotypes 431 18.6 62 10.4 17 2.8 -8.2 (-11.4 to -5.1) -44.1 (-57.9 to -26.9) -15.8 (-18.0 to -13.6) -84.9 (-91.3 to -75.6) 
6A 70 3.0 9 1.5 6 1.0 -1.5 (-2.7 to -0.3) -50.1 (078.1 to +0.3) -2.0 (-3.1 to -0.9) -67.3 (-88.4 to -25.1) 
PCV13-additional 
serotypes 
476 20.6 88 14.8 38 6.3 -5.8 (-9.4 to -2.2) -28.2 (-43.5 to -9.7) -14.3 (-17.0 to -11.6) -69.5 (-78.7 to -57.6) 
Non-PCV13 
serotypes 
353 15.3 83 13.9 63 10.4 -1.3 (-4.7 to +2.1) -8.7 (-28.9 to +16.3) -4.9 (-7.9 to -1.8) -31.9 (-48.7 to -10.7) 
HIV-uninfected           
All serotypes 114 5.9 17 3.4 4 0.8 -2.5 (-4.5 to -0.5) -42.1 (-67.4 to -3.1) -5.1 (-6.5 to -3.8) -86.5 (-96.4 to -64.6) 
PCV7 serotypes 43 2.2 4 0.6 0 - -1.4 (-2.5 to -0.03) -63.9 (-90.6 to -0.5) -2.2 (-2.9 to -1.6) - 
6A 3 0.2 0 - 0 - -0.2 (-0.3 to +0.2) - -0.2 (-0.3 to +0.02) - 
PCV13-additional  
serotypes 
48 2.5 7 1.4 2 0.4 -1.1 (-2.3 to +0.2) -43.3 (-78.4 to +25.9) -2.1 (-3.0 to -1.2) -84.0 (-98.1 to -39.0) 
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Non-PCV 13 
serotypes 
21 1.1 6 1.2 2 0.4 +0.1 (-0.9 to +1.2) +11.0 (-63.3 to +184.4) -0.7 (-1.4 to +0.03) -63.5 (-95.9 to +49.5) 
HIV-infected           
All serotypes 1216 310.2 225 222.3 120 117.9 -87.9 (-121.8 to -54.0) -28.3 (-38.1 to -17.3) -192.3 (-219.7 to -164.9) -62.0 (-68.8 to -54.1) 
PCV7 serotypes 388 99.0 58 57.3 17 16.7 -41.7 (-59.4 to -23.9) -42.1 (-56.9 to -23.6) -82.3 (-94.9 to -69.6) -83.1 (-90.3 to -72.6) 
6A 67 17.1 9 8.9 6 5.9 -8.2 (-15.3 to -1.1) -47.9 (-77.2 to +4.8) -11.2 (-17.4 to -5.0) -65.5 (-87.8 to -20.9) 
PCV13-additional 
serotypes 
428 109.2 81 80.0 36 35.4 -29.2 (-49.4 to -8.9) -26.7 (-42.9 to -6.9) -73.8 (-89.3 to -58.3) -67.6 (-77.6 to -54.4) 
Non-PCV13 
serotypes 
332 84.7 77 76.1 61 59.9 -8.7 (-27.9 to +10.7) -10.2 (-30.8 to +15.4) -24.8 (-42.3 to -7.2) -29.2 (-47.1 to -6.8) 
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Among HIV-uninfected adults, the incidence (per 100,000) of overall serotype, PCV7, 
PCV13 additional and non PCV13 serotype IPD were 114, 43, 48 and 21, respectively in the 
pre-PCV era; Figure 6.3e and Table 6.3. The incidence of PCV7 serotype IPD subsequently 
declined by 63.9% in 2010 (p=0.016), whilst no PCV7 cases were observed in 2012 
(p<0.001). Similar decline (-84.0%) were observed in incidence of PCV13-additional IPD 
(p=0.001); whilst non-vaccine serotypes were not significantly different (1.1 vs 0.4; p=0.076) 
between the pre-PCV era and 2012.   
 
Among HIV-infected adults, the incidence (per 100,000) of overall, PCV7, PCV13 additional 
and non PCV13 serotype IPD were 1 216, 388, 428 and 332, respectively in the pre-PCV era; 
Figure 6.3f and Table 6.3. By 2010, the incidence of PCV7 serotype IPD had declined by 
42.1% (p<0.001); and further by 83.1% (p<0.001) in 2012.  Similarly, we observed a 26.7% 
(p=0.004) reduction in PCV13additional serotypes between the pre-PCV era and 2010 (109.2 
vs. 80 cases); and a further decline by 2012 (-67.6%; p<0.001); Figure 6.3f and Table 6.3.  A 
more modest decline in incidence of non-vaccine serotype IPD from 84.7 in the pre-PCV era 
to 59.9 in 2012 (-29.2%; p=0.005) was also observed.  
 
Among HIV-infected adults 18-45 years age, the incidence of overall serotype, PCV7 
serotype, PCV13 additional serotypes and non PCV13 serotype IPD incidence (per 100,000) 
were 1216, 388, 428 and 332, respectively in the pre-PCV era; Figure 6.3f and Table 6.3. By 
2010, the incidence of PCV7 serotype IPD had declined by 42.1% (p<0.001) and further by 
83.1% (p<0.001). Similarly, we observed a 26.7% reduction in PCV13 additional serotypes 
between the pre-PCV era and 2010 (incidence 109.2 vs.  80; p=0.004); and a further decline 
by 2012 (-67.6%; p<0.001); Figure 6.3f and Table 3.  A more modest decline in incidence of 
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non-vaccine serotype IPD from 84.7 in the pre-PCV era to 59.9 in 2012 (29.2%; p=0.005) 
was also observed.  
IPD trends in women aged 18-45 years are presented in Section 6.3.3, Tables 6.4 and 6.5. 
 
6.3.5 Evaluation of model using temporal nasopharyngeal 
colonization to Predict IPD incidence  
 
Using a model proposed by Weinberger et al., we simulated the expected incidence of IPD 
for overall serotypes, PCV7 serotype, PCV13 additional serotype and non-vaccine serotype; 
based on the observed prevalence of pneumococcal colonization for these serotype groups in 
the pre-PCV era and then in 2010 and 2012. This was undertaken for HIV-uninfected 
children aged >3-24 months and for HIV-infected and HIV-uninfected women 18-45 years 
age in whom pre-PCV era and PCV era colonization data were available. Also, we compared 
for HIV-infected children aged >3-24 months, and for both HIV groups among children age 
>24-60 months and women 18-45 years, the predicted incidence of IPD using colonization 
prevalence in 2010 (PCV7 era) compared to 2012 (PCV13 era). The results of the model are 
shown in Figures 6.5 and 6.6 and Tables 6.4 and 6.5. 
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PCV7 serotypes 
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Figure 6.5 Comparison of observed and model-predicted IPD changes in children >3mths-2 years, >2-5 years old and women 18-45 
years old during pre- and post-vaccination periods for all pneumococcal, PCV7 and additional PCV13 IPD 
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Figure 6.6 Comparison of observed and model-predicted IPD changes in children >3mths-2 years, >2-5 years old and women 18-45 
years old during pre- and post-vaccination periods for   PCV13 and non-vaccine serotype IPD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                  HIV-uninfected     HIV-infected          HIV-uninfected             HIV-infected 
                                          Children                                      Women 
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Table 6.4 Observed and model-predicted changes in overall incidence of invasive pneumococcal disease and disease due to vaccine serotypes  
  All pneumococcal disease PCV7 serotype disease Additional PCV13 serotype disease 
Group Years compared Observed IPD Predicted IPD Observed IPD Predicted IPD Observed IPD Predicted IPD 
  % change  
(95% CI) 
% change  
(95% CI) 
% change  
(95% CI) 
% change  
(95% CI) 
% change 
(95% CI) 
% change 
(95% CI) 
Children        
HIV-  (>3mnths-2yrs) Pre-PCV era
1
  vs 2010
2
 -87.9 
(-93.6, -78.8) 
-20.2 
(-32.1, -7.64) 
-94.5 
(-98.5, -85.4) 
-29.6 
(-43.3, -13.5) 
-74.7 
(-91.6, -36.0) 
-24.8 
(-10.5, +71.2) 
 Pre-PCV era vs 2012
3
 -91.7 
(-96.1, -84.2) 
-53.5 
(-62.2, -42.7) 
-98.7 
(-100, -92.5) 
-72.1 
(-80.1, -61.4) 
-91.9 
(-99.1, -67.4) 
-62.2 
(-81.1, -27.1) 
 2010 vs 2012 -26.2 
(-44.6, -2.27) 
-12.9 
(-32.2, 10.2) 
-76.2 
(-99.5, 140.8) 
-55.3 
(-69.5, -35.8) 
-68.2 
(-96.9, +77.7) 
--69.3 
(-82.8, -46.7) 
 (>2-5 years) 2010 vs 2012 -0.71 
(-81.5, 133.1) 
3.39 
(-32.1, 46.9) 
-100.0 -36.8 
(-60.3, -0.37) 
-0.71 
(-92.8, +1270) 
-54.2 
(-72.7, -25.2) 
HIV+ (>3mnths-2yrs) 2010 vs 2012 -9.11 
(-64.8, 129.5) 
-11.4 
(-25.6, 4.31) 
-45.5 
(-91.2, 155.4) 
-35.1 
(-51.3, -14.7) 
-100.0 
- 
-14.0 
(-53.6, +54.6) 
 (>2-5 years) 2010 vs 2012 -60.1 
(-89.1, 24.4) 
-28.3 
(-40.6, -14.1) 
-12.3 
(-98.9, 120.0) 
-56.1 
(-68.8, -39.2) 
-43.0 
(-90.8, +167) 
-25.4 
(-55.3, +21.4) 
Mothers (18-45yrs)        
HIV- Pre-PCV era vs 2010 -70.1 
(-85.3, -43.1) 
-73.2 
(-77.8, -68.1) 
-58.5 
(-93.1, 81.6) 
-63.0 
(-74.2, -47.7) 
-77.7 
(-92.5, -44.5) 
-62.4 
(-75.1, -44.3) 
 Pre-PCV era vs 2012 -93.1 
(-98.6, -78.4) 
-79.8 
(-84.5, -73.3) 
-100.0 -88.8 
(-93.6, -81.1) 
-96.4 
(-99.9, -77.9) 
-69.9 
(-81.6, -52.0) 
 2010 vs 2012 -77.4 
(-95.9, -17.9) 
-25.8 
(-49.2, -0.16) 
-100.0 -74.9 
(-84.9, -59.2) 
-83.7 
(-99.6, +34.2) 
-35.7 
(-60.1, +1.50) 
HIV+ Pre-PCV era vs 2010 -71.5 
(-76.2, -66.0) 
-66.9 
(-72.1, -61.0) 
-76.3 
(-83.2, -67.2) 
-63.4 
(-73.0, -51.0) 
-67.9 
(-75.9, -57.8) 
-31.4 
(-56.5, +5.7) 
 Pre-PCV era vs 2012 -86.2 
(-89.3, -82.6) 
-73.0 
(-78.0, -66.4) 
-94.5 
(-97.3, -89.9) 
-80.0 
(-85.8, -72.3) 
-88.8 
(-92.9, -83.0) 
-53.7 
(-70.7, -28.6) 
 2010 vs 2012 -51.7 
(-63.6, -36.5) 
-27.9 
(-40.5, -13.1) 
-76.6 
(-89.1, -54.2) 
-47.2 
(-65.1, -21.6) 
-65.1 
(-78.8, -44.2) 
-25.9 
(-49.0, +5.8) 
n/a –there were no PCV7 serotypes detected in HIV-uninfected women during 2012 
1
Pre-PCV era, 2005 to 2008, 
2
2010 as PCV7 era, 
3
2012 as PCV13 era 
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Table 6.5 Observed and model-predicted changes in non-vaccine serotype and additional 
PCV13 serotypes IPD  
  Non-vaccine serotype disease PCV13 serotype disease 
Group Years compared Observed IPD Predicted IPD Observed IPD Predicted IPD 
  % change  
(95% CI) 
% change  
(95% CI) 
% change 
(95% CI) 
% change 
(95% CI) 
Children      
HIV-  (>3mnths-2yrs) Pre-PCV era
1
  vs 2010
2
 -78.4 
(-94.7, -34.5) 
-19.9 
(-39.5, +4.5) 
-89.7 
(-95.2, -80.1) 
-17.2 
(-31.5, -0.75) 
 Pre-PCV era vs 2012
3
 -64.0 
(-87.3, -9.6) 
+44.9 
(+7.7, +92.0) 
-97.0 
(-99.4, -91.1) 
-70.7 
(-77.1, -62.9) 
 2010 vs 2012 +66.8 
(-57.6, +677) 
+36.4 
(+9.4, +68.3) 
-71.4 
(-94.9, 11.1) 
-60.1 
(-68.9, -49.5) 
 (>2-5 years) 2010 vs 2012 +98.6 
(-89.7, +11616) 
+56.3 
(+25.7, +91.8) 
-33.8 
(-94.5, 117.8) 
-44.8 
(-59.0, -26.9) 
HIV+ (>3mnths-2yrs) 2010 vs 2012 +90.9 
(-51.5, +789) 
+26.2 
(+0.4, +56.8) 
-59.1 
(-93.0, 70.4) 
-30.9 
(-46.3, -12.3) 
 (>2-5 years) 2010 vs 2012 -71.5 
(-99.4, +188.1) 
+44.4 
(+15.8, +77.9) 
-49.9 
(-89.2, 97.1) 
-45.7 
(-57.9, -30.8) 
Mothers (18-45yrs)      
HIV- Pre-PCV era vs 2010 -57.0 
(-90.3, +54.1) 
-78.2 
(-82.4, -73.4) 
-73.6 
(-88.9, -43.6) 
-62.7 
(-71.1, -52.5) 
 Pre-PCV era vs 2012 -79.0 
(-97.8, +1.50) 
-78.8 
(-83.6, -72.9) 
-97.1 
(-99.9, -82.5) 
-80.3 
(-86.6, -71.6) 
 2010 vs 2012 -51.1 
(-95.6, +240) 
+1.7 
(-22.2, +31.4) 
-89.1 
(-99.8, -21.6) 
-55.0 
(-67.7, -38.3) 
HIV+ Pre-PCV era vs 2010 -70.5 
(-79.3, -58.8) 
-73.8 
(-78.9, -67.9) 
-71.9 
(-77.3, -65.3) 
-56.3 
(-65.8, -44.8) 
 Pre-PCV era vs 2012 -72.5 
(-80.8, -61.2) 
-72.6 
(-78.2, -66.0) 
-90.8 
(-93.5, -87.1) 
-73.1 
(-79.7, -64.8) 
 2010 vs 2012 -6.5 
(-39.6, +44.5) 
-10.2 
(-27.1, +9.6) 
-69.7 
(-79.7, -55.6) 
-35.9 
(-51.3, -16.8) 
 
1Pre-PCV era, 2005 to 2008; 22010, PCV7 era; 32012, PCV13 era 
 
 
 
Among HIV-uninfected children 3-24 months age, the model underestimated the decline in 
overall-serotype IPD between the pre-PCV7 era and 2012 ( observed- 91.7%; 95% CI:-96.1 
to -84.2 vs. predicted  -53.5%;  95%CI:-62.2 to -42,7), and similarly for PCV7 serotype 
(observed -98.7%; 95%CI:-100 to -92 vs. predicted -72.1%; 95%CI: -80.1 to -61.4).  The 
observed decline between the pre-PCV era and 2012 in PCV13  additional serotype IPD was 
-91.9% (95%CI:-99.1 to -67.4), which although higher than the predicted point estimate 9-
62.2%; 95%CI: --81.1 to -27.1) there was overlap of the 95% confidence(Figure 6.5a and 
Table 6.4). For non-vaccine serotype IPD, we observed a decrease of 64.0% (95% CI:-87.3 to 
-9.6) whereas the model predicted an increase of 44.9% (95%CI: 7.7 to 92.0); Figure 6.6b 
and Table 6.5. A similar trend was observed when comparing the pre-PCV era to 2010. The 
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model’s predicted compared to observed changes in IPD incidence was, however, more 
comparable when limited to comparing changes in prevalence of colonization between 2010 
and 2012 only, for all serotypes (observed:-26.2%, 95%CI: -44.6 to -2.27  vs. predicted -
12.9%, 95%CI: -32.2 to 10.2), PCV7 serotypes (observed: -76.2%, 95%CI:-99.5 to 140.8 vs. 
predicted -55.3%, 95% CI: -69.5 to -35.8), and PCV13 additional serotypes (observed: -
68.2%, 95%CI: -96.9 to +77.7 vs. predicted of -69.3%, 95% CI: -82.8 to -46.7). 
 
In older unvaccinated HIV-uninfected children aged >24-60months, comparing the pre-PCV 
era to 2012 the model underestimated the decline in PCV7 serotype disease (observed: -100% 
vs predicted -36.8%, 95% CI: -60.3 to -0.37). The wide confidence interval for PCV13 
additional and non-vaccine serotypes did not allow for further comparison of the observed 
and predicted changes in this in this age-group. 
 
In HIV-infected children, in whom pre-PCV colonization data were unavailable, between 
2010 and 2012 in children aged >3-24 months, the point-estimate of the observed (-9.11%, 
95%CI:-64.8 to 129. 5) and predicted (11.4%, 95% CI; -25.6 to 4.31) decrease in overall IPD 
were similar, albeit not significant for either. Similar point estimates were also observed for 
PCV7 serotype IPD, observed (-45.5%, 95%CI: -91.2 to +155.4) and predicted (-35.1, 
95%CI: -51.3 to -14.7). There was, however, a 100% decline (in PCV13 additional serotype 
IPD between 2010 and 2012, whereas the model prediction was a non-significant decline of 
14.0% (95%CI: -53.6 to +54.6). The predicted point estimate for non PCV13 serotypes 
(+26.2%, 95% CI +0.4 to +56.8) was lower than the observed (+90.9%, 95% CI: -51.5 to 
+789). 
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Among older HIV-infected children (>24 to 60 months) the predicted point estimate for 
decrease in incidence of overall serotype IPD   (-28.3%, 95%CI: -40.6% to -14.1%) was 
lower than the observed decline (-60.1%, 95%CI: -89.1% to +24.4%). There was overlap of 
the 95% CI between the observed (-43.0%, 95%CI: -90.8 to +167) and predicted decline in 
PCV13 additional serotype IPD (-25.4%, 95% CI:-55.3, to +21.4).   
  
Among HIV-uninfected women aged 18-45 years comparing the pre-PCV era and 2012, the 
observed reduction in overall serotype IPD (-93.1%, 95% CI: -98.6 to -78.4) was similar to 
the model predicted estimate (-79.8%, 95% CI: -84.5 to -73.3). Similarly, the observed and 
model-predicted reductions were similar for PCV7 serotype IPD (-100% vs -88.8%, 95% CI: 
93.6, -81.1), PCV13 additional serotypes (-96.4%, 95% CI: -99.9 to -77.9 vs  -69.9%, 95% 
CI: -81.6 to -52.0), and non-vaccine serotype IPD ( -79.0%, 95% CI: -97.8, +1.50 vs  -78.8, 
95% CI: -83.6 to -72.9).  Similar synergies in the observed and predicted estimates were 
observed when comparing the pre-PCV era to 2010. 
    
Similarly, among HIV-infected women when comparing the pre-PCV era to 2012, the 
observed estimates closely mirrored the model-predicted reductions in IPD for all serotypes (-
86.2% [95% CI: -89.3 to -82.6] vs -73.0 [95% CI: -78.0 to -66.4]), PCV7 serotype (-94.5% 
[95% CI: -97.3 to -89.9] vs -80.0% [95% CI: -85.8  to -72.3]) and non-vaccine serotypes (-
72.5% [95% CI: -80.8 to -61.2] vs  -72.6% {95% CI: -78.2 to -66.0]). The model predicted 
estimates in reduction for PCV13 additional serotype  (-31.4%, 95% CI: -56.5, +5.7) was, 
however, lower compared to observed reduction (-67.9%, 95% CI: -75.9 to -57.8).The model 
predicted and observed changes in IPD data between 2010 and 2012 were comparable, for all 
serotypes, PCV7 serotypes, PCV13 additional serotypes and non PCV13 serotypes. 
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6.4 Discussion 
 
Our study shows that the introduction of PCV into the South African childhood national 
immunization program resulted in reduction of vaccine serotype IPD among all ages. These 
changes were mirrored by a decline in colonization of vaccine serotypes temporally 
associated with childhood PCV immunization, including among HIV-infected and HIV-
uninfected PCV-unvaccinated older children and women as discussed in Chapter 4 (179). In 
this analysis, we expand on the latter observations and illustrate that serial studies on NP 
vaccine serotype  colonization can be used to predict post-PCV changes in the incidence of 
IPD among children and women, particularly in age groups not targeted for vaccination.  
 
The effectiveness of a 2+1 schedule on IPD in South Africa has been previously evaluated in 
a case control study in South Africa, (180) in which two or more doses of PCV7 were shown 
to be 74% effective in reducing IPD among HIV-uninfected, whereas no significant reduction 
was observed in HIV-infected children [12% (95% CI, −449% to 77%)]. Similarly three or 
more doses of PCV7 conferred 90% protection against vaccine serotype IPD among HIV-
uninfected; whereas the reduction in  HIV-infected children was not significant (-57%; 95% 
CI: -96 to 371) (180). We, however, observed significant decreases in IPD among HIV-
infected children during the study period similar to the observation at national level (112). In 
this study non-vaccine serotype IPD was unchanged among HIV-infected children although 
national data observed a decrease that was alluded to the increase in anti-retroviral therapy  
usage among children (112). 
 
Childhood PCV immunization in South Africa reduced the burden of IPD among older 
children and women/adults through reduced transmission of vaccine serotype pneumococci 
(or the commonly isolated serotypes in both carriage and IPD). In our population the decrease 
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in IPD among individuals 19-45 years of age, represents a significant public health impact of 
infant PCV vaccination as this group has the highest HIV prevalence. The reduction in 
vaccine serotype disease among HIV-uninfected unvaccinated groups can be attributed 
mainly to indirect effects, although this may also result from secular trends.  However, 
among HIV-infected individuals in addition to the effect of PCV, increased availability of 
ART also resulted in a reduction in IPD including non-vaccine serotype disease (112). The 
indirect protection against IPD observed in our study, is similar to observations  in the USA, 
where indirect protection was observed following implementation of the childhood PCV7 
immunization program  (10, 11). In the USA across all age groups  between 1998/99 (pre-
PCV era) and 2003 there was a 75% decline in IPD due to any serotype and  94% decrease in 
IPD caused by PCV7 serotypes, including among individuals greater than 65 years 
supporting an indirect effect on vaccination (10, 11, 110).   
 
In children, we observed substantial replacement of non-vaccine serotype colonization, but 
no concomitant increase in IPD due to these non-vaccine serotypes. Similarly,in the UK 
despite an increase in non-vaccine serotype carriage there was a net reduction in IPD and this 
was attributed to smaller case carrier ratios (i.e., low invasiveness) of these serotypes (59). In 
the USA, the incidence of IPD due to non-vaccine serotypes , in particular 19A, increased by 
58% among children aged less than 2 years and by 135% in children aged 2 to 4 years in the 
PCV era compared to the pre vaccine introduction period (114). This effect was manifest as 
early as three years post PCV introduction (114, 115). Similarly in the UK, serotype 19A 
increased significantly following PCV7 vaccination of infants (59). However, serotype 19A 
increases have also been described in unvaccinated communities (117). In our population the 
transitioning from PCV7 to PCV13 within a short period of time may have prevented the 
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emergence of increase in any of the additional serotypes (including 19A) which are included 
in PCV13.  
 
An important component of our study was to determine whether serial studies on 
nasopharyngeal colonization, which is easier and cheaper to undertake than surveillance for 
IPD, could be used to impute the magnitude of changes in IPD following introduction of 
childhood PCV immunization. In this regard, we observed a strong association in temporal 
decline of colonization by vaccine serotype and IPD among age-groups that were not targeted 
for PCV vaccination, when comparing the pre PCV era to the PCV era. The strength of this 
association was, however, less evident in young children 3-24 months of age, in whom the 
reduction in IPD exceeded the percentage change in colonization by the vaccine serotypes. 
Consequently, using the serial colonization studies and pre PCV era IPD incidence, we 
observed that the magnitude of a model-predicted reduction in vaccine serotype IPD was 
similar to the observed reduction of vaccine serotype IPD for HIV-infected and HIV-
uninfected adults and children outside the age group that were targeted for  PCV 
immunization.  
 
 We found similarity in the model predicted and observed IPD reductions in vaccine serotype 
IPD among women 18-45 years old, regardless of HIV-status. This is despite HIV-infected 
adults having higher  prevalence of pneumococcal, including vaccine serotype, colonization; 
(47, 153, 159, 160, 181) and a higher incidence of IPD (112). This reflects that the risk of 
IPD is inherently associated with colonization, hence among adults in whom there is 
generally a low-modest prevalence of pneumococcal colonization, serial surveillance of 
changes in colonization can be used to determine whether an indirect effect against IPD is 
materialising in the community. Also, among children aged 2 to 5 years in whom we did not 
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have pre PCV era data, the model also performed well for vaccine serotypes regardless of 
HIV status when comparing early and post-vaccination years. Estimates for non-vaccine 
serotypes were, however, less accurate for both HIV-infected and HIV-uninfected 
unvaccinated individuals. 
 
The model predicted changes in vaccine serotype IPD was, however, less well aligned to the 
observed reductions in the age group (>3 to 24 months) who were targeted for PCV 
immunization. This is likely because the model does not account for the direct protection 
against progression to IPD which vaccinated children derive through humoral immunity 
induced by vaccination, (122) over and above any further reduced risk secondary to lesser 
community wide transmission of the vaccine serotypes. The model predicted reduction in 
PCV serotypes among this young age group (<3 to 24 months) was, however, somewhat 
closer to the observed reduction in HIV-infected than HIV-uninfected children. This could be 
because of the poorer immunogenicity and lesser direct protection through PCV 
immunization in HIV-infected children; as had been alluded to in the case control study and 
the previous 9 valent PCV efficacy trial in South Africa (54, 180). 
 
Although the theoretical model predicted reductions that were similar to the observed 
reductions in women, regardless of HIV-status, significant changes in anti-retroviral 
treatment might  alter the susceptibility of HIV-infected individuals to IPD and this may 
render the modelling results less accurate (122). However, a previous study  from our setting 
showed no changes in the incidence of IPD in HIV-infected individuals with increase in ART 
coverage (154). Also, the additional serotypes included in  PCV13, including  1 and 5 which 
account for approximately 20% of pneumococcal disease in African children, are infrequently 
identified in healthy individuals and have much greater invasive potential (36, 50). The 
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model, however, assumes equal reduction in carriage and IPD, irrespective of the serotype, 
and hence may be less accurate in identifying changes in disease due to these serotypes which 
are infrequently identified among healthy individuals. Measuring colonization at the time of 
IPD (16) may improve the accuracy of estimates including among vaccinated children. Also, 
the smaller sample size for our data compared to national estimates may have impacted on 
accuracy of estimates (122).  Despite, these shortfalls, our analysis indicate that  the 
introduction of PCV resulted in a marked reduction in both vaccine serotype carriage 
prevalence in both vaccinated and non vaccinated groups and that any significant decreases in 
carriage resulted in proportional declines in vaccine serotype IPD. 
 
A limitation of our study is that we did not have carriage data for HIV-infected children prior 
to the introduction of PCV in the national immunization program, so some analysis was 
limited to HIV-uninfected children. This may, however, become less important in settings 
such as ours where  mother to child HIV transmission rate is now <2% (128), and will 
continue to fall with improvement in HIV care and treatment.  
 
In summary, our study show that PCV use in South Africa reduced vaccine serotype carriage 
and IPD in vaccinated children as well as in unvaccinated mothers. In the vaccinated age 
group, the effectiveness of the vaccine on IPD is greater than the effectiveness of the vaccine 
on colonization. On the other hand, changes in colonization due to the vaccine in un-
vaccinated individuals can approximate IPD changes in the same population and can 
potentially be used in resource limited settings to predict post PCV introduction vaccine 
serotype changes in IPD including in HIV-infected populations. For both vaccinated and 
unvaccinated individuals model estimates for non-vaccine serotypes were not comparable. 
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Chapter 7                             Integrated Discussion and Conclusion 
 
 
The United Nations set a 2015 target to achieve a series of Millennium Development Goals 
(MDG). Many low-income countries will be unable to attain MDG Goal 4 i.e. “to reduce by 
two thirds, between 1990 and 2015, the under-five mortality rate”(182). Among children 
aged five years and less, pneumonia and diarrhoea remain leading causes of disease and death 
(183) and the prevention of  these diseases needs to be prioritised. Most cases  of severe 
pneumonia, including deaths, are due to bacterial infections, particularly due to S. 
pneumoniae, H. influenzae and S. aureus (183). 
 
In the absence of PCV immunization, S. pneumoniae was responsible for 18.3% of severe 
pneumonia cases globally (17) and at least 20-37% of pneumonia associated with alveolar 
consolidation on CXR (53, 54).  PCV immunization has the potential to reduce under-5 
childhood pneumonia mortality in low-income countries, where 97% of pneumonia deaths 
occur (184). The higher pneumococcal colonization prevalence in low and medium income 
country settings mirror the disproportionate burden of pneumonia and IPD in these countries 
compared to high-income countries. Furthermore, childhood PCV immunization could 
indirectly reduce  pneumococcal disease even among PCV-unvaccinated age-groups, due to 
immunization of young children interrupting the transmission of the vaccine serotypes in the 
community (185).  
 
This thesis evaluated the effect of PCV introduction on the epidemiology of nasopharyngeal 
colonization in South Africa, a country with a high prevalence of HIV among adults. In 
addition we examined the effect of childhood PCV immunization on colonization by other 
potential bacterial pathogens, i.e.  S. aureus and H. influenzae. Lastly, we sought to address 
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whether studies on changes in prevalence of serotype-specific colonization could be used to 
predict IPD disease trends post-vaccine introduction in HIV-infected and HIV-uninfected 
individuals.  
 
We have described NP pneumococcal colonization prior and during the time after PCV 
introduction occurred by age-group and HIV-status in two study settings in South Africa 
(162, 176). This work highlights the high prevalence of pneumococcal carriage in young 
children and up to 12 years of age. In addition, HIV-infected adults were twice as likely to be 
colonized by pneumococcus, including PCV serotypes, compared to HIV-uninfected adults 
prior to and during the PCV era  (176). These findings are consistent with other studies in 
Zambia and South Africa (132, 140, 181). We initially hypothesised that in the absence of 
adult PCV vaccination, HIV-infected adults could serve as a reservoir of vaccine serotype 
colonization in the population, hence possibly undermining the indirect effect of childhood 
PCV immunization. Our studies, however, subsequently showed that transmission of 
pneumococcus  adults to children was minimal even in settings with a high prevalence of 
adult HIV-infection  (186).  
 
Following childhood PCV immunization, decline in vaccine serotype colonization prevalence 
were observed in age groups targeted for vaccination. Furthermore, we observed a temporal 
reduction in prevalence of pneumococcal colonization among unvaccinated age groups. The 
reduction in vaccine serotypes colonization among adults 18-45 years of age with a high 
prevalence of HIV-infection provides the first evidence that infant PCV immunization 
confers indirect protection against NP colonization among HIV-infected adults who remain at 
high risk (20-fold greater) of invasive pneumococcal disease even when treated with ART. 
However, we also observed that the prevalence of pneumococcal colonization remained 
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higher in HIV-infected compared to –uninfected women overall as well as for PCV13-
serotypes during the PCV-era. This likely contributes to HIV-infected individuals remaining 
at greater risk of developing IPD, albeit at lower incidence than in the pre-PCV era. The Joint 
Committee on Vaccination and Immunisation in the United Kingdom has  not recommended 
PCV vaccination for high risk groups, based on them likely benefiting from indirect 
protection (187). Given the high cost of PCV vaccination for governments, improvements in 
ART management and ensuring high levels of infant PCV vaccine coverage might be 
adequate to protect HIV-infected adults against vaccines-serotype IPD in settings such as 
South Africa. 
The high nasopharyngeal pneumococcal colonization prevalence among age groups not 
targeted for PCV immunization may have implications for the  magnitude of the indirect 
effects and duration of time it would take to materialize, more so where there are no  catch up 
campaigns for older children (123). Using a unique dosing schedule of PCV, given at 6, 14 
and 40 weeks of age (2+1) of age (infant PCV immunization without a catch-up campaign for 
older children in South Africa, was associated with reduction in NP vaccine serotype (PCV7  
and PCV13 additional serotypes) colonization across all age-groups. Children younger than 2 
years targeted in most PCV immunization  programs are “key transmitters” (16) and it may 
be adequate to vaccinate only this age group. This is supported by our study findings; and 
similarly in a study from  Kenya where a similar magnitude of indirect effect on vaccine 
serotype IPD was observed among older  children between a setting where  a catch-up 
campaign was initiated  (76) compared to another where there was no catch-up campaign 
(77). Also, our studies have shown that indirect effects can materialize with PCV vaccine 
coverage of just over 50% in young children (<12 months) as was the case in rural South 
Africa. Vaccine coverage rates of 65-75% were also sufficient to induce indirect effect in 
both Kenya and Massachusetts (76, 188).  
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While an increase in non-vaccine serotype colonization was observed among PCV  
vaccinated children, a decrease in non-vaccine serotype colonization was observed among 
adults in rural South Africa and in HIV-infected women during the PCV era (162, 179). The 
decrease in non-vaccine serotype among these groups could be due to temporal fluctuations 
in circulation of these serotypes, rather than a specific effect of childhood PCV 
immunization.  Furthermore, we hypothesise that transmission of non-vaccine serotypes from 
children to adults is less efficient, and there might be a lag when colonization replacement 
due to these non-vaccine serotypes materializes among unvaccinated age groups. 
Additionally, improved management of HIV-infected adults with ART over the same period 
when PCV immunization of young children was being rolled out, could have contributed to 
the decrease in non-vaccine serotypes observed in HIV-infected adults. 
 
With the introduction of PCV into national immunization programs, there is a need to 
determine what other changes might occur in nasopharyngeal bacterial colonization which 
could indicate whether disease due to these other potential pathogens might also change. In 
this thesis we  described the concurrent changes in H. Influenzae and S. aureus colonization 
following PCV7 infant immunization in a rural African community with a high HIV 
prevalence among adults (189).  
Our study showed temporal reductions in pneumococcal and H. influenzae nasopharyngeal 
colonization among children targeted for vaccination. Additionally, S. aureus colonization 
was unchanged in vaccinated children, whilst there was a decrease in S. aureus among 
unvaccinated age-groups. In a randomised controlled trial, higher colonization prevalence of 
S. aureus and H. influenzae was observed in children as well as their parents following infant 
vaccination with PCV7 (108). An increase in S. aureus colonization has also been reported in 
vaccinated children but not among PCV unvaccinated controls following PCV7 vaccination 
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of infants (104). This was evident at 12 months of age, but not at an older age. Also, studies  
from the USA indicate  that the increase in S. aureus following PCV immunization was only 
transient, with no long term increase in S. aureus colonization observed (171). The 
relationship between S. aureus and non-vaccine serotype colonization may therefore be 
different to the known negative relationship between vaccine serotype and S. aureus 
colonization. This could explain our observation in which S. aureus colonization was 
unchanged in children, despite the significant increase in non-vaccine serotype colonization. 
Continuous monitoring on the impact of childhood PCV immunization on colonization by 
these bacteria are, however, warranted to rule out any possible  increase in disease due to 
these bacteria which have disease causing potential  (190).  
 
Pneumococcal carriage prevalence mirrors IPD incidence by age group. In our population, 
IPD incidence was highest in young children aged <2 years and in adults 18-45 years age 
(179). The high incidence in adults aged 18-45 years is due to the high prevalence of HIV-
infection in this age group. Additionally, for all age-groups, HIV-infected individuals had 
higher rates of IPD compared to HIV-uninfected age-groups (112, 179). For children, <2 
years age among HIV-uninfected children, although we did not have data on HIV-exposure 
status, there is emerging evidence that these children are three-fold more likely to develop 
IPD compared to HIV-unexposed uninfected children (191). This is particularly important as 
the population of HIV-infected children decreases but HIV-uninfected exposed children 
increase. The effectiveness of PCV in HIV-exposed uninfected children has, however, been 
shown to be similar compared to HIV-unexposed children (180).  In our study setting of 
Soweto, we observed a 93% decrease in PCV7 serotype IPD in children age 3-24 months of 
age comparing the pre-PCV era to 2012. This compared well to the 88% decrease observed 
nationwide in South Africa during the same period (112). Similar reductions in vaccine 
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serotype IPD has also been observed in countries that adopted a 3+ 1 vaccine dosing schedule 
(56, 192). HIV-infected children, who are still at high risk of IPD even in the PCV–era, had 
lower reductions in IPD compared to HIV-uninfected children (112, 179).  Similarly, among 
HIV-infected adults aged 18-45 years, the observed reductions in vaccine serotype IPD were 
smaller than those in HIV-uninfected individuals (179).  
 
In the USA, between 1998/1999 (pre-PCV era) and 2007, a 91% reduction in PCV7 serotype 
IPD was described in HIV-infected adults (14). Similarly, a 67% reduction in PCV7 serotype 
IPD was observed among HIV-infected adults in Spain within six years of childhood PCV 
introduction (193). Continued reductions in IPD incidence in HIV-infected individuals is 
therefore expected with more years of vaccine use, in addition to improved access to anti-
retroviral treatment. The demonstration of indirect effect in this age group is important and 
indicates the added public health benefit of PCV immunization which is specifically targeted 
at infants in countries where there is a substantial burden of adult HIV-infection.  
 
While an increase in non-vaccine serotype colonization was observed in childhood age-
groups targeted for PCV immunization, we did not identify an increase in IPD due to these 
non-vaccine serotypes (112, 179). In South Africa transitioning from PCV7 to PCV13 within 
two years most likely mitigated against some of this increase, in particular due to some of the 
additional serotypes included in PCV13 (i.e. 19A and 7F) which were associated with higher 
rates of IPD post PCV7 introduction in some settings.  Among HIV-infected individuals, a 
decrease was observed in non-vaccine serotype IPD among HIV-infected adults, while this 
remained unchanged in HIV-uninfected adults. Improved access to ART among adults could 
have contributed to this decline of non-vaccine serotype IPD among the HIV-infected adults. 
This indicates that in addition to PCV infant immunisation, improved ART management of 
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HIV-infected individuals is needed to further reduce the burden of IPD in settings such as 
ours.  
 
Colonization and IPD data was available pre and post vaccine introduction for mother-infant 
pairs in Soweto. We applied a theoretical model that has been used to predict changes in IPD 
based on colonization data in three settings (among American Indians, British Population and 
Portugal) (122). Our analyses was stratified by HIV-status, as interventions in HIV 
management may affect changes in risk for IPD (113). Our findings showed that the model 
correctly predicted changes in vaccine serotype IPD for unvaccinated mothers regardless of 
HIV status.  However, estimates for non-vaccine serotype were not comparable. Furthermore, 
among childhood age groups targeted for vaccination, the observed reductions in IPD were 
greater than the predicted estimates. This was likely due to  the direct effect of PCV 
vaccination in this age group preventing progression to IPD  not being accounted for in the  
model (122). Alternatively, to improve accuracy of estimates it has been proposed to swab 
individuals at time of illness to allow for the detection of serotypes 1, 4, 5 and 7F which are 
seldom isolated from carriage in healthy children (16).  
 
Natural fluctuations of circulating pneumococcal serotypes may account for some of the 
observations in our data. However, the effect of PCV introduction was evident in both 
colonization and IPD studies. We also sampled participants in the winter season each year to 
account for any seasonal variation. Also the IPD surveillance program has been ongoing for 
at least 15 years and provides a good baseline for evaluating the effect of infant PCV 
immunization. Ideally we would have liked to confirm self-reported HIV status in the 
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Agincourt area. However, our results even though limited to self-reporting of HIV status are 
comparable to those among confirmed HIV-infected adults in Soweto.  
   
 In conclusion, infant PCV-immunization with fairly modest vaccine coverage and in the 
absence of a catch-up campaign of older children was associated with indirect protection 
against vaccine serotype colonization and IPD in a high HIV-prevalent setting. Currently, 
there is no evidence of increases in S. aureus and H. influenzae in the nasopharynx. However, 
continuous monitoring is required to measure the long-term effects of infant PCV 
immunization on bacterial interactions in the nasopharynx at a population level. Finally, the 
use of serial colonization surveys has the potential to help estimate the indirect effect of 
childhood PCV immunization against vaccine serotype IPD in age groups not targeted for 
immunization, including among high risk HIV-infected adults.  
  
List of future research 
1. Continued NVT monitoring in carriage. Although NVT are less commonly associated 
with disease, however, these serotypes may acquire virulence factors associated with 
disease causing potential. As such continued monitoring of trends in colonization and 
IPD is essential to fully evaluate the impact of pneumococcal conjugate vaccine  
introduction 
2. A study tailored to evaluate bacterial interactions at population level and stratified by 
HIV status is essential. While our study does not show significant shifts at the 
moment, this may change with continued vaccine pressure. 
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3. Measuring colonization at the time of disease maybe more accurate than colonization in 
healthy population. This study will evaluate the fitness of colonization data in 
estimating changes in IPD.  
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Section 1:Study site 
Soweto [___] Agincourt [___] 
Clinic  
PHRU = 01 
RMPRU = 02 
PHC=03 
[___][___] Village [___][___] 
File number  Dwelling   
[___][___][___][___]  
Field worker 
(enter name) 
 Field worker 
(enter name) 
 
Visit date [___][___][___][___] /[___][___] /[___][___] Visit Date [___][___][___][___] /[___][___] /[___][___]  
 
Section 2: Demographic information 
Q1 Name (not to be entered on 
database) 
Name :    1a 
Surname: 1b 
Q2 Participants number  2  
[___][___][___][___][___][___] 
Q3 Date of birth  3  
[___][___][___][___] /[___][___] /[___][___]  
Q4 Gender   Male = 01 
Female=02 
4  
[___][___] 
Q5 Occupation 
 
Mining =01 
Farming= 02 
Construction=03 
Other=04 
Unemployed =05 
Pensioner=06 
School=07 
5  
 
 
[___][___] 
 
 
 
 
Section 3: Risk factors 
Q6 Do you smoke? Yes = 01(Q7) 
 No =02 (Q9) 
6  
[___][___] 
Q7 How many cigarettes a day? 7  
[___][___] 
Q8 Do you smoke indoors? Always = 01 
Sometimes = 02 
Rarely = 03 
Never = 04 
8  
[___][___] 
Q9 Do you take snuff? Yes=01(Q10) 
No = 02 (Q11) 
9  
[___][___] 
Q10 How many days a week do you take snuff? 10  
[___] 
Q11 Do you drink alcohol? Yes=01(Q12) 
No=02 (Q13) 
11  
[___][___] 
Q12 How often do you drink alcohol Almost 12  
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everyday=01 
On 
weekends=02 
Social 
occasions=03 
 
 
[___][___] 
Q13 Do you suffer from any chronic 
illnesses? 
Yes= 
01(Q14) 
No= 02 
(Q15)  
13  
 
[___][___] 
Q14 If Yes to 
above please 
specify? 
 
Hypertension =01 
Diabetes=02 
Malignancy=03 
Current TB=04 
Other =05 
More than one of the above=06 
14  
 
 
[___][___] 
Q15 Do you know your HIV status? Yes=01 
(Q16) 
No=02(Q21) 
15  
[___][___] 
Q16 Complete? 
 
Positive =01 (Q17) 
Negative=02 (Q21) 
Refused to disclose=03(Q21) 
16  
[___][___] 
Q17a 
 
17b 
 
17c 
 
 
17d 
 
17c 
Last CD4+ count 
 
%CD4+ 
 
State date when last CD4+ was 
taken 
 
Viral load 
 
State date when last viral load was 
taken 
 17a 
 
17b 
 
17c 
 
 
17d 
 
17e 
[___][___][___] 
 
[___][___].[___] 
 
 
[___][___][___][___] /[___][___] /[___][___]  
 
 
 
[___][___][___][___] 
 
[___][___][___][___] /[___][___] /[___][___]  
 
Q18a Are you on Co-trimoxazole 
(Bactrim, Septran, Triprim) 
prophylaxis? 
Yes=01 
(Q18b) 
No=02( Q19) 
18a  
[___][___] 
Q18b Compliance 
 
Most of the time (5-7days) = 01 
Regular (3-4days) = 02 
Poor (1-2days) = 03 
Never =04 
18b  
[___][___] 
Q18c State date when Co- trimoxazole 
prophylaxis was started 
 18c [___][___][___][___] /[___][___] /[___][___]  
 
Q19 Are you on ARV’s Yes=01Q20 
No=02Q21 
19  
[___][___] 
Q20 Complete table below  20  
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Details of ARV therapy 
 Name Abbreviation Date started 
Q20a Lamivudine (Epivir) 3TC  
[___][___][___][___] /[___][___] /[___][___] 
Q20b Stavudine (Zerit) d4T  
[___][___][___][___] /[___][___] /[___][___] 
Q20c Efavirenz (Stocrin) EFV  
[___][___][___][___] /[___][___] /[___][___] 
Q20d Neverapine (Viramune) NVP  
[___][___][___][___] /[___][___] /[___][___] 
Q20e Lopinavir/Ritonavir 
(Kaletra) 
LPV/r,   
[___][___][___][___] /[___][___] /[___][___] 
Q20f Didanosine (Videx) ddI,   
[___][___][___][___] /[___][___] /[___][___] 
Q20g Zidovudine( Retrovir) AZT,   
[___][___][___][___] /[___][___] /[___][___] 
Q20h Abacavir(Ziagen) ABC,   
[___][___][___][___] /[___][___] /[___][___] 
Q20i Ritonavir (Norvir) RTV  
[___][___][___][___] /[___][___] /[___][___] 
Q20j Nelfinavir (Viracept) NFV  
[___][___][___][___] /[___][___] /[___][___] 
Q20k Other (specify)   
[___][___][___][___] /[___][___] /[___][___] 
 
 
Section 4: Current symptomatic disease 
 
Q21 
 
 
Documented current fever  
 
 
Yes=01  
No=02  
21 
 
 
 
[___][___] 
Q22 
 
 
 
Are you currently coughing? Yes=01 
No=02   
22 
 
 
 
 
[___][___] 
Q23 
 
 
 
Are you currently sneezing/having 
a runny nose? 
Yes=01 
No=02  
 
23 
 
[___][___] 
Q24 Are you currently on TB 
treatment? 
Yes=01 
(Q27) 
No=02  
(Q25) 
24  
[___][___] 
Q25 Have you been treated for TB in 
the past year? 
Yes= 
01(Q26) 
No =02 
25  
 
[___][___] 
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(Q28)) 
Q26 State date of completion of 
treatment 
 26  
[___][___][___][___] /[___][___] /[___][___]  
 
Q27 Enter codes of anti TB drugs*  
[___][___],      [___][___],       [___][___],     [___][___],          [___][___] 
 
Q28 Are you suffering from any other 
illness at the moment (specify) 
 
 
* Rifampicin ® = 01, Isoniazid (H) = 02,  Pyrazinamide (Z) = 03,  Ethambutol (E) = 04, 
Streptomycin (S) = 05, other = 06 
 
Section 5: Examination 
 
Q29 Record actual temperature 29  
[___][___].[___] 
 
Q30 Record if cough/runny 
nose/sneezing was noted during 
the interview 
Yes = 01   
 No = 02 
30  
[___][___] 
Q31 Sore throat/Pharyngitis noted on 
examination 
Yes = 01  
 No = 02 
31  
[___][___] 
 
 
Section 6: Current antibiotic treatment 
 
Q32 Are you currently taking any 
antibiotics 
Yes = 01  
(Q33) 
 No = 02 ( 
Q34) 
32  
 
[___][___] 
Q33 Tick all that apply    
 
Details of current antibiotic therapy 
 Name Code** 
(see 
below) 
 
Start Date Comment(eg medication 
seen) 
Q33a.    
[___][___][___][___] /[___][___] /[___][___] 
 
 
Q33b.      
[___][___][___][___] /[___][___] /[___][___] 
 
 
Q33c.    
[___][___][___][___] /[___][___] /[___][___] 
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Section 7: Previous hospitalization 
 
Q34 Have you been hospitalized in the past 
3 months*** (see codes below) 
Yes=01(Q35) 
 
No=02 end of 
questionnaire) 
35  
 
[___][___] 
Q35 a)Duration of hospital stay 
 
b)Diagnosis 
i) [___][___]  
ii) [___][___]  
iii) [___][___]  
 
***Less than 3 days = 01,  3-7days = 02,  7-14days = 03,  Greater than 14days = 04 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Q33d.    
[___][___][___][___] /[___][___] /[___][___] 
 
 
 
**β –lactams = 01, Co-trimoxazole = 02, Cephalosporins = 03, Metronidazole = 04, 
Macrolides = 05, Tetracycline  =06,  Aminoglycosides  = 07,  Quinolones = 08, Other=09 
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Section 1:Study site 
Soweto [___] Agincourt [___] 
Clinic site 
PHRU = 01 
RMPRU = 02 
PHC = 03  
 Village [___][___] 
File number  Dwelling   
[___][___][___][___]  
Mothers ID  
[___][___][___][___][___][___] 
 
Field worker 
(enter name) 
 Field worker 
(enter name) 
 
Visit date [___][___][___][___] /[___][___] /[___][___] Visit Date [___][___][___][___] /[___][___] /[___][___]  
 
Section 2: General information 
Q1 Name(not to be entered on 
database) 
1aName 
1b. Surname 
Q2 Study ID  2  
[___][___][___][___][___][___] 
 
Q3 Date of birth  3  
[___][___][___][___] /[___][___] /[___][___]  
 
Q4 Is child still breastfeeding Yes =  01(Q6) 
  No = 02 (Q5) 
4  
[___][___] 
Q5 Has child ever been breastfed? Yes =  01 (Q6) 
  No = 02 (Q7) 
5  
[___][___] 
Q6 If Yes to Q4 and Q5 state duration of breastfeeding to 
the nearest month? 
6  
[___][___] 
Q7 Current weight in kilograms  7  
[___][___][___].[___][___] 
 
Q8 Current height in centimeters  8  
[___][___][___] 
Section 3: Daycare/School attendance 
Q9 Does this child attend 
daycare/regular play 
group/school? 
Yes =  01 
  No = 02 
9  
[___][___] 
Q10 If yes how many times a week  10 [___] 
Section 4: Risk factors 
Q11 Do you know the HIV status of 
this child? 
Yes = 01(Q12) 
  No = 02(Q13) 
11  
[___][___] 
Q12 If Yes specify 
 
Positive = 01 (Q15) 
Negative = 02 (Q19) 
 
12a  
[___][___] 
12b State date when last tested 12b  
[___][___][___][___] /[___][___] /[___][___] 
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Q13 Was mother tested for HIV?   Yes= 01(Q14) 
  No= 02 (Q19) 
13  
[___][___] 
Q14 State result Positive = 01 (Q19) 
Negative = 02 ( Q19) 
Refused to disclose = 03 
(Q19) 
Unknown= 04 (Q19) 
14  
[___][___] 
14b State date when last tested 14b  
[___][___][___][___] /[___][___] /[___][___] 
 
Q15 
 
a) Last CD4+ count of child 
 
b) % CD4+ 
 
c) Date when last CD4+ was taken 
 
d) Viral load 
 
e) Date when last viral load was 
taken 
  
15a 
 
15b 
 
15c 
 
15d 
 
15e 
 
 
[___][___][___] 
 
[___][___].[___] 
 
[___][___][___][___] /[___][___] /[___][___] 
 
 
[___][___][___][___] 
 
[___][___][___][___] /[___][___] /[___][___] 
 
 
Q16 a) Is child on Co-trimoxazole 
(Bactrim, Septran, Triprim) 
prophylaxis? 
Yes = 01( 
Q16b) 
No = 02 (Q17) 
16a  
[___][___] 
 
 
 
 
 b) Compliance (How often does 
child take Co- trimoxazole 
prophylaxis) 
Most of the time 
(5-7days) = 01 
Regularly (3-
5days) = 02 
Poor (1-2days) = 
03 
Never = 04 
16b  
[___][___] 
 c) State start date of Co-
trimoxazole prophylaxis 
 16c  
[___][___][___][___] /[___][___] /[___][___] 
Q17 Is child on ARV’s Yes=01 (Q18) 
No=02 (Q19) 
Q17  
[___][___] 
Q18 If yes complete table     
 
 
Details of ARV therapy 
 Name Abbreviation Date started 
Q18a Lamivudine (Epivir) 3TC  
[___][___][___][___] /[___][___] /[___][___] 
Q18b Stavudine (Zerit) d4T  
[___][___][___][___] /[___][___] /[___][___] 
Q18c Efavirenz (Stocrin) EFV  
[___][___][___][___] /[___][___] /[___][___] 
Q18d Neverapine (Viramune) NVP  
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[___][___][___][___] /[___][___] /[___][___] 
Q18e Lopinavir/Ritonavir 
(Kaletra) 
LPV/r,   
[___][___][___][___] /[___][___] /[___][___] 
Q18f Didanosine (Videx) ddI,   
[___][___][___][___] /[___][___] /[___][___] 
Q18g Zidovudine( Retrovir) AZT,   
[___][___][___][___] /[___][___] /[___][___] 
Q18h Abacavir(Ziagen) ABC,   
[___][___][___][___] /[___][___] /[___][___] 
Q18i Ritonavir (Norvir) RTV  
[___][___][___][___] /[___][___] /[___][___] 
Q18j Nelfinavir (Viracept) NFV  
[___][___][___][___] /[___][___] /[___][___] 
Q18k Other (specify)   
                     [___][___][___][___] /[___][___] /[___][___] 
 
 
 
Section 5: Current disease 
 
Q19 
 
19b 
Documented current fever  
 
Record actual temperature 
Yes =01 
No =02 
19 
 
19b 
[___][___] 
 
[___][___].[___] 
Q20 Is child currently coughing? Yes =01 
No =02 
20 
 
[___][___] 
 
Q21 Does child have a runny nose 
 
Yes =01 
No =02 
21 
 
 
[___][___] 
 
Q22 Is child currently on TB treatment? Yes=01 
(Q24) 
No=02  
(Q23) 
22 [___][___] 
Q23 Has the child been treated for TB in the 
past one year? 
Yes=01 
(Q24) 
No=02 
(Q26) 
23  
[___][___] 
Q24 If Yes to Q23, please state date of 
completion of treatment 
 24  
[___][___][___][___] /[___][___] /[___][___] 
Q25 Give codes of TB drugs if Yes to 
Q22 above* 
 
 
 
[___][___],      [___][___],       [___][___],     [___][___],          [___][___] 
Q26 Is child suffering from any other 
medical illness at the moment 
(specify) 
 
 
* Rimcure = 01, Rimatacid = 02,  Streptomycin (S) = 03,  Other  = 04 
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|Section 6: Examination 
Q27 Record actual temperature 27  
[___][___].[___] 
 
Q28 Record if cough/runny 
nose/sneezing was noted during 
the interview 
Yes = 01   
 No = 02 
28  
[___][___] 
Q29 Sore throat/Pharyngitis noted on 
examination 
Yes = 01  
 No = 02 
29  
[___][___] 
 
 
 
Section 7: Current antibiotic therapy 
 
Q30 Is child currently taking any antibiotics Yes = 01  
(Q31) 
 No = 02 
(Q32) 
30  
[___][___] 
Q31 If Yes list below    
Details of current antibiotic therapy 
**β –lactams = 01, Co-trimoxazole = 02, Cephalosporins = 03, Metronidazole = 04, 
Macrolides = 05, Tetracycline  =06,  Aminoglycosides  = 07,  Quinolones = 08, Other=09 
 
 
 
 
 
 
 
 Name Code** 
(see 
below) 
 
Start Date Comment(eg medication 
seen) 
Q31a.    
[___][___][___][___] /[___][___] /[___][___] 
 
Q31b.      
[___][___][___][___] /[___][___] /[___][___] 
 
 
Q31c.    
[___][___][___][___] /[___][___] /[___][___] 
 
 
Q31d.    
[___][___][___][___] /[___][___] /[___][___] 
 
 
 
Q31e.    
[___][___][___][___] /[___][___] /[___][___] 
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Section8: Previous hospitalization 
 
Q32 Have you been hospitalized in the past 
3 months 
Yes=01(Q33) 
 
No=02 (Q34) 
32  
[___][___] 
Q33 a)Duration of hospital stay (for each admission)*** b) Diagnosis 
i)  
[___][___] 
 
ii)  
[___][___] 
 
iii)  
[___][___] 
 
 
***Less than 3 days = 01,  3-7days = 02,    7-14days = 03,   Greater than 14days = 04 
 
 
Section 9: Immunisation history 
Q34a) Road to health card seen   Yes=01 (Q31b)    No= 02 (end of questionnaire)                      
[___][___] 
 
Q34b) Immunisation history (please provide date when vaccine was administered) 
 
Age of 
Child 
Vaccines needed Date when vaccine given Tick if 
not given 
At birth BCG  
[___][___][___][___] /[___][___] /[___][___] 
 
 
Polio (0)  
[___][___][___][___] /[___][___] /[___][___] 
 
 
6 weeks Polio (1) IPV                  [___] 
OPV                [___] 
Not recorded   [___] 
 
 
[___][___][___][___] /[___][___] /[___][___] 
 
 
DPT aPettussis        [___] 
wPertussis       [___] 
Not recorded   [___] 
 
[___][___][___][___] /[___][___] /[___][___] 
 
 
Haemophilus Influenza B  
[___][___][___][___] /[___][___] /[___][___] 
 
Pentaxim  
[___][___][___][___] /[___][___] /[___][___] 
 
 
Hepatitis B (1)  
[___][___][___][___] /[___][___] /[___][___] 
 
 
Pneumoccocal Conjugate 
Vaccine (PCV) 1 
 
[___][___][___][___] /[___][___] /[___][___] 
 
 
Rotavirus  
[___][___][___][___] /[___][___] /[___][___] 
 
 
10 weeks Polio IPV                 [___] 
OPV                [___] 
 
[___][___][___][___] /[___][___] /[___][___] 
 
 
Child Questionnaire 
Participants number   [___][___][___][___][___][___] 
Completed by: ________________ 
Date:    ___________________ 
191 
Not recorded  [___]  
DPT aPettussis          [___] 
wPertussis         [___] 
Not recorded     [___] 
 
[___][___][___][___] /[___][___] /[___][___] 
 
 
Vaccine Date when vaccine was given Tick if 
not given 
Haemophilus Influenza B  
[___][___][___][___] /[___][___] /[___][___] 
 
Hepatitis B  (2)  
[___][___][___][___] /[___][___] /[___][___] 
 
 
14 weeks Polio IPV                 [___] 
OPV                [___] 
Not recorded   [___] 
 
[___][___][___][___] /[___][___] /[___][___] 
 
 
DPT aPettussis          [___] 
wPertussis        [___] 
Not recorded    [___] 
[___][___][___][___] /[___][___] /[___][___] 
 
 
 
 
Haemophilus Influenza B 
 
 
[___][___][___][___] /[___][___] /[___][___] 
 
 
 
Pentaxim 
 
[___][___][___][___] /[___][___] /[___][___] 
 
 
Hepatitis B (3)  
[___][___][___][___] /[___][___] /[___][___] 
 
 
PCV (2)  
[___][___][___][___] /[___][___] /[___][___] 
 
 
Rotavirus  
[___][___][___][___] /[___][___] /[___][___] 
 
9 months Measles (1)  
[___][___][___][___] /[___][___] /[___][___] 
 
PCV (3)  
[___][___][___][___] /[___][___] /[___][___] 
 
18 months Polio (4) IPV                  [___] 
OPV                 [___] 
Not recorded   [___] 
 
[___][___][___][___] /[___][___] /[___][___] 
 
 
 
DPT aPettussis          [___] 
wPertussis         [___] 
Not recorded     [___] 
 
[___][___][___][___] /[___][___] /[___][___] 
 
 
Haemophilus Influenza B  
[___][___][___][___] /[___][___] /[___][___] 
 
Pentaxim  
[___][___][___][___] /[___][___] /[___][___] 
 
 
Measles (2)  
[___][___][___][___] /[___][___] /[___][___] 
 
 
5years Td-1 (Tetanus and reduced 
strength Diphtheria) 
 
[___][___][___][___] /[___][___] /[___][___] 
 
 
12 years Td2   
[___][___][___][___] /[___][___] /[___][___] 
 
 
Household/ participant number  [___][___][___][___][___][___] 
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Effect of Introduction of PCV upon nasopharyngeal ecology  
Section 1:Study site  
Soweto [___] Agincourt [___] 
Clinic name 
PHRU = 01 
RMPRU= 02 
PHC = 03 
[___][___] Village [___][___] 
Dwelling   
[___][___][___][___]  
Field worker 
(enter name) 
 Field worker 
(enter name) 
 
Visit date [___][___][___][___] /[___][___] /[___][___] Visit Date [___][___][___][___] /[___][___] /[___][___]  
                      
Section 2: List of household residents, relationship to household head and study participation 
Q1 Q2 Q3 Q4 Q5 Q6 
Name (not to be 
entered in database) 
Gender 
Male = 01 
Female=02 
Date of birth Relationship
* (see codes 
below) 
Primary care giver to any of 
the children under 5years 
Yes=01 
No=02 
Enrolled 
Yes= 01 
No = 02 
  
[___][___] 
 
[___][___][___][___] /[___][___] /[___][___] 
 
 
[___][___] 
 
[___][___] 
 
[___][___] 
  
[___][___] 
 
[___][___][___][___] /[___][___] /[___][___] 
 
 
[___][___] 
 
[___][___] 
 
[___][___] 
  
[___][___] 
 
[___][___][___][___] /[___][___] /[___][___] 
 
 
[___][___] 
 
[___][___] 
 
[___][___] 
  
[___][___] 
 
[___][___][___][___] /[___][___] /[___][___] 
 
 
[___][___] 
 
[___][___] 
 
[___][___] 
  
[___][___] 
 
 
[___][___][___][___] /[___][___] /[___][___] 
 
 
[___][___] 
 
[___][___] 
 
[___][___] 
  
[___][___] 
 
[___][___][___][___] /[___][___] /[___][___] 
 
 
[___][___] 
 
[___][___] 
 
[___][___] 
  
[___][___] 
 
[___][___][___][___] /[___][___] /[___][___] 
 
 
[___][___] 
 
[___][___] 
 
[___][___] 
 
 
  
*01= Household head, 02=Spouse, 03=Son or daughter, 04= Sister, 05= Brother, 06=Nephew/Niece, 07=Parent, 08= Uncle/Aunt, 11= 
other relative 12=grandchild 13= son in law/daughter in law 14=parent in law 15=adopted/foster/step child
Household/ participant number  [___][___][___][___][___][___] 
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Section 3: General household questions 
Q7 7.1 How many adults live in the household? 
 
7.2 How many children 6- 18years live in the household? 
 
7.3 How many children aged 5 or less live in the household? 
 
7.4 Total number of people in the household [add 6.1 and 6.2 and 6.3] 
7.1 
 
7.2 
 
7.3 
 
7.4 
[___][___] 
 
[___][___] 
 
[___][___] 
 
[___][___] 
 
Q8 For any of  the children aged 5 or less did they 
attend daycare/regular playgroup during the 
past month? 
Yes= 01 
No= 02 
8  
Q9 How many people smoke in the dwelling? 9  
[___][___] 
Q10 How many rooms are used for sleeping in the dwelling? 10  
[___][___] 
Q11 What fuel is used for cooking in the dwelling? Electricity   = 01 
Paraffin/gas= 02 
Coal/wood  = 03 
11  
[___][___] 
 
 
Q12 What fuel is used for heating in the dwelling? Electricity   = 01 
Paraffin/gas= 02 
Coal/wood  = 03 
  No heater  = 04 
12  
[___][___] 
 
 
 
 
 
 
